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For instance, on the planet Earth, man had always assumed that he was more intelligent than 
dolphins because he had achieved so much – the wheel, New York, wars and so on – whilst 
all the dolphins had ever done was muck about in the water having a good time. But 
conversely, the dolphins had always believed that they were far more intelligent than man – 
for precisely the same reasons. 
from A Hitchhiker's Guide to the Galaxy by Douglas Adams 
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Abstract 
By mediating the extravasation of leukocytes from the blood stream, selectins are involved in 
a key step of the inflammatory cascade. The excessive recruitment of leukocytes into 
inflamed tissue is responsible for the onset and the progression of various inflammatory 
diseases (e.g. rheumatoid arthritis, reperfusion injuries or asthma). Furthermore, selectins 
contribute to the development and metastasis of cancer. Given the health impact of these 
diseases, selectins represent a valuable drug target. 
Many research efforts for the development of small-molecule E-selectin antagonists have 
been based on sialyl Lewis
x
 (sLe
x
), the minimal carbohydrate epitope recognized by the 
selectins. From this lead with affinities in the millimolar range, antagonists with more drug-
like properties and affinities in the low micromolar range have been developed. However, the 
selectins have shaped up as difficult drug targets with only relatively few successful 
applications in vivo and no marketed anti-selectin drug. The comparably low affinities of E-
selectin antagonists are an important reason for the lack of clinical success in this field. 
In this work, the problem of modest affinity was approached from a new direction using a 
fragment-based approach (Figure I), as the possibility of forming high-affinity ligands from 
low-affinity fragments is one particular advantage of fragment-based drug discovery. Using a 
known sLe
x
 mimic (! first-site ligand) as starting point, an NMR-based screening was 
performed to identify small fragments (! second-site ligands) binding to a proximate second 
binding site. This led to the identification of 5-nitroindole as a second-site ligand. In situ click 
experiments based on the Huisgen 1,3-dipolar cycloaddition were performed to screen for a 
suitable linker to connect the two fragments. As this approach failed, a library of triazole–
nitroindole antagonists was synthesized, and a ranking was performed using a specifically 
designed Biacore experiment. 
The detailed investigation of the five most potent ligands identified in the screening revealed 
potent E-selectin antagonists with affinities ranging from 30 to 89 nM and improved binding 
kinetics, i.e. prolongued ligand–receptor half-life times in the range of minutes. Derivatives 
of the most potent antagonist were synthesized providing first insights into structure–activity 
relationships and a basis for the future development of these antagonists, also with respect to 
their physicochemical and pharmacokinetic properties. 
 Figure I. Schematic representation of the "fragment-based in situ combinatorial approach" for the 
identification of high-affinity E-selectin antagonists. A) Identification of second-site ligands based on 
their transverse magnetization decay induced by the protein; B) identification of proximal second-site 
ligands using a spin-labeled first-site ligand; C) incubation of E-selectin with alkyne/azide libraries of 
first- and second site ligands (in situ click experiment) for the determination of a suitable linker 
pattern ; D) high-affinity ligand generated by receptor-mediated triazole formation. E-selectin is 
shown in green. 
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1. Introduction 
Dolor, calor, rubor, tumor – the classical cardinal symptoms of inflammation have been 
known since before christ (1), indicating that the struggle with inflammation-associated 
problems has a long record in the history of mankind. Indeed, inflammatory processes play 
an important role in many diseases reaching far beyond their manifestation in the clinical 
symptoms mentioned above (for illustrative examples, see (2) or (3)), which themselves are 
troublesome enough. Examples for such "unhealthy" involvements of inflammation are 
cancer or reperfusion injuries. Rheumatoid arthritis and asthma are more direct 
manifestations of inflammation with a severe health impact. 
The therapeutic relevance of anti-inflammatory and chemotherapeutic drugs is evident from 
the severity and prevalence of inflammatory and associated diseases. However, these drugs 
often cause severe side-effects or have limited efficacy, which explains the need for 
therapeutic alternatives. The specific role of the selectins at an early stage in the 
inflammatory cascade makes them an attractive target for the therapy of inflammation-related 
diseases. Here, a fragment-based approach towards the inhibition of the leukocyte–selectin 
interaction is presented. 
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1.1. Structure and function of the selectins 
1.1.1. Structure of the selectins 
The selectins are a family of Ca
2+
-binding C-type lectins. Lectins are carbohydrate-binding 
proteins participating in cellular recognition (4). The selectin family comprises three 
members, E-, P-, and L-selectin1, that have common structural features, as shown in Figure 
1-1: The N-terminal carbohydrate recognition or lectin domain (CRD) is attached to an 
epidermal growth factor (EGF) domain, which is followed by a varying number (L-selectin: 
2, E-selectin: 6, P-selectin: 9; in humans) of complement-like consensus repeats, a 
transmembrane region and a cytoplasmic tail at the C terminus (5). 
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Figure 1-1. Structures of L-, E-, and P-selectin. After (6). 
Among the 3 selectins, the lectin and the EGF domains show the highest degree of sequence 
homology (7). The lectin domain carries the carbohydrate binding site, which is 
conformationally stabilized by a Ca
2+
 ion (5), itself participating in ligand binding (8). With 
                                                
 
1 There exist alternative names: E-selectin: CD62E, ELAM-1, or LECAM-2; P-selectin: CD62P, 
GMP-140; L-selectin: CD62L, LAM-1, or LECAM-1). 
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5.8 and 10%, the content of tryptophan and tyrosine, respectively, is unusually high in the 
lectin domain (9). The EGF domain is required for binding, yet its function is not completely 
understood, and it may affect ligand binding either directly or via an allosteric effect (10, 11). 
Recently, a single residue in the EGF domain was suggested to be involved in the catch bond 
behavior of selectins (see Section 1.2.2) (9).  
The consensus repeats are thought to act as spacers that allow an efficient presentation of the 
lectin domains on the cell surface (12). The extracellular part of the selectins is anchored in 
the cell membrane via the transmembrane domain. The cytoplasmic tail is thought to 
transduce outside-in signals triggered by ligand binding (13). 
1.1.2. Natural selectin ligands 
The natural selectin ligands are glycoproteins or glycolipids typically carrying terminal 
sialylated and fucosylated oligosaccharides or sulfopolysaccharides as their minimal binding 
epitopes (14-16). Four carbohydrates were found to represent common carbohydrate epitopes 
recognized by all three selectins: the trisaccharides Lewis
x
 (Le
x
, 1) and Lewis
a
 (Le
a
, 2) as 
well as the respective sialylated derivatives sialyl Lewis
x
 (sLe
x
, P1) and sialyl Lewis
a
 (sLe
a
, 
3; Figure 1-1) (14, 15, 17). 
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Figure 1-2. The minimal carbohydrate epitopes of E-selectin. 
The following physiological selectin ligands have been identified so far (an overview of the 
ligands and their interactions is given in Figure 1-3): 
! L-selectin: 
Gly-CAM-1 (18), CD34 (19), MAdCAM-1 (20, 21), podocalyxin-like protein (22), 
endomucin (23), endoglycan (24), and PSGL-1 (24).  
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Gly-CAM-1 is the best-characterized L-selectin ligand. For its binding to L-selectin, sialic 
acid, fucose, and oligosaccharide sulfation were found to be critical (18, 25-29). 
! P-selectin: 
PSGL-1 (30).  
P-selectin glycoprotein ligand 1 (PSGL-1) is the major natural ligand of P-selectin (30). 
For binding to P-selectin, two of the three N-terminal tyrosine residues (Tyr46, Tyr48, and 
Tyr51) need to be sulfated (31-33). 
! E-selectin: 
E-selectin ligand 1 (ESL-1), PSGL-1 (34-38), and L-selectin (39).  
For functional binding in vivo, E-selectin has different requirements than L- and P-
selectin, as it does not require ligand sulfation (14, 34, 35). 
 
Figure 1-3. The selectins and their natural glycoprotein ligands. Adapted from (6). 
1.1.3. Selectins in the inflammatory cascade 
An inflammation is the body's reaction to a local damage, which can be of physical, 
chemical, infective, immunological or nutritive origin, and its progression can be acute, 
subacute or chronical. One of the processes triggered by an inflammatory stimulus is the 
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recruitement of leukocytes, on whose activities innate and adaptive immune responses 
depend, to the site of infection. The recruitement proceeds via 3 necessary key steps (40, 41): 
1) Tethering and rolling of leukocytes on vessel walls, 2) release of chemoattractants 
inducing the expression of integrins on the leukocyte cell surface, which lead to 3) firm 
adhesion of the cell. Subsequently, the cell can penetrate the endothelium and migrate to the 
site of inflammation. The first process, i.e. the tethering and rolling of leukocytes, is mediated 
by the selectins, which are expressed on the cell surface upon the release of inflammatory 
mediators (Figure 1-4). 
 
Figure 1-4. Schematic representation of the inflammatory cascade (42) 
The selectins show overlapping, but temporally and spatially distinct expression patterns, 
which is exploited for a precise regulation of leukocyte recruitement (40, 41, 43).  
E-selectin is expressed de novo upon the release of TNF-#, IL-1 or bacterial LPS exclusively 
on endothelia (44, 45). It peaks 3 to 4 h after stimulation to reach basal levels again within 16 
to 24 h (46). A particular feature of E-selectin is its constitutional expression on skin and 
bone microvessels (47, 48).  
P-selectin is special in that it is stored in #-granules of Waibel-Palade bodies cells, which 
allows it to be presented on the cell surface within minutes after stimulation by thrombin, 
histamine and other agonists (49, 50). As well as quick, this expression is transient, with the 
P-selectin being internalized rapidly (51). Additionally, TNF-#, IL-1 or LPS can induce the 
de novo synthesis of P-selectin, causing a later appereance on the cell surface after 2 to 4 h 
(52-54). While the latter process is restricted to endothelia, the quick expression occurs also 
on platelets, which is unique among the selectins.  
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L-selectin plays an important role in "secondary tethering". During this process, leukocytes 
adhere to already associated leukocytes on endothelia, thereby increasing the number of cells 
recruited to sites of inflammation (55, 56). Owing to its expression on different leukocytes, 
L-selectin is responsible for lymphocyte recirculation, and, like E- and P-selectin is involved 
in leukocyte recruitment during inflammation (43). 
Firm adhesion is enabled by the cytokine-mediated activation of integrins, which bind to 
integrin ligands such as VCAM-1, ICAM-1, and MAdCAM-1 on endothelial cells (57, 58). 
Firmly attached cells can now penetrate the endothelial wall and migrate to the site of 
inflammation in the tissue (cf. Figure 1-5). 
 
Figure 1-5. Left: leukocyte rolling on endothelial cells; right: migration into tissue (59). 
1.1.4. Pathophysiological roles of E-selectin 
Many acute or chronic inflammatory diseases are characterized by the excessive recruitment 
of leukocytes into inflamed tissues. Investigations with a number of mouse models showed 
that interfering with this process has a strong impact on the progression of these diseases (60-
62). In humans, the importance of selectin–ligand interactions for appropriate immune 
responses was illustrated by cases of a rare genetic disorder, type 2 leukocyte adhesion 
deficiency (LAD-2). Patients affected by this disease exhibit reduced rolling of leukocytes, 
causing, among other severe symptoms, recurrent infections (63, 64). 
In a number of diseases, selectins appear to play a detrimental role. Examples include 
reperfusion injury (65, 66), asthma (67-70), rheumatoid arthritis (71-74), and host-versus-
graft disease (75, 76). Several model systems have demonstrated positive effects of blocking 
the selectin-mediated leukocyte recruitment, for example in the case of reperfusion injury 
(77, 78), asthma (79, 80), rheumatoid arthritis (81, 82), or host-versus-graft disease (75). 
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Inflammation is not only a direct cause of disease, but is also involved in the progression of 
tumors, as inflammatory cells contribute significantly to the tumor microenvironment (2). 
Specifically, the selectins are involved in cancer on three different levels: 1) Tumor cells 
form clusters with platelets and leukocytes, by means of which they circulate in the blood 
stream, 2) they use the same selectin-mediated pathway for extravasation as leukocytes, and 
3) they exploit pro-malignancy signals delivered via the action of selectins (83). The potential 
usefulness of selectins in therapy of cancer was, for example, demonstrated by studies 
showing that the survival of colorectal cancer patients with high levels of sLe
x
 and sLe
a
 could 
be increased by suppressing the vascular expression of E-selectin (84). 
For a more detailed account of the pathophysiological roles of selectins, one may consider the 
following recent reviews: (83, 85-89). 
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1.2. The ligand binding of selectins 
1.2.1. Sialyl Lewis
x
 
In all three selectins, sialyl Lewis
x
 (sLe
x
, P1) is the minimal carbohydrate epitope (14, 15, 17) 
showing a modest binding affinity in the millimolar range (90). It has served as a lead 
structure for the development of glycomimetic antagonists (91-93).  
The pharmacophores of sLe
x
 were determined by systematic derivatization of functional 
groups. This revealed that the 3- and 4-hydroxyls of fucose (94, 95), the 4- and 6-hydroxyls 
of galactose (96, 97), and the carboxyl group of neuraminic acid contribute to binding (cf. 
Figure 1-7) (98, 99). In P-selectin, the neuraminic acid makes additional contributions to 
binding by the 4- hydroxyl and via hydrophobic interactions, as was revealed by the crystal 
structure of P-selectin co-crystallized with sLe
x
 (8). The GlcNAc moiety is not directly 
involved in binding but rather serves as a spacer that orients fucose and galactose in an 
optimal position (94, 98, 99).  
The crystal structure of the lectin/EGF domains of E- and P-selectin co-crystallized with sLe
x
 
was solved in 2000 by Somers et al. (8). In contrast to the co-crystal structure of mannose 
binding protein (MBP-A) with its glycans (100), the Ca
2+
 ion was found to be complexed by 
the 3- and 4-hydroxyls of fucose, and not by the 2- and 3-hydroxyls (Figure 1-6 and Figure 
1-7). 
 
Figure 1-6. Interactions between sLe
x
 and E-selectin in the crystal structure by Somers et al.. A) 
Interactions of fucose; B) interactions of the galactose and the neuraminic acid. Adapted from (8). 
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Figure 1-7. Schematic representation of sLe
x
 binding to E-selectin as identified in the crystal 
structure by Somers et al.. 
1.2.2. The shear threshold requirement and catch bonds 
Figure 1-8 illustrates a surprising phenomenon associated with selectin-mediated leukocyte 
rolling: a shear above a critical threshold is required to promote and maintain rolling. This 
effect was first described for L-selectin (101), but but also occurs with P- and E-selectin 
(102). The shear threshold requirement is a result of the selectins' ability to form catch bonds, 
which could be shown by single-molecule atomic force microscopy (103, 104). Such bonds, 
which are also found in FimH-mediated bacterial adhesion (105), show an increase of the 
mean bond lifetime with force below a critical value and a decrease when the force exceeds 
that value. This is in contrast to a "conventional" bond (slip bond), whose lifetime decrases 
with force (105, 106). 
 
Figure 1-8. A) L-selectin mediated neutrophil tethering at different shear shear stresses; B) 
Neutrophil rolling velocity on PSGL-1. Adapted from (107). 
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The cause of the catch bond effect in selectins is not yet fully understood, but evidence 
suggests that the extension of the flexible region (interdomain region) between the selectin's 
lectin and EGF domains is crucial in this respect (108, 109):  
The selectin crystal structures revealed two different selectin conformations, "bent" and 
"extended", differing by the angle between the EGF and the lectin domains (8, 110) (cf. 
Figure 1-9). In the absence of ligand (110) or after soaking the crystals with sLe
x
, the bent 
conformation was obtained (8), but co-crystallization of P-selectin with a PSGL-1 fragment 
yielded the extended conformation, and thus it was hypothesized that P-selectin had a low- 
and a high-affinity state (8). This hypothesis was supported by investigations on selectin 
mutants (111). Phan et al. introduced a sterically demanding glycan in the hinge region of P-
selectin (" wedge mutant), which was predicted to induce the extended conformation of P-
selectin. Indeed, compared to the wild-type protein, the wedge mutant's affinity to PSGL-1 
was increased by a factor of 5, and cells expressing the mutant P-selectin exhibited stronger 
tethering. Likewise, an L-selectin–N138G mutant, which misses a hydrogen bond showed 
stronger tethering to PSGL-1–coated surfaces. This can be explained by the fact that, without 
the hydrogen bond, the extended conformation is favored (108). Lou et al. investigated the 
same modification using a single-molecule force probe. They found that the mutant needed 
less force to enter the catch-bond regime, i.e. bond lifetimes were prolongued. This finding is 
in accordance with the assumption that, in vivo, the pulling force applied by the rolling cell 
acts as an allosteric effector to induce the high-affinity bent conformation (Figure 1-9). 
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Figure 1-9. Bent (A) and extended (B) conformation of P-selectin and the application of force (B). 
Adapted from (9). 
Two models were suggested to rationalize the different affinities of the two protein 
conformations, the "sliding–rebinding" (109, 112) and the "allostery" (9, 113) model.  
According to the sliding–rebinding model, force-induced extension of the lectin/EGF 
domains leads to an alignment of the ligand–protein interface with the force vector. This 
allows the ligand to slide along the protein surface and to make new interactions on multiple 
overlapping binding sites, which then favors rebinding to the original site (Figure 1-10). 
Conformational changes of the binding site are not considered in this process. 
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Figure 1-10. Sliding–rebinding model. Adapted from (109). 
However, compared to the bent conformation, the crystal structure of extended P-selectin 
revealed pronounced structural changes throughout the lectin domain. These involve the 
movement of the Asn83–Asp89 loop towards the sLe
x
 binding site ("switch 3" in Figure 
1-11), which establishes hydrogen bonds with the complexed Ca
2+
 and the sLe
x
 fucose (8). 
These observation are the basis of the allostery model, which proposes a single binding site 
that can adopt high- and low-affinity conformations. The bent and extended protein 
conformations are assumed to be in equilibrium, whereby the application of directional force 
(cf. Figure 1-11) favors the extended conformation (113). According to the allostery model, 
the movements of the lectin and EGF domains are allosterically transmitted via 3 switch 
regions to the Asn83–Asp89 loop. The movements of the switch regions are supported by a 
rigid part of the lectin domain, whereby the high Trp and Tyr content, two disulfide bridges, 
and two $-sheets act as "stiffeners" (Figure 1-11) (9). This explanation of allosteric 
transmission over the lectin domain is supported by a study in which a bulky substituent, i.e. 
the side chain of histidine, favoring the extended conformation was introduced into the lectin 
domain by a A28H mutation. The mutant had a 2.5-fold higher affinity and a 2-fold lower 
dissociation rate constant (koff) than the wild type protein, suggesting that there indeed exists 
Introduction 
13 
an "allosteric pathway" for the transmission of allostery from the hinge region to the ligand 
binding site. The differential staining of the mutant provided some indirect evidence for a 
conformational change induced by the mutation (113). 
 
Figure 1-11. Allosteric transmission. The purple lines illustrate the movements of the switch regions. 
Adapted from (9). 
It is noteworthy that the affinity increase described above cannot be explained by the sliding–
rebinding model. In the SPR assays used for affinity determination, ligand dissociation is 
exclusively governed by Brownian motion and not by an external directional force as 
postulated by the sliding–rebinding model. Thus, unlike suggested by this model, the 
orientation of the binding site was irrelevant for ligand dissociation in these experiments 
(111). 
The special characteristics of the selectins outlined above might be of considerable relevance 
for the development of selectin antagonists, especially for rational design approaches 
involving molecular modeling. On the one hand, the complexity of the system with the 
possibility of large structural arrangements aggravates predictions, e.g. by static docking 
experiments or even molecular dynamics simulations. On the other hand, these findings may 
open new possibilities for ligand design, for example by exploiting a potentially favorable 
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induced fit effect. Furthermore, given that the catch-bond behavior is a prerequisite for 
function in vivo, selectin inhibition could be achieved by allosterically preventing the protein 
from entering the catch-bond regime, i.e. by stabilizing the bent or low-affinity conformation. 
Allosteric antagonists might avoid some of the diffuculties typically encountered with 
carbohydrate mimetics (cf. Section 1.3.1).  
However, structural data are needed to thoroughly validate the models suggested above. The 
current interpretations are solely based on predicted structural features of mutants. Only in 
the case of the P-selectin–A28H mutation, some indirect evidence was provided by 
differential antibody staining (113). 
1.2.3. Ligand preorganization 
Ligand preorganization is an important concept in medicinal chemistry. It was successfully 
used to rationalize the binding of sLe
x
 and of antagonists derived from it. According to this 
concept, the match of a ligand's preferred solution and bioactive conformations leads to an 
affinity improvement due to a smaller loss of conformational entropy upon binding (In 
practise, the prediction of the effect of ligand prieorganization on binding enthalpies and 
entropies is challenging, as demonstrated in a recent systematic study (114).).  
Molecular dynamics simulation (MC(JBW)/SD) studies performed by Kolb and Ernst (90, 
115) implied that the solution conformation of sLe
x
 is similar to its E-selectin–bound 
conformation as determined in transfer-NOE NMR experiments (116, 117) (see Figure 
1-13A). For these simulations, two internal coordinates ("acid orientation" and "core 
conformation") defining the sLe
x
 conformation were introduced (Figure 1-12). This allows to 
compare the solution conformations of different ligands. Ligands showing a high probability 
for conformations in the bioactive window usually exhibited higher affinity to E-selectin, 
which is a result of the better preorganization in the bioactive conformation. 
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Figure 1-12. Graphical representation of the internal coordinates used for defining sLe
x
 
conformations. After (90). 
 
Figure 1-13. A) Bioactive conformation of sLe
x
 determined by Scheffler et al. (transfer-NOE NMR), 
adapted from (59); B) Representation of A) in an internal coordinate plot using the internal 
coordinates shown in Figure 1-12; C) solution conformation of sLe
x
 calculated by MC(JBW)/SD 
simulation, adapted from (90). 
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1.3. Selectin antagonists 
The applicability of selectin inhibition to treat inflammatory disorders was demonstrated by 
Cylexin, an sLe
x
 pentasaccharide. Although not successful as a drug candidate, Cylexin can 
be seen as an initiator of the efforts directed towards identifying more drug-like selectin 
antagonists (59). 
The use of conceptually different in vitro assays aggravates the comparison of standardized 
IC50 values reported in literature (118). Relative IC50s (rIC50) are more suitable for such 
comparisons, whereby the IC50 of sLe
x
 is measured along with the analytes. The IC50 of the 
latter is given relative to the one of sLe
x
, whereby the rIC50 of sLe
x
 is set to 1. Furthermore, 
traces of polyanions released from ion exchange resins were found to be potent selectin 
antagonists (119). As these impurities are difficult to detect with the routine analytical tools, 
the existence of false-positive results originating from such contaminations cannot be 
exluded. 
1.3.1. Challenges by glycomimetics 
Typically, carbohydrate leads do not have drug-like properties (87), which is a result of 
! unfavorable pharmakokinetic properties leading to low oral bioavailability (due to the 
high polarity and molecular weight) and a short plasma half-life time (due to fast renal 
excretion); 
! low hydrolytic and metabolic stability; 
! low affinity, especially in the case of lectins. It is a result of the typically shallow and 
unstructured binding site with a high solvent accessibility. In vivo, as functional affinity is 
often achieved via multivalency effects; 
! structural complexity leading to difficult synthetic access. 
These general drawbacks also apply to sLe
x
, which has widely been used as a lead structure 
for the development of selectin antagonists. Furthermore, the dissociation half-life times (t1/2) 
of ligand–selectin complexes are in the range of seconds only (120-122), while ranges of 
minutes to hours are expected for typical drugs (123, 124). The clinical relevance of a short 
t1/2 (or a high dissociation rate constant, koff) are further discussed in Section 1.5.3). 
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The efforts in the development of selectin antagonists have been targeted at solutions to 
overcome the typical drawbacks of carbohydrate leads. Two strategies were applied, namely 
(1) de novo design guided by the spatial orientation of sLe
x
 in the bioactive conformation and 
(2) structural modification of sLe
x
 using drug-like replacements for L-fucose, N-acetyl-D-
glucosamine, D-galactose or N-acetyl-neuraminic acid (59). 
The discussion below focuses on the development of the E-selectin antagonists that are 
relevant for this work. For a comprehensive overview of selectin antagonists, the reader is 
pointed at the following reviews: (59, 87, 91, 125-127). 
1.3.2. Replacement of GlcNAc and Neu5Ac 
As previously mentioned, GlcNAc does not directly interact with the selectins but rather 
serves as a spacer orienting the fucose and galactose moieties (94, 98, 99). Thus, it lends 
itself for a replacement by spacers with optimized properties. Among others, (1R,2R)-trans-
cyclohexanediol (128) was a particularly interesting mimic, combining higher activity 
(threefold compared to sLe
x
), lower complexity and higher lipophilicity. 
In the interaction with E-selectin (but not P-selectin), sialic acid is in direct contact to the 
protein only via the carboxyl group. As for GlcNAc, replacements with less structural 
complexity and polarity were desirable. The modeling tool introduced by Ernst et al. (90, 
115) (see Section 1.2.3) proved to be useful in the search of mimics, correctly predicting the 
suitability of (S)-cyclohexyl lactic acid. Albeit chemically simple, it is capable of correctly 
positioning the carboxyl in the bioactive conformation. Furthermore, it was found to be the 
best among a series of other replacments, e.g. (S)-phenyl or (S)-adamantanyl lactic acid (125, 
129) . 
The simultaneous replacement of GlcNAc and Neu5Ac led to antagonist CGP69669 (4), 
which showed a tenfold improvement of affinity compared to sLe
x
 (Figure 1-14) (90). 
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Figure 1-14. Replacement of GlcNAc and Neu5Ac by (1R,2R)-trans-cyclohexanediol and (S)-
cyclohexyl lactic acid. 
1.3.3. Modifications of the GlcNAc mimic to increase preorganization 
The concept of preorganization outlined in Section 1.2.3 was further exploited by the 
introduction of modicifactions at the cyclohexanediol moiety. Such modifications include 
equatorial substituents at the former 2-position of GlcNAc, which exert their effect via 
beneficial steric constraints imposed on the fucose moiety, as was shown by the investigation 
of interglycosidic NOE effects. These were used to quantify the proximity of the fucose and 
galactose moieties. As shown in Figure 1-15, the NOEs correlated nicely with the affinity 
towards E-selectin. Antagonists 7 to 9 show that bulkier substituents do not lead to an 
additional increase in affinity. Furthermore, the lack of affinity of the flexible antagonist 5 
clearly emphazises the importance of ligand preorganization (130). 
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Figure 1-15. Ligand preorganization by substituents on the GlcNAc mimic. After (130). 
An in-depth investigation of the substituent effects at the former 2-position of GlcNAc was 
performed by Schwizer (131, 132), Weckerle (133), Wagner, and Ernst (Table 1-1).  
This newer class of antagonists has modified cyclohexanediols as GlcNAc replacements and 
may carry additional substituents (R
1
) at the 2'-position of galactose (see Section 1.3.4) and at 
the former position of the ring oxygen of GlcNAc (R
3
). The latter substitutions tend to 
increase the affinity, although, based on the crystal structure of sLe
x
 bound to E-selectin (8), 
no interaction with the protein is expected at the R
3
 position. Instead, these substituents may 
stabilize the cyclohexanediol chair conformation, which was found to be distorted in 
antagonists with larger R
2
 substituents such as cyclopropyl (131).  
Table 1-1 shows that the introduction of a methyl group for R
2
 (! 12) causes a 5-fold, the 
introduction of a benzoate for R
1
 (!14) a 2-fold increase in affinity compared to the 
unsubstituted reference CGP69669 (4). The combination of these modifications is additive, 
i.e. derivative GMI-1077 (15) is 20 (rIC50) to 30 (Biacore) times more potent than the 
reference. The rigid cyclopropyl substituent at R
2
 is not tolerated well and shows a markedly 
reduced affinity compared to the methyl derivative GMI-1077 (15), while smaller and 
flexible residues such as ethyl (13), n-butyl (17), or methyl propionate (19) do not cause a 
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pronounced affinity change. Also the effect of the methyl ester at R
3
 appears to be small. Due 
to its bulkiness, the tert-butyl residue at this position (! 21) is expected to cause a strong 
preference for the all-equatorial chair conformation. However, 21 binds only weakly to 
E-selectin, which may result from poor solutility or from unfavorable interactions with the 
protein. Table 1-1 further illustrates that, generally, there is a good  agreement of rIC50s and 
KD values determined by Biacore. 
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Figure 1-16. General structure of antagonists with modified cyclohexanedioles as GlcNAc 
replacements. 
Table 1-1. rIC50 values (131) and KDs obtained by Biacore (133). 
Compound R
1
 R
2
 R
3
 rIC50
a)
 KD ["M]
b)
 
CGP69669 (4) H H H 0.080 45 
12 H Me H 0.016 7.9 
13 H Et H 0.009 – 
14 Bz H H 0.040 19 
GMI-1077 (15) Bz Me H 0.004 1.5 
16 Bz Et H 0.007 1.5 
17 Bz nBu H 0.009 – 
18 Bz cPr H 0.032 5.4 
19 Bz (CH2)2CO2Me H 0.008 1.6 
20 Bz Me CO2Me 0.002 1.9 
21 Bz H tBu > 10 – 
a) sLe
x
 (IC50 = 1 mM; rIC50 = 1) was used as reference; b) determined by Biacore 
from a steady state response fit to a 1:1 binding model. 
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1.3.4. Substituents at the 2'-position of galactose 
Given the beneficial effects of benzoates at the 2'-position, a series of alternative substituents 
was investigated (Figure 1-17, Table 1-1) (133). Strikingly, a sub-micromolar KD was 
measured for the para-methoxy–substituted antagonist 22, which corresponds to a 20-fold 
increase in affinity compared to the unsubstituted reference 12. Yet, this finding is not 
reflected in the rIC50 values. Also the non-aromatic substitutions (23 and 25) have a 
pronounced positive effect on binding affinity, comparable to the benzoate. 
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Figure 1-17. Antagonists with different 2'-substituents. 
Table 1-2. 2'-modifications 
Compound rIC50
a)
 KD ["M]
b)
 
12 0.016 7.9 
GMI-1077 (15) 0.004 1.5 
22 0.006 0.4 
23 – 1.2 
24 0.005 1.3 
25 0.006 2.0 
a) sLe
x
 (IC50 = 1 mM; rIC50 = 1) was used as reference; b) determined by 
Biacore from a steady state response fit to a 1:1 binding model. 
 
The affinity gain resulting from the substitutions at the 2'-position of galactose are difficult to 
rationalize, because crystallographic data for sLe
x
 (8) (see Figure 3-17) suggest that the 2-
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hydroxyl group is exposed to bulk solvent, which is supported by docking experiments 
[unpublished results by Martin Smiesko, University of Basel]. In contrast to this, recent STD 
NMR studies (133) showed large STD values for the benzoate, indicating a direct interaction 
with E-selectin (Figure 1-18). Currently, these experiments lead to the conclusion that there is 
indeed an interaction of the benzoate with E-selectin. However, crystal structure data is 
needed to definitely elucidate the binding mode of benzoate-substituted antagonists. 
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Figure 1-18. Epitope mapping of GMI-1077 (15) performed with monomeric E-selectin monomeric 
E-selectin (LecEGF_CR2). 
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1.4. Fragment-based drug discovery 
In the past 15 years, the lack of productivity in pharmaceutical industry has been a concern. It 
was argued that short-sighted "strategical" considerations may have made some unhealthy 
contributions to the lack of innovation. However, the drug discovery process itself was also 
seen as one of the shortcomings (134, 135). Specifically, it became clear that high-throughput 
screening (HTS) cannot be reduced to a "game of numbers" (136) with  rather blindfold 
screening of millions of compounds. There may well exist a positive correlation between the 
hit rate in a screening program and the size of the library being screened, but the screening is 
just one initial step in the development of a new chemical entity. The generally low hit rates 
of HTS, especially for challenging drug targets (137), may be further diminished by the high 
attrition rate of HTS hits in the development process. Often, this is attributed to inappropriate 
ADME properties of HTS hits (e.g. (138)), although this effect is probably overestimated 
(139). As a concequence, besides optimizing the HTS libraries with regard to drug- or lead-
likeness, an alternative method, fragment-based drug discovery (FBDD), attracted the 
attention of pharmaceutical companies. 
1.4.1. Characteristics 
The underlying concept of FBDD, namely treating a ligand as a component of distinct parts 
was already raised in the 1980s (140), but the lack of suitable screening techniques for the 
detection of the inherently weak fragment affinities prevented the practical application of 
fragment-based approaches. Consequently, the publication by Fesik et al. (141), which 
describes the development of nanomolar ligands from low-affinity fragments using screening 
by NMR, is often seen as the first practical application of the concept (136). Since then, the 
methodologies have evolved, and FBDD has gained the status of a complementary strategy to 
HTS (142), which has led to a number of leads entering clinical trials (137).  
What is responsible for the rapid and quite profound success of FBDD? Below, some of the 
main characteristics of fragment-based approaches are discussed based on several recent 
reviews (137, 138, 142-148) and a book (149) on the topic. Overall, FBDD is seen as a 
promising "new paradigm", which has been successfully applied to a variety of drug targets, 
including some where HTS failed to afford suitable hits. However, the experience with with 
FBDD is still quite limited, and the true value of this methodology may not yet be fully 
assessable (139). 
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Fragments 
According to the Oxford Advanced Learner's Dictionary, a fragment is 1) "a small part or 
piece broken off sth", or 2) "a small part of sth, not complete in itself". In the language of 
chemistry, the following criteria are relevant for defining a good fragment (142): 1) 
physicochemical properties, 2) aqueous solubility, 3) molecular diversity, 4) chemical 
tractability, 5) absence of undesired chemical functionalities, 6) druglikeness (precedence of 
the structural moieties in oral drugs and natural products), and 7) sampling of priviledged 
medicinal chemistry scaffolds. In analogy to Lipinski's "rule of five", a "rule of three" was 
suggested for fragments, which resulted from an analysis of a diverse set of fragment hits 
(150): 
! MW < 300 
! number of hydrogen-bond donors % 3 
! number of hydrogen-bond acceptors % 3 
! ClogP % 3 
The chemical universe and complexity 
Quite in contrast to HTS, FBDD has haystack-burning2 properties because it reduces the 
number of compounds that have to be screened for covering a certain fraction of chemical 
space. Consequently, a typical fragment library is much smaller (thousands of compounds) 
than a HTS library (up to millions of compounds). This can be explained by the smaller 
number of drug-like molecules with 11 or less heavy atoms (approx. 10
9
) compared to the 
total number of compounds (with heavy atom count < 36) that fulfill Lipinsky's rule-of-five 
(151), which was estimated to be 10
20
 to 10
200
. A library of 1000 fragments therefore 
represent 1 millionth of the fragment universe, while 10
6
 "large" molecules account for 10
14
 
to 10
194
 times (!) less of their universe. Besides being advantageous to pharmaceutical 
companies the small fragment libraries make screening approaches more accessible to 
academic research.  
The small size of fragments is furthermore advantageous in that less complex molecules are 
                                                
 
2 "If you want to find the needle, burn down the haystack". Quote of unknown origin. 
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more probable to match a receptor binding site without the occurrence of unfavorable 
interactions (138, 145). In fact, such "foul" parts in a larger molecule could even mask 
otherwise interesting structural features. 
Entropy's soft spot for fragment linking 
Fragments usually have KDs in the high micromolar to millimolar range (145), a factor of 10
3
 
to 10
6
 lower than what is expected for a typical drug. Yet, linking two such fragments leads 
to a pronounced gain of free energy, which is much higher than the binding energy 
contribution from the individual fragments (140, 152, 153). Besides the additivity of the 
fragments' intrinsic binding engergy ("the Gibbs free energy change for the binding [of a 
fragment] in the absence of strain and losses in translational and rotational entropy") (140), 
the linking is highly advantageous by reducing the loss of rotational and translational rigid-
body entropy: Upon binding to a target, a ligand has to overcome a significant entropic 
barrier as it loses 3 translational and 3 rotational degrees of freedom (153). Two individual 
fragments accordingly lose twice as many degress of freedom upon binding as if they were 
linked. In terms of energy, this can account for as much as 15 to 20 kJ/mol or 3 orders of 
magnitude in affinity (154).  
These considerations apply to two of the FBDD strategies, fragment linking and fragment 
fusion (the third stategy, fragment growth, consists of expanding and optimizing a single 
fragment using rational design) (136). Some pitfalls are associated with fragment linking, 
which is relevant in the context of this work. In particular, it can be difficult to link two 
fragments without disrupting the quality of the fragments' individual interactions, and binding 
sites to which two fragments can bind simultaneously seem to be relatively rare, e.g. due to 
space restrictions (136, 138, 146). In the case of E-selectin or other proteins with a shallow 
and unstructured binding site (cf. Figure 3-17), spatial limitations are probably less of a 
concern. The fragment-linking is disscussed further in depth in Section 3.5.1.  
Flexible linkers can be used to overcome the problem of inappropriate fragment orientation, 
particularly when no structural information is available. In such cases, the fragment-linking 
approach is additionally attractive because it allows to conduct target-guided screening 
procedures (see Section 2). However, the freezing of rotatable bonds in flexible linker is 
associated with entropic costs (5 kJ/mol per 2 bonds or a factor 10 in affinity). The linker 
itself may furthermore interact with the protein leading to positive or negative contributions 
to affinity. 
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Small but nice 
Since the introduction of Lipinski's "Rule of five" (151), molecular weight has become an 
important criterion in drug development. According to these rules, compounds with a 
molecular weight < 500 Da have a higher probability of being orally available and thus 
increasing the size of lead molecules should be well justified, i.e. be accompanied by a 
reasonably high improvement of affinity. Ligand efficiency (LE) is a useful quantity for 
judging the quality of additions made to a molecule. It relates a ligand potency to size, for 
example by dividing ligand potency (pIC50, pKi or &G) by the size (e.g. number of heavy 
atoms) (155). Analyses of the evolution of LEs during the lead optimization process 
essentially showed that the development of fragments proceeds more efficiently, thereby 
increasing the probability of developing a drug-like compound. 
1.4.2. Screening methods 
Nuclear magnetic resonance (! "SAR by NMR" (141)) was the first analytical technique to 
overcome the detection problem that initially prevented the advancement of fragment-based 
discovery strategies. In the meantime, MS, X-ray crystallography, SPR, and ITC have been 
added to the fragment screening toolbox (156). Figure 1-19 gives an overview of these 
technologies in the "fragment-to-lead process" (147). 
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Figure 1-19. Crystallography, NMR, ITC, SPR and HCS in FBDD. HCS: high-concentration 
screening (functional and direct binding assays). From (147). 
NMR-based screening 
In general, NMR-based screening approaches have the advantage of producing fewer false 
positive hits and of providing some (but limited) information on the binding mode and/or 
location of fragments. Although NMR has a comparably low intrinsic sensitivity, its high 
dynamic range (i.e. the range of fragment affinities that can be detected) allows one to 
identify low-affinity fragments that are not be detectable with other screening methods (157). 
The often large amounts of protein needed represent a drawback, however (156). The 
methodologies can be divided into target- and ligand-based (144, 147), where signals of the 
protein and the ligands are observed, respectively.  
Protein-based detection, of which "SAR by NMR" (141) is an example, relies on chemical 
shift perturbations induced by ligand binding and can detect interactions in the nano- to 
millimolar affinity range. It has the advantage of providing precise information about the 
location of the ligand binding site. On the other hand, it may require a relatively high 
concentration of labeled protein and of the ligands, which can be limited by low solubility of 
the protein or the ligands. Yet, there exist improvements of this technology, e.g. employing 
cryogenic NMR probes, 
13
C labeling of methyl groups or protein deuteration, which allows 
the investigation of larger proteins at lower concentrations, accompanied by higher 
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throughput and by mor precise structural information (147, 157).  
Ligand-based methods include WaterLOGSY, STD, and relaxation rate experiments (157). 
Generally, they require smaller amounts of protein and abolish the need for isotopic labeling, 
but deliver less structural information. Furthermore, the detection of high-affinity ligands (KD 
% 10
-8
 M) can be impaired by slow off rates, causing these ligands to be in the slow-exchange 
limit for chemical shifts and relaxation times (158). This limitation can be overcome by 
competition experiments or by the use of 
19
F-labeled "spy" molecules (147). If one of the 
fragments or a binding site is already known, the introduction of a spin label allows the 
detection of ligands that bind simultaneously and in the vicinity of the existing ligand or the 
binding site (see Section 3.5.1) (159, 160). The spin-label also allows to derive the relative 
orientation of a fragment with respect to the spin label (161). The spin-label approach is 
further outlined in Section 2.  
An overview of the use of NMR in FBDD is given in Figure 1-20. 
 
Figure 1-20. Frequently used NMR approaches for FBDD. From (147). 
X-ray crystallography 
The major advantage of X-ray crystallography is its inherent ability to provide very detailed 
structural information about fragment hits that are complexed with the target protein. The 
need for protein crystals has some inherent disadvantages, such as the relatively high protein 
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consumption, lower throughput or high technical hurdles. The application of robotics and 
analysis software as well as the advances in X-ray technology have helped increase the 
throughput, however. In addition, the information gained from the crystals can be vital for 
developing the fragments into leads and may thus compensate the initial slowness. One can 
discriminate between co-crystallization and soaking methods. The latter, where fragments are 
soaked into pre-formed crystals, is especially suited for high-throughput applications and 
requires lower protein amounts. In contrast, co-crystallization is tolerant to large induced-fit 
changes of protein conformation that may remain hidden in pre-formed crystals (147). 
Nevertheless, conformational changes of the target protein were also observed in ligand 
soaking screens (162). 
Surface plasmon resonance 
SPR screening is particularly beneficial in terms of protein consumption and the potentially 
high information content. In one measurement, kon, koff and KD can be determined. 
Measurements at different temperatures could furthermore be used to obtain thermodynamic 
parameters. Such information is valuable in the decision-making for further development of 
the fragment hits (157). At the same time, throughput of SPR is reasonably high due to the 
existence of multiple biosensor channels or its use in microarry assay formats (156). A 
biosensor channel can additionally serve as reference cell, thus allowing the distinction of 
specific and nonspecific binding. One limitation of SPR is fragment solubility, which can 
prevent the detection of low-affinity fragments, especially for large proteins (157, 163). 
Isothermal titration calorimetry 
Owing to its low throughput, ITC is, at present, predominantly used for the thermodynamic 
evaluation of fragment-screening hits (There is a mention of the use of ITC as a "popular 
primary screening technique" in the review of Niimi et al. (147), referring to a conference 
report). The low affinity of fragments may necessitate competitive experiments for a full 
characterization (164). However, &H can also be measured for weakly-interacting fragments, 
thus allowing the incorporation of enthalpic efficiency measures into the decision making. 
For the selection of fragment hits, it can be advantageous to know whether the fragment's 
interaction is enthalpically or entropically driven, because it is generally more difficult to 
increase affinity via enthalpic interactions. Therefore, starting from a fragment with favorable 
enthalpic interactions may be preferrable (165). 
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Mass spectrometry 
Despite the advantageous features of MS, e.g. the lack of analyte labeling, the high sensitivity 
and specificity and the possibility to perform qualitative or quantitative affinity analyses 
(166), examples of MS-driven fragment screening are rare. In 2005, an "SAR by MS" 
approach was described for small molecules binding to hepatitis C virus RNA (167). Here, a 
low-affinity hit (KD > 100 "M) was identified and further improved (! KDs: 0.72-17 "M) 
with the assistance of MS. 
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1.5. Optical biosensors exploiting surface plasmon resonance 
For simplicity, the optical biosensors exploiting surface plamon resonance are below referred 
to as Biacore (BIA: biomolecular interaction analysis; Biacore is a trademark of GE 
healthcare. For the analysis of the antagonists presented in this work, a Biacore
®
 3000 system 
was used). 
1.5.1. Technology 
Surface plasmon resonance (SPR) is a phenomenon ultimately resulting from a light beam 
passing through two non-absorbing media of different refractive index. The occurrence of 
SPR leads to absorption of the incident light, while it is reflected when there is no SPR effect. 
In a Biacore instrument (cf. Figure 1-21), the first medium consists of a gold-coated glass 
chip (sensor chip), while the second medium is made up by the target structures (usually 
protein) immobilized on the sensor chip and floating in buffer. Given this setup, the 
occurrence of SPR, i.e. absorption, depends on the light's incident angle and on the refractive 
index of the second medium. The latter changes upon ligand binding to the target structures 
on the chip, whereby the strength of the effect is related on the ligands' mass. As a 
consequence, ligand binding induces a shift of the SPR angle, which can be detected and used 
for the real-time monitoring of ligand binding. The shift of SPR angle is expressed in 
resonance units (RU), 1 RU corresponding to approximately 10
-4
 °. 
 
Figure 1-21. Setup of an optical biosensor. Adapted from (168). 
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Appropriate immobilization of the target is crucial to a Biacore experiment, as the target's 
binding properties must be retained. A summary of different immobilization techniques is 
given in (168). In the present context, the capture assay, as shown in Figure 1-22, is of 
particular relevance. The target is captured in a site-specific manner by a suitable capturing 
molecule (e.g. an antibody) linked to a dextrane matrix. Here, the antibody is chemically 
linked via amine coupling, the most frequently used immobilization technique (168). 
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Figure 1-22. Schematic representation of the capture assay relevant in the present context. 
1.5.2. Kinetic evaluation 
In Figure 1-23, the course of the resonance signal during a typical Biacore experiment is 
illustrated (! sensorgram). Four phases can be distinguished: 1) An association phase 
(ligand is floated over the sensor surface, resulting in its net association to the immobilized 
target), 2) a steady state (not shown; equilibrium of ligand binding and dissociation, 3) a 
dissociation phase (the ligand supply in the buffer is stopped, leading to net ligand 
dissociation, and 4) a regeneration phase (the original state of the surface is re-established). 
The maximum equilibrium response (Req) measured during an injection cycle depends on the 
concentration of the ligand that was injected. 
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Figure 1-23. Biacore sensorgram. Adapted from (168). 
The data points of the sensorgram can be fit to a 1:1 binding model, as represented by 
Equation 1 (kon: association rate constant; koff: dissociation rate constant): 
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The KD can be directly derived from kon and koff via Equation 2, 
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or from the steady state signals at different concentrations (saturation binding plot, equation 
not shown).  
kon and koff further allow the determination of the ligand–receptor half-life time (t1/2, 
Equation 3) or the target residence time (', Equation 4). Although they are not identical by 
definition, the terms half-life time and residence time are often used interchangeably. 
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With sensorgrams recorded at different temperatures, van't Hoff thermodynamic analyses can 
be performed, giving access to interaction enthalpies and entropies (169). 
1.5.3. The relevance of binding kinetics in drug discovery 
In vivo, the ligand concentration a protein is exposed to is not constant, e.g. due to ligand 
metabolism and excretion (ligand depletion). Therefore, the sole investigation of KDs during 
in vitro compound evaluation may be oversimplified because it does not reflect in vivo 
pharmacodynamics. For example, target residence time was found to impact efficacy, 
efficacy duration, target selectivity, and even in vitro cellular assays. Taken together, the 
relevance of target residence time for the in vivo situation makes Biacore a valuable tool for 
the early selection of lead candidates with properties that are beneficial for a drug (123, 124). 
The relevance of binding kinetics for the development of E-selectin antagonists is further 
discussed in Section 2. 
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1.6. In situ click chemistry 
The fragment-screening with a TEMPO spin label allows to identify a second-site ligand with 
a minimum of structural information (160). However, the lack of structural information is a 
drawback for the design of a suitable linker connecting the fragments. This problem can be 
addressed by target-templated synthesis, where the structural information contained in the 
protein is used to guide a chemical reaction towards products having a structure 
complementary to the protein. In general, this selection process can be under thermodynamic 
or kinetic control, and the corresponding approaches are termed in situ dynamic 
combinatorial chemistry (DCC) or in situ click chemistry, respectively (170).  
In DCC, dynamic combinatorial libraries (DCLs) are generated from the reversible but 
covalent reactions between fragments carrying suitable functional groups. The addition of 
target protein to such a library may remove complementary structures from the equilibrium 
and thus favor the formation of the most active products. Huc and Lehn (171) first 
demonstrated the applicability of the DCC approach by using it for the identification of 
carbonic anhydrase inhibitors formed from aldehyde and amine fragments. Since then, the 
approach has been applied successfully in a number of applications (172, 173). However, the 
DCC approach often employs strong nucleophilic and electrophilic functional groups, which 
may question its bioorthogonality in certain cases (170).  
Also when using in situ click approaches, where the target protein (ideally (174)) selects 
complementary products by accelerating the reaction between the corresponding substrates 
(! kinetic target-guided synthesis (175); cf. Figure 1-24), the degree of bioorthogonality 
depends on the reactants used. For example, Huc and Nguyen (176) generated carbonic 
anhydrase inhibitors from a thiol and an #-chloroketone in the presence of the target. 
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Figure 1-24. Free energy diagram of a spontaneous (left) and a target-guided (right) linking reaction. 
Simultaneous binding of ligands A and B to a template reduces the activation energy (&G
‡
complex < 
&G
‡
free) of a given coupling reaction and thus increases its rate. Ideally, but not necessarily, the 
product formed in the template-assisted reaction is tightly bound to the template, and thus (&G
0
complex 
> &G
0
free). After (174). 
However, Sharpless and coworkers (177) introduced an in situ click approach devoid of these 
problems. It relies on the Huisgen 1,3-dipolar cycloaddition (178) between an alkyne and an 
azide, two functional groups unlikely to react with biomolecules under physiological 
conditions. The cycloaddition is very slow at room temperature, but can be accelerated by a 
suitable supramolecular template, e.g. a protein. The usability of the in situ click procedure 
has been demonstrated in several publications with different protein targets. In the case of 
acetylcholinesterase, inhibitors with low pico- to femtomolar KDs were discovered (177, 179, 
180), and in the case of bovine carbonic anhydrase II (181), Kolb, Tseng et al. (182) 
demonstrated the applicability of methodology in a microfluidic setup, and Heath et al. (183) 
discovered nanomolar-affinity peptide ligands of carbonic anhydrase via an iterative 
screening based on a one-bead–one-compound (OBOC) library. HIV-1 protease was targeted 
by Elder, Fokin et al. (184), who observed selective formation of a (previously known) 
nanomolar-affinity triazole antagonist. Further targets include DNA (185), chitinase (186), 
and, as a most recent example, myelin associated glycoprotein (MAG) (160). For a more 
detailed overview of these examples, the recent review by Finn et al. (187) is recommended. 
In principle, the applicability of the Huisgen 1,3-dipolar cycloaddition for target-guided 
synthesis was demonstrated already in 1983 by Mock et al. (188). They found that catalytic 
amounts of cucurbit[6]uril strongly accelerate the alkyne–azide cycloaddition and render the 
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reaction regiospecific, leading to the exclusive formation of anti isomer 27 (Figure 1-25). The 
authors concluded that simultaneous binding and encapsulation of 26 and 27 preoriented the 
alkyne and azide moieties, thereby reducing entropic costs. Additionally, the investigation of 
binding constants suggested that the simultaneous binding of the substrates induces some 
strain into the substrates, which further contributed to the rate acceleration (188, 189). 
 
Figure 1-25. A) Kinetic study of triazole formation mediated by cucurbit[6]uril; KD values: 26: 
0.65 mM, 27: 2.5 mM (188, 189); B) Cucurbit[6]uril. An ammonium cation as in 26 and 27 can 
hydrogen bond to the urea carbonyl oxygens. Sufficiently small alkyl residues can be accomodated 
within the cavity mediated by the hydrophobic effect (190). Reproduced from (191) (modified); C) 
Conjectured cross-sectional representations of the cucurbituril–substrate and –product complexes 
(outlines: van der Waals radii) illustrating the strain-induced compression of the substrates (shaded 
region). Image taken from (189). 
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1.7. Triple quadrupole mass spectrometry (QQQ-MS) 
For the analysis of the in situ click experiments (c.f. chapter 3.6), a triple quadrupole LC-MS 
equipped with an electrospry ionization (ESI) source was used. Quadrupole mass analyzers 
are particularly suitable for quantification (192) and offer the possibility to perform tandem 
mass spectrometry (MS/MS), which can be useful for the analysis of the products formed in 
an ISC experiment (! Section 3.6.1.2). Figure 1-26 shows a schematic representation of the 
triple quadrupole MS available at the Institue of Molecular Pharmacy. In the present context, 
the three quadrupoles (the second "quadrupole" is actually a hexapole) are of particular 
interest. 
 
Figure 1-26. Schematic representation of the Agilent 6410 triple quadrupole MS. 
A quadrupole is a parallell arrray of four circular or hyperbolic rods. Opposite pairs of rods 
are connected, and direct current (DC) negative potentials are applied to one, direct current 
positive potentials to the other pair. These potentials are superimosed by a radiofrequency 
(RF) potential, which is phase-shifted by 180° from one pair to the other. This setup allows to 
generate an oscillating electric field, which induces an oscillating movement in ions that are 
accelerated through the quadrupole. For a given m/z ratio, only a specific ratio of DC and RF 
voltages (! Mathieu stability diagram) leads to a stable trajectory through the quadrupole. 
Thus, by setting the quadrupole to specific DC/RF voltage ratios, a quadrupole acts as a filter 
for ions with a specific m/z ratio. In the present case, quadrupoles 1 and 3 (Q1 and Q3) act as 
such mass filters.  
Q2, on the other hand, serves as a collision cell where ions selected by Q1 are fragmented in 
a process called collision-induced dissociation (CID). The fragmentation is usually achieved 
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by introducing an inert gas such as N2 into the collision cell. Upon collisions with the gas 
molecules, the kinetic energy of the ions is converted into internal energy, which may 
eventually lead to bond cleavage. Equation 5 shows this process, in which a product or 
daughter ion md
–
 is generated from the precursor or parent ion mp
–
. Neutral fragments (mn) 
may also be formed. 
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The charged product ion is passed on to Q3, where a second m/z filtering can be applied. The 
sequential arrangement of the three quadrupoles allows for different scan modes, which can 
extract different kinds of information from the analyzed sample. For the present work, 
product ion scan and selected reaction monitoring (Figure 1-27A and Figure 1-27D) were 
used to identify suitable fragments that could be used for the monitoring of the in situ click 
experiments based on these fragments (! product ion scan, cf. Section 3.6.1.2). Figure 1-27E 
shows the selected ion monitoring (SIM) mode. Here, neither Q1 or Q2 are operational, and 
only Q3 serves as a mass filter. This allows a detection with high sensitivity and selectivity. 
 
Figure 1-27. Main scan modes in (tandem) mass spectrometry. A) product ion scan, B) 
precursor/parent ion scan, C) neutral loss scan, D) selected reaction monitoring, E) selected/single ion 
monitoring. Reproduced from (193) (modified). 
Clearly, QQQ-MS is not only defined by the nature of the mass analyzer, which was 
discussed here due its direct relevance for the different experiments that were performed. A 
more detailed discussion of other aspects, e.g. the ionization technique, is thus beyond the 
scope of this work. 
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2. Results and Discussion (paper manuscript) 
This part of the thesis is presented in the form of a paper manuscript forming a discrete part 
of the thesis. This includes compound numbering, which restarts at 1 in this section. In the 
other parts of the thesis, compounds appearing in this chapter are referred to as "P1234". 
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Abstract 
Selectins, a family of C-type lectins, play a key role in inflammatory diseases (e.g. asthma or 
arthritis). However, the millimolar affinity of sialyl Lewis
x
, which is the common 
tetrasaccharide epitope of all physiological selectin ligands, has been a major obstacle to the 
development of selectin antagonists for theraptic applications. In a fragment-based approach 
guided by NMR, ligands binding to a second binding site in close proximity to a sLe
x
 mimic 
were identified. A library of antagonists obtained by linking the sLe
x
 mimic with the best 
second-site ligand via triazole linkers of different length was evaluated by surface plasmon 
resonance. The detailed analysis of the five most promising candidates revealed antagonists 
with KD values ranging from 30 to 89 nM. In contrast to carbohydrate-lectin complexes with 
half-lifes (t1/2) generally in the second range or even below, these fragment-based selectin 
antagonists exhibit t1/2 of several minutes. They exhibit a promising starting point for the 
development of novel anti-inflammatory drugs. 
 
Introduction 
Extravasation of leukocytes from the bloodstream into surrounding tissues is a crucial step in 
inflammation. Selectins, a family of calcium-dependent lectins (E-, L-, and P-selectin), 
mediate the first step in this process, the tethering and rolling of leukocytes on the endothelial 
surface.
[1]
 This rolling is a prerequisite of the subsequent firm attachment mediated by the 
interaction of integrins with members of the IgG superfamily. In the final step, leukocytes 
extravasate and migrate to the site of inflammation. Excessive infiltration of leukocytes into 
the adjacent tissue leads, however, to its destruction as has been observed in many 
inflammatory diseases such as myocardial ischemia-reperfusion injury, asthma or rheumatoid 
arthritis. In these cases, E-selectin–mediated recruitment of leukocytes is associated with the 
etiology or progression of the disease.
[4]
 Furthermore, tumor cells that extravasate out of the 
bloodstream use the selectin pathwayto metastazise.
[3]
 Owing to their specific way of action, 
E-selectin antagonists have therefore untapped potential for the treatment of inflammatory 
and related diseases as well as cancer.
[3,4]
 A recent example is the pan-selectin antagonist 
GMI-1070,
[4a]
 which was shown to reverse acute vascular occlusions in sickle cell mice.
[5]
 It 
has successfully completed clinical phase 1 studies, and its efficacy is currently investigated 
in humans with sickle cell disease.
[6]
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Sialyl Lewis
x
 (1, sLe
x
, Figure 1) is the minimal carbohydrate epitope recognized by E-
selectin.
[7]
 Like carbohydrate–lectin interactions in general, the sLe
x
/E-selectin interaction is 
characterized by a low binding affinity (IC50 ! 1 mM
[8]
) and a short half-life (t1/2) in the range 
of seconds,
[4]
 a result of the shallow and solvent-accessible binding site of E-selectin. While 
this behavior is necessary for the selectin's physiological function,
[14]
 it is a challenge for the 
development of selectin antagonists. Although numerous contributions presenting mimetic 
structures with considerably improved affinities have been published,
[9]
 E-selectin 
antagonists with high affinities and slower dissociation rates
[16]
 are still required. 
The concept of fragment-based drug discovery (FBDD) has led to a paradigm shift in drug 
discovery.
[17]
 One of the most striking features of FBDD is the fact that potent ligands can be 
obtained from low-affinity fragments, provided they are properly linked. The observed high 
affinity can be rationalized by the additivity of intrinsic binding energies of the fragments
[22]
 
and the loss of translational and rigid-body entropy costs upon fragment linking.
[23]
 Fragment 
screens can be performed using analytical technologies that are broadly available, e.g. nuclear 
magnetic resonance (NMR), surface plasmon resonance (SPR), or isothermal titration 
calorimetry (ITC).
[17d]
 Finally, suitable linkers can be identified by various procedures, e.g. 
(i) by rational design, (ii) by an in situ click chemistry approach as described by Sharpless 
and coworkers
[28]
 or (iii) by the synthesis and biological screening of a classical ligand 
library. 
Recently, we described the fragment-based discovery of high-affinity ligands for the myelin-
associated glycoprotein (MAG), a member of the sialic acid binding immunoglobulin-like 
lectin familiy (Siglecs).
[25]
 For this purpose, a suitable fragment (second-site ligand) was 
linked via triazole formation to a known carbohydrate-mimetic (first-site ligand, KD = 134 
µM) resulting in a new ligand with a more than 700-fold improved affinity (KD = 190 nM). 
Because the challenges in the development of selectin antagonists are similar to those 
encountered with MAG (shallow, unstructured binding site),
[4]
 a similar fragment-based 
approach was applied for the improvement of existing E-selectin antagonists. 
 
Results and Discussion 
Our starting point was the sLe
x
 mimic 2, exhibiting low micromolar affinity for the 
carbohydrate recognition domain (CRD) of E-selectin (Figure 1).
[10a]
 For the identification of 
second-site ligands binding in close proximity of the sLe
x
 mimic 2, a low-molecular-weight 
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fragment library was screened by NMR. Binding was detected based on the accelerated 
transverse magnetization decay experienced by fragments bound to the target protein.
[26]
 In a 
second step, these fragments were then subjected to spin-spin relaxation NMR 
experiments,
[27]
 which allow to select those second-site hits that bind in the vicinity of the 
first-site ligand equipped with a spin label. Furthermore, the distance-dependence of the 
paramagnetic relaxation enhancement was exploited to obtain information about the relative 
orientation of the second-site ligands with respect to the first-site ligand.
[BC1]
 In the last step, 
similar to our work on MAG,
[25]
 the [3+2]-Huisgen cycloaddition
[27a]
 of azides and alkynes 
was applied for linking first-site and second-site ligands. 
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Figure 1. Sialyl Lewis
x
 (1) and the glycomimetic 2
[30b]
 which serves as first-site ligand. Via the modified 
cyclohexane moiety (! 3) a spin-label is introduced (! i). From a fragment library, second-site ligands binding 
to E-selectin are identified. With a spin-spin relaxation NMR experiment those second-site ligands binding in 
proximity of the first-site ligand i are identified. In a final step, first- and second-site ligand are linked (! ii). 
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Screening for second-site ligands. For the identification of fragments binding to E-selectin, 
NMR was used to screen a library composed of 80 water-soluble molecules obeying to the 
"Rule of Three"
[44]
 for fragment libraries (MW ! 300, clogP ! 3, number of hydrogen-bond 
donors ! 3, number of hydrogen-bond acceptors ! 3). To perform the screens, the library was 
divided into sublibraries according to two criteria. First, 6 to 8 components that do not 
interact/react with each other were pooled. Second, each component can be identified by at 
least one isolated resonance in the 
1
H NMR spectrum of the sublibrary. 
The transverse magnetization decay of a nucleus is related to local fluctuations in its 
magnetic field and therefore, through molecular diffusion, to the molecular weight of the 
molecule. Nuclei in large molecules such as proteins exhibit a fast magnetization decay 
compared to those in small molecules. Likewise, when a small molecule binds to a large 
molecule such as a protein, it becomes a large molecule on his part. As a consequence, the 
magnetization decay of a small ligand's nuclei will be accelerated. This property can be 
exploited to identify ligand binding.
[45]
 Accordingly, the rate of magnetization decay of the 
components of the sublibraries was determined by measuring the sxignal intensity of selected 
protons at different relaxation times in the absence and presence of E-selectin. With this 
approach, 5-nitroindole (4) (for an example of the experimental outcome see Figure 3a & 3b), 
benzimidazole derivative 5, 3-phenylpyrazol (6), benzothiazoxle derivative 7, and biphenyl-
4-yl-methanol (8) were identified as fragments binding to E-selectin (Figure 2). 
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Figure 2. Second-site ligands 4 - 8 identified NMR screening of fragment libraries. 
 
Synthesis of the spin-labeled first-site ligand. For the introduction of the spin label and 
later on for linking the first-site ligand with the second-site ligands, the sLe
x
 mimic 2
[30b]
 was 
equipped with a methyl ester (! 3). Docking studies and the structural information from 
crystal structure of E-selectin soaked sLe
x[13]
 suggested that the methyl ester in 3 is 
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positioned in a non-binding, sterically not restricted region, and therefore is suitable for the 
introduction of the 2,2,6,6-tetramethylpiperidin-1-oxyl (TEMPO) spin label (! 18•) as well 
as for the attachment of a second-site ligand (see below). 
For the synthesis of GlcNAc mimic 11, we started from commercial cis-1,2,3,6-
tetrahydrophthalic anhydride (9), which was transformed by literature procedures into (R)-
cyclohex-3-ene carboxylic acid (10) with an enantiomeric excess of 96.3% ee, determined by 
chiral GC.[30b] Selective "-fucosylation[37] (! 13) followed by desilylation yielded the 
glycosylacceptor 14. Its glycosylation with donor 15[43] and dimethyl(methylthio)sulfonium 
triflate (DMTST) as promoter afforded !-selectively the tetrasaccharide mimic 16. 
Hydrogenolysis of the benzyl groups with Pd(OH)2/C and saponification under Zemplén 
conditions yielded the 2-monobenzoylated antagonist 3. 
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Scheme 1. a) TBAF, THF, rt, 13 h (76%) b) DMTST, MS 4 Å, DCM, rt (80%); c) i. Pd(OH)2/C, H2, 
dioxane/H2O, ii. NaOMe, MeOH (71%); d) ethane-1,2-diamine, 65-70 °C, 2 h (93%); e) HBTU, HOBt, 4-
carboxy-TEMPO, DIPEA, DMF, rt, 1 h (48%); f) Na-L-ascorbate, MeOH, rt, 1 h (68%). 
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As direct aminolysis of ester 3 with 4-amino-TEMPO gave only trace amounts of the amide, 
a diaminoethane spacer was introduced (! 17). The amide was then coupled to 4-carboxy-
TEMPO using HBTU/HOBt for activation to afford the spin-labeled first-site ligand 18•. For 
obtaining a high resolution NMR spectra, oxyl 18•  was reduced to hydroxide 18* by adding 
Na-L-ascorbate. 
Biological evaluation. The interactions between E-selectin and the antagonists 2, 3 and 18•  
towards E-selectin/IgG were analyzed by surface plasmon resonance (Biacore) at 25 °C.[43a] 
6000-7000 RU of E-selectin/IgG - for preparation and purification see ref[61] - were 
immobilized on the chip surface via polyclonal goat anti-human Fc antibody as described in 
the experimental part. A reference cell providing only the antibody was used to compensate 
for unspecific binding to the matrix. Dilution series of the first-site ligands 2, 3 and 18•  were 
prepared from stock solutions in DMSO using HBS-P buffer and passed over the flow cells. 
Neither the introduction of the ester (antagonist 3) nor the TEMPO moiety (antagonist 18•) 
had a substantial effect on the affinity and the kinetic profile of these first-site ligands (Table 
1). 
Identification of second-site fragments binding adjacent to the first-site ligand. In the 
next step, the spin-labeled antagonist 18•  was used to identify those fragments that bind 
simultaneously and in the vicinity of the sLex-binding site. The unpaired electron of the 
TEMPO spin label dramatically enhances the rate of transverse magnetization decay of 
surrounding protons within approximately 10 Å,[46] because the gyromagnetic ratio of an 
unpaired electron is 658 times larger than the one of a proton. This phenomenon, called 
paramagnetic relaxation enhancement, is distance dependent and thus allows the 
identification of second-site ligands binding in the vicinity of the first-site ligand. As 
illustrated in Figure 3c, the addition of 18•  further reduced the signal intensity (48% 
remaining) compared to the situation with only E-selectin (Figure 3b), suggesting 
simultaneous binding and proximity of 5-nitroindole (4) and 18• . To ensure that the observed 
effect was truly a result of the spin label, we reduced the radical 18•  by adding Na-L-
ascorbate to the NMR-sample (! 18*). Indeed, this canceling of the paramagnetic effect led 
to an almost complete recovery of the signal (60% remaining, Figure 3d), indicating that 5-
nitroindole (4) is a true second-site ligand. Corresponding experiments were performed with 
the other second-site ligands 5-8. In this process, also 5 was confirmed as a second-site ligand 
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binding to E-selectin in vicinity of the first-site ligand. In contrast, for the derivatives 6-8 the 
presence of 18•  did not cause an enhancement of the paramagnetic relaxation, indicating that 
these fragments do not bind to E-selectin in the vicinity of the first-site ligand. 
 
Figure 3. Principle of screening second-site ligands. 
1
H NMR spectra of the H-4 of 5-nitroindole (4) recorded at 
spin lock times of 10 ms (red spectra) and 200 ms (green spectra) in different NMR samples: a) 5-nitroindole 
free in solution; b) decay of the transverse magnetization caused by the addition to E-selectin/IgG to the NMR 
sample; c) paramagnetic relaxation enhancement caused by the spin-labeled ligand 18•; d) recovery of the 
signal by reduction of 18•  to 18* by Na-L-ascorbate. 
 
Orientation of the second-site ligand. The distance dependency of the relaxation 
enhancement of the radical
[46]
 was further exploited to determine the orientation of the 
second-site ligand relative to the spin label, i.e. to the first-site ligand. In our case, the 
determination of the orientation was performed using the resonances of H-3, H-4 and H-7 of 
5-nitroindole (4) because they show no (H-3 and H-4) or only minimal (H-7) overlap with 
resonances of 18• . The differences in relaxation rates (indicated as ! in Figure 4) obtained in 
the presence of 18•  or 18* indicate that H-7 is located closer to the radical than H-3 and H-4. 
For the benzimidazole derivative 5, the orientation cannot be determined unambigusously 
due to the inability to quantify a relaxation rate for H-7 and the conformational flexibility of 
the hydroxypropyl side-chain. Yet, the imidazole part of the molecule appears to point 
towards the spin label. 
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Figure 4. Relative orientation of the second-site ligands relative to the spin label. The changes in relaxation 
rates (!) experienced upon addition of 18•  to a mixture of nitroindole (4) and benzimidazole 5 with E-
selectin/IgG reflect the distance of a nucleus to the unpaired electron. 
 
Synthesis of the first-site library. The synthesis of the trimethylsilyl-protected amines 
started from the corresponding commercially available alcohols 20a-c and by silylation of 
hex-5-yn-1-ol (19d) (Scheme 2). Mesylation (! 21a-d) and substitution by azide (! 22a-d) 
yielded, after reduction by a Staudinger reaction, the amines 23a-d. In contrast to the 
treatment with diaminoethane (3!12, Scheme 1), direct aminolysis of 3 with alkyne amines 
23a-d afforded the amides 25a-d only in moderate yields (2-18%). A possible reason is the 
low stability of the amines 23a-d at elevated reaction temperatures (65-130 °C), leading to 
polymerization after cleavage of the trimethylsilyl group. In addition, the electron-
withdrawing effect of the acetylene leads to a reduced nucleophilicity of the amines 23a-d. 
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Scheme 2. a) 
t
BuLi, Me3SiCl, THF, -90 to -10°C; b) MeSO2Cl, Et3N, DCM, -78 °C to rt; c) NaN3, DMF, 65 °C; 
d) PPh3, THF/H2O, 50 °C (23a: 83% over 3 steps; 23b: 80% over 3 steps; 23c: 43% over 3 steps; 23d: 62% over 
4 steps); e) NaOH, MeOH/H2O, rt (79%); f) i. HBTU (1.2 eq), HOBt (3 eq), DMF, ii. alkyne amine, rt (25a: 
35%; 25b: 70%; 25c: 40%; 25d: 44%); g) TBAF, THF, rt (26a: 80%; 26b: 93%; 26c: 98%; 26d: 87%). 
 
In an alternative route, diacid 24 was selectively activated using standard peptide coupling 
reagents HBTU and HOBt. This gave the desired amides 25a-d were obtained with excellent 
selectivity (93-99%) and fair to good yields (34-72%). Amides of the lactic acid (Lac) moiety 
are formed only in traces and could be removed by conventional HPLC-MS. The unexpected 
regioselectivity could result from different accessibilities of the two carboxylates in 24, e.g. 
due to formation of intramolecular hydrogen bonds, other steric constraints or a reduced 
reactivity of the lactic acid moiety resulting from the electron-withdrawing oxygen in the !-
position. Finally, the alkynes 26a-d were obtained after cleavage of the trimethylsilyl groups 
with tetrabutylammonium fluoride (TBAF). 
 
Synthesis of a second-site library. Of the two second-site fragments, 5-nitroindole (4) and 
the benzimidazole 5, the former offers synthetic advantages and does not contain a highly 
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flexible side chain. In addition, its relative orientation could be determined more reliably, 
which made 4 the molecule of choice for the synthesis of a second-site library. 
 
According to the orientation of 5-nitroindole (4) towards the first-site ligand (see Figure 4), 
the azidoalkyl linkers were introduced in 4 via N-alkylation (! 28a-d, Scheme 3) and, for 
proof of concept, in the 3-position as well (! 32a-d). N-alkylated 5-nitroindoles with 2-
azidoethyl , 3-azidopropyl, and 4-azidobutyl linkers were obtained by N-alkylation of 4 with 
the corresponding dibromoalkanes followed by nucleophilic substitution with sodium azide 
(! 28b-d). For the introduction of the azidomethyl linker, hemiaminal 29 was synthesized 
from 4 and formaldehyde. Azide 28a was obtained after in situ formation of the mesylate 
followed by nucleophilic substitution with sodium azide. 
 
The C-alkylated 5-nitroindole 32a was obtained via a Vilsmeier formylation of 4
[47]
 (! 30), 
followed by reduction to alcohol 31, which was directly converted to azide 32a using 
diphenylphosphoryl azide (DPPA).
[48]
 The syntheses of the nitroindoles with 3-azidoethyl (! 
32b), 3-azidopropyl (! 32c), and 3-azidobutyl (! 32d) linkers via a Larock indole 
synthesis
[49,50]
 have been previously reported.
[25]
 
Results and Discussion (paper manuscript) 
52 
H
N
NO2
27b-d
N
NO2
N3
m
N
NO2
Br
m
H
N
NO2
H
O
H
N
NO2
HO
H
N
NO2
N3
N
NO2
HO
N
NO2
N3
28b, m = 2
28c, m = 3
28d, m = 4
30 31
32a
29 28a
4
g)f)
a) or b) c)
e)
h)
H
N
NO2
mN3
32b,[25] m = 2
32c,[25] m = 3
32d,[25] m = 4
d)
[25] [25]
 
Scheme 3. a) Br(CH2)2Br or Br(CH2)3Br, KOH, DMF, rt (27b: 19%; 27c: 46%); b) Br(CH2)4Br, K2CO3, TBAB, 
EtOAc, 50 °C (27d: 46%); c) NaN3, DMF, 60 °C (28b: 52%; 28c: 82%; 28d: 79%); d) 30% aq. CH2O, K2CO3, 
EtOH, 60 °C (66%); e) i. MeSO2Cl, Et3N, THF, -15 °C to rt; ii. NaN3, rt (34%); f) POCl3, DMF, -15 °C to rt 
(90%); g) NaBH4, MeOH, rt (90%); h) DPPA, DBU, toluene/THF, -15 °C to rt, (78%). 
 
In situ click experiments. In a first attempt to identify a suitable linker to connect the first- 
and second-site ligands, a series of in situ click experiments
[25,28]
 were performed. However, 
despite careful optimization of the experimental conditions with regard to ligand and protein 
concentrations, no evidence for the preferential formation of a specific linker combination 
was found. Obviously, the present example illustrates one limitation of the in situ click 
approach. With its distinctively flat binding site, E-selectin may not be an effective 
supramolecular catalyst for the alkyne–azide cycloaddition, since even upon simultaneous 
binding of first- and second-site ligand, their azide- and acetylene-substituted linkers may not 
be sufficiently pre-organized to accelerate the cycloaddition reaction. Furthermore, the 
ligands' low affinities in the micromolar (first-site ligand) and millimolar (second-site ligand) 
range leads to a small concentration of ternary complex, thus aggravating the detection of 
catalytically formed triazoles. 
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Synthesis and ranking of triazole antagonists. As the in situ click chemistry approach did 
not lead to the identification of a suitable linker pattern, a library of triazole antagonists with 
different linker lengths between first- and second-site fragment was synthesized using the 
copper-catalyzed alkyne-azide cycloaddition (CuAAC)
[36]
 (Scheme 4). 
 
Scheme 4. a) Na-L-ascorbate, CuSO4!5 H2O, 
t
BuOH/H2O/THF, rt, 2 to 3 h (21-98%). 
 
For the ranking, surface plasmon resonance (SPR) signals were recorded at a single 
antagonist concentration (0.05 "M). Since in SPR measurements of a biomolecular 
interaction the refractive index alters proportional to the mass of the bound ligand, the 
measured intensities (corresponding to resonance units [RU]) were adjusted according to the 
molecular weight of the ligand. To eliminate intensity differences resulting from the use of 
different chips and protein batches, 46 was used as internal standard. Five of the 21 tested 
antagonists showed a distinctively strong intensity/molecular weight ratio and were therefore 
subjected to a comprehensive SPR evaluation to obtain their KD values and the on and off 
rates of binding. While the ester in 3 or the butynyl amide in 26b did not affect the binding 
parameters, the triazole-nitroindole antagonists 35, 41, 43 and 45 bound E-selectin with a 16- 
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to 48-fold higher affinity (equilibrium KDs between 89 and 30 nM) compared to 2. The order 
of affinities in the detailed analysis was the same as in the ranking procedure. In addition to 
the improved affinities, the triazole-nitroindole antagonists also exhibited substantially 
improved binding kinetics, with ligand-receptor half-lives of 4 to 5 minutes instead of the 
previsously observed half-lifes in the range of a second or even shorter (Figure 5). 
 
Table 1. Kinetic and affinity evaluation of the best-ranked triazole-nitroindole antagonists and the precursors 2, 
3, and 18• . KD,eq is obtained from a steady-state fit to a single binding site model; KD,kin was obtained from kon 
and koff using KD = koff/kon; t1/2 is obtained from koff using t1/2 = ln 2/koff. 
 
Analyte KD, eq 
[!M] 
KD, kin 
[!M] 
kon  
[10
5 
M
-1
s
-1
] 
koff  
[s
-1
] 
t1/2 
[s] 
2 1.45 1.0 8.5 0.9 0.77 
3 1.90 1.7 11 1.9 0.37 
18•  1.25 1.2 3 0.36 1.9 
26b 1.12 1.12 35.4
 
3.98 0.174 
35 0.089 0.036 0.635 0.0023 301 
41 0.057 0.037 0.68 0.0025 280 
43 0.030 0.018 1.42 0.0026 250 
45 0.049 0.035 0.797 0.0028 240 
51 0.050 - - - - 
57 0.544 - - - - 
58 0.186 0.189 0.3 0.0056 124 
 
The five antagonists that were comprehensively evaluated by SPR had rather long linkers 
containing four (35 and 41), five (51) or six (43 and 45) methylene groups, and except for 
one case (35), the "nitroindole part" of the linker contained either three or four CH2 groups. 
Four (35, 41, 43 and 45) of the five best antagonists contained an N-linked nitroindole, which 
supports the finding that the nitroindole preferentially binds with its indole nitrogen oriented 
towards the first-site ligand (see Figure 4). However, 51 represents a case where the linker 
configuration allows a favorable positioning of a C-linked nitroindole. 
Tetrasaccharide mimics such as 3 interact with E-selectin mainly via a set of well-defined 
electrostatic interactions.
[13]
 The high water accessibility of their binding site and the high 
degree of ligand pre-organization allows a fast exchange of ligand and solvent molecules, 
which may be the cause of the typical fast association and dissociation seen for these types of 
Results and Discussion (paper manuscript) 
55 
ligands.
[4]
 In contrast, the prolonged association and dissociation phases seen for the triazole–
nitroindole antagonists indicate that the binding event might be accompanied by more 
pronounced structural rearrangements of the ligand and/or the protein. 
 
Figure 5. Sensorgrams of A) the tetrasaccharide mimic 3 with the characteristic block-like shape 
indicating fast on/off rates and B) sensorgram of the best triazole-nitroindole antagonist 43. 
 
Derivatization of the nitro group. The metabolic biotransformation of nitro arenes involves 
several reactive intermediates (e.g. nitroso derivatives or hydroxyl amines) with toxic or 
mutagenic potential.
[51]
 Therefore, possible replacements for the nitro group were explored. 
Modifications leading to a decrease of the lipophilicity appeared particularly interesting. 
Accordingly, starting from 43 derivatives with a 5-aminoindole moiety (! 58) and the 
corresponding acetamide (! 57) were prepared (Scheme 5). 
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Scheme 5. a) Pt2O, H2, Boc2O, EtOH, rt (72%); b) NaN3, DMF, rt (90%); c) TFA, DCM, rt (86%); d) 
Ac2O, Et3N, DCM, rt (86%); e) 26c, Na-L-ascorbate, CuSO4!5H2O, 
t
BuOH/H2O/THF, rt (95%); f) 
Pt2O, H2, morpholine, rt (54%). 
 
The affinities of 57 and 58 are reported in Table 1. Surprisingly, the effect of the nitroindole 
modification on the affinity was quite strong. Compared to the parent compound 43, the 
affinity of amine 58 (KD = 186 nM) was reduced by a factor of 6, and for the acetamide 57 
(KD = 544 nM) even by a factor >16. The 5-position of the indole is apparently crucial for the 
binding of the second-site ligand. Although amines and amides are better hydrogen bond 
acceptors than the nitro group,
[52c]
 the orientations of their acceptor lone pairs differ, making 
beneficial interaction impossible. In addition, nitro groups may electrostatically interact with 
carbonyl groups that are oriented orthogonal or antiparallel to the plane of the nitro group.
[52]
 
Additionally, unfavorable desolvation effects may explain the reduced affinity of amine 58 
and acetamide derivative 57. 
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Conclusions 
With a previously published NMR approach, which we had successfully applied for the 
identification of Siglec-4 antagonists,
[25]
 5-nitroindole (4) and benzimidazole 5 were 
identified as small fragments binding in the vicinity of and simultaneously with a known 
selectin antagonist. For synthetic and structural reasons, the indole derivative 4 was selected 
for the further study. Since in situ click experiments
[25, 28-34]
 failed, a library of 21 triazole–
nitroindole antagonists was synthesized, and the antagonists were ranked according to their 
relative affinities using surface plasmon resonance experiments. The five most potent 
antagonists were characterized in detail using SPR, which revealed antagonists with KD 
values between 30 and 89 nM and kinetic parameters characterized by extended ligand-
protein half-lifes to the range of 4 to 5 minutes. This is a substantial improvement, since the 
half-lifes of carbohydrate-lectin interactions are generally in the range of seconds. 
As shown for antagonist 43, the nitro group of the indole moiety is substantial for binding 
and could not be replaced by an amino- (! 58) or acetamido group (! 57). In addition to the 
contribution of the second-site ligand to binding, the role of the linker is also of interest and 
may afford additional opportunities for ligand optimization. Thus, reduction of linker 
flexibility could be desirable in terms of reducing the entropy loss upon binding. 
Additionally, the present molecules have a pronounced amphiphilic nature, i.e. the 
introduction of polarity into the linker might be beneficial in terms of solubility. 
The development of high-affinity ligands of lectins in general and E-selectin in particular has 
proven to be a notoriously difficult task. E-selectin antagonists with low nanomolar affinities 
therefore constitute a substantial step forward in the search for novel anti-inflammatory drugs 
and may foster a better understanding of binding processes at non-obstructed interfaces. 
These results further illustrate the usefulness of a fragment-based approach for the 
improvement of existing ligands with relatively low affinity which have proven to be difficult 
to optimize using “conventional” approaches. 
Materials and Methods 
NMR screening: All NMR experiments were performed on a Bruker AVANCE III 500 MHz 
(Bruker BioSpin AG, Fällanden, Switzerland) equipped with Z-gradient SEI probe at 298 K. 
Each NMR sample contained 0.5 mg/mL of E-selectin/IgG, equivalent to 15 !M of binding 
site (estimated by Bradford assay). The E-selectin/IgG was prepared in d11-Tris buffer (50 
mM d11-Tris, 150 mM NaCl, 1 mM CaCl2). Shigemi NMR tubes (Sigma Aldrich GmbH, 
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Buchs, Switzerland) were used for samples containing E-selectin/IgG (sample volume: 250 
µL) and ordinary 5 mm NMR tubes were used for samples containing only ligands (sample 
volume: 500 !L). Bruker software XWINNMR 3.6 and TOPSPIN 2.1 were used as the 
interface with the spectrometer and to analyze the NMR data. MestReNova 5.2.3 was used 
for off-line analysis of the spectra. Prism 4 (GraphPad Software Inc., San Diego, USA) was 
used to fit the relaxation data. 
 
Spin-spin relaxation experiments: The E-selectin/IgG was present at 20-30 !M in binding 
site concentration as determined by Bradford assay. A 50 mM stock solution of compound in 
d6-DMSO was prepared and diluted with deutrated buffer (pH 7.4, 20 mM d11-Tris, 150 mM 
NaCl, 1 mM CaCl2 in D2O, Armar Chemicals) to a final sample concentration of 1-5 mM. 
The pulse sequence used for T1! determination was adapted from Hajduk.[45] To determine 
the T1! relaxation rate, six experiments were performed with different durations of the 
continuous-wave spin-lock applied with a field strength of 2 kHz (10, 50, 100, 150, 200, 250 
ms). Traces of non-deuterated D2O resulted in significant water signals in samples containing 
the protein. Therefore, a DPFGSE water suppression sequence was added at the end of the 
pulse sequence.
[56]
 For each experiment, eight scans were measured preceded by two dummy 
scans. The recovery delay between successive scans was set to 10 s and the fid was digitally 
sampled for 2 s. 
 
Surface plasmon resonance (SPR) analysis: Biomolecular interaction analyses by surface 
plasmon resonance (SPR) were performed on a Biacore 3000 system (GE Healthcare, 
Uppsala, Sweden). CM5 research grade sensor chips, amine coupling immobilization kit, 
maintenance supply and HPS-P buffer were purchased from GE Healthcare (Freiburg, 
Germany). HBS-P buffer (10 mM HEPES, 150 mM NaCl, 0.005% P20, pH 7.5) 
supplemented with 5% (v/v) DMSO (D8418, Sigma-Aldrich Chemie, Steinheim, Germany) 
and 20 mM CaCl2 (C3306, Sigma-Aldrich, Steinheim, Germany) was used as running buffer 
in all binding experiments. The capture assay for the immobilization of E-selectin/IgG was 
performed as follows. A polyclonal goat anti human Fc antibody (I2136, Sigma-Aldrich, 
Buchs, Switzerland) was first immobilized onto a CM5 sensor chip via the standard amine 
coupling method according to the manufacturers protocol. After the antibody immobilization, 
a solution of E-selectin/IgG (50 !g/mL, in acetate buffer 10 mM, pH 5.5) was injected at 5 
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!L/min for 20 min over a single-flow cell, designated as the active flow cell. A reference cell 
without immobilized E-selectin/IgG was prepared. Before injecting the antagonist, the 
reference and active flow cells were equilibrated for 2 h in running buffer, at 5 !L/min. For 
the evaluation of first-site ligands, serial dilutions were prepared in running buffer and 
injected using the KINJECT command with a 60 s association time and 60 s dissociation time 
at a flow rate of 20 !L/min over the reference and the active flow cell. Prior to each assay, a 
DMSO calibration was performed.
[60]
 For the ranking of the triazole antagonists, the 
association and dissociation times were increased up to 600 s. SPR signals were recorded at a 
single concentration of ligand (50 nM, in running buffer) at a flow rate of 20 !L/min, a mean 
of the signal recorded 500 to 600 s after injection (plateau) was calculated and divided by the 
molecular weight of the analyte. To eliminate intensity differences resulting from the use of 
different chip batches and surfaces, the obtained results were normalized to the response of 
an internal standard (46) injected at a concentration of 50 nM. In addition, blank injections 
were performed between each injection of ligand to prevent the presence of residual traces of 
compound in the system. Similar conditions were applied for the KD, koff, and kon 
determinations of the best antagonists, which were selected according to the data obtained by 
the ranking procedure. For each antagonist ten dilutions were measured. The data were 
processed with Scrubber 2.0a (BioLogic Software, Campbell, Australia) for equilibrium 
binding constants (KD) measurements and determination of kinetik parameters (kon, koff). KDs 
were determined using a simple steady-state affinity 1:1 binding model. Double referencing 
(subtraction of reference surface and blank injection) was applied to correct bulk effects and 
other systematic artifacts.
[57]
 
 
Acknowledgement 
We are grateful to GlycoMimetics Inc., Gaithersburg, MD, USA for financial support. The 
authors also thank Mr. Werner Kirsch, Microanalytical Services of the Departement of 
Chemistry of the University of Basel for performing the microanalyses. 
 
Results and Discussion (paper manuscript) 
60 
References 
[1] a) D. Neil Granger and G. Schmid-Schönbein, Physiology and Pathophysiology of 
Leukocyte Adhesion, Oxford University Press, New York 1995; b) G. S. Kansas, Blood 
1996, 88, 3259-3287. 
[3] S. Gout, P.-L. Tremblay, J. Huot, Clin. Exp. Methastasis 2008, 25, 335-344. 
[4] B. Ernst and J.L. Magnani, Nat. Rev. Drug Discovery 2009, 8, 661-677. 
[4a] J. L. Magnani, J. T. Patton, A. K. Sarkar, S. A. Svarovsky and B. Ernst, Preparation of 
hetero-bifunctional pseudooligosaccharides as pan-selectin inhibitors and inflammatory 
agents, J. L. Magnani, J. T. Patton, A. K. Sarkar, S. A. Svarovsky, B. Ernst, 
PTC/WO2007/028050 A1, priority date: September 2, 2005. 
[5] J. Chang, J. T. Patton, A. Sarkar, B. Ernst, J. L. Magnani and P. S. Frenette, Blood 
2010, 116, 1779-1786. 
[6] http://clinicaltrials.gov/ct2/results?term=pan-selectin 
[7] a) M. L. Phillips, E. Nudelman, F. C. A. Gaeta, M. Perez, A. K. Singhal, S. I. 
Hakomori, J. C. Paulson, Science 1990, 250, 1130-1132; b) G. Walz, A. Aruffo, W. 
Kolanus, M. Bevilacqua, B. Seed, Science 1990, 250, 1132-1135. 
[8a] a) R. M. Cooke, R. S. Hale, S. G. Lister, G. Shah, M. P. Weir, Biochemistry 1994, 33, 
10591-10596; b) L. Poppe, G. S. Brown, J. S. Philo, P. V. Nikrad, B. H. Shah, J. Am. 
Chem. Soc. 1997, 119, 1727-1736. 
[9] a) B. Ernst, H. C. Kolb, O. Schwardt in Carbohydrate Mimetics in Drug Discovery 
(Eds.: D. E. Levy, P. Fügedi), CRC Press/Taylor & Francis, Boca Raton, 2006, pp. 803-
845; b) N. Kaila, B. E. Thomas, Med. Res. Rev. 2002, 22, 566-601; c) E. E. Simanek, 
G. J. McGarvey, J. A. Jablonowski, C. H. Wong, Chem. Rev. 1998, 98, 833-862; d) H. 
C. Kolb, B. Ernst, Chem. Eur. J. 1997, 3, 1571-1578. 
[13] W. S. Somers, J. Tang, G. D. Shaw, R. T. Camphausen, Cell 2000, 103, 467-479. 
[14] a) K. Baumann, D. Kowalczyk, T. Gutjahr, M. Pieczyk, C. Jones, M. K. Wild, D. 
Vestweber, H. Kunz, Angew. Chem. Int. Ed. 2009, 48, 3174-3178; b) M. K. Wild, M. 
C. Huang, U. Schulze-Horsel, P. A. van der Merwe, D. Vestweber, J. Biol. Chem. 
2001, 276, 31602-31612. 
Results and Discussion (paper manuscript) 
61 
[16] R. A. Copeland, D. L. Pompliano, T. D. Meek, Nat. Rev. Drug Discovery 2006, 5, 730-
739. 
[17] a) A. G. Coyne, D. E. Scott and C. Abell, Curr. Opin. Chem. Biol. 2010, 14, 299-307; 
b) C. Murray and D. Rees, Nature Chemistry 2009, 1, 187-192; c) G. Chessari ,A. J. 
Woodhead, Drug Discovery Today 2009, 14, 668-675; d) M. Congreve, G. Chessari, D. 
Tisi, A. J. Woodhead, J. Med. Chem. 2008, 51, 3661-3680; e) P. J. Hajduk and J. Greer, 
Nat. Rev. Drug Discovery 2007, 6, 211-219. 
[22] W. Jencks, Proc. Nat. Acad. Sci. U.S.A. 1981, 78, 4046-4050. 
[23] a) A. V. Finkelstein and J. Janin, Protein Eng. 1989, 3, 1-3; b) C. W. Murray and M. L. 
Verdonk, J. Comput.-Aided Mol. Des. 2002, 16, 741-753. 
[25] S. Shelke, B. Cutting, X. Jiang, H. Koliwer-Brandl, D. Strasser, O. Schwardt, S. Kelm 
and B. Ernst, Angew. Chem. Int. Ed. 2010, 49, 5721-5725. 
[26] G. Otting, Curr. Opin. Struct. Biol. 1993, 3, 760-768. 
[27] W. Jahnke, L. B. Perez, C. G. Paris, A. Strauss, G. Fendrich and C. M. Nalin, J. Am. 
Chem. Soc. 2000, 122, 7394-7395. 
[27a] a) R. Huisgen, G. Szeimies and L. Moebius, Chem. Ber. 1967, 100, 2494-2507; b) R. 
Huisgen in 1,3-Dipolar Cycloaddition Chemistry, Vol. 1 (Ed.: A. Padwa), Wiley, New 
York, 1984, pp. 1-176. 
[30a] a) G. Cerichelli, C. Grande, L. Luchetti and G. Mancini, J. Org. Chem. 1991, 56, 3025-
3030; b) H. J. Gais and K. L. Lukas, Angew. Chem. Int. Ed. Engl. 1984, 23, 142-143; c) 
S. M. Roberts, Biocatalysts or Fine Chemicals Synthesis, John wiley and Sons, 
Chichester, 1999; d) D. H. R. Barton, D. Crich, W. B. Motherwell, J. Chem. Soc., 
Chem. Commun. 1983, 939-941; e) D. H. R. Barton, D. Crich, W. B. Motherwell, 
Tetrahedron Lett. 1983, 24, 4979-4982. 
[10a] D. Schwizer, J. T. Patton, B. Cutting, M. Smie!ko, B. Wagner, A. Kato, C. Weckerle, 
F. P. C. Binder, S. Rabbani, O. Schwardt, J. L. Magnani, B. Ernst, Chem. Eur. J. 2012, 
18, 1342-1351. 
[28] a) H. D. Agnew, R. D. Rohde, S. W. Millward, A. Nag, W. Yeo, J. E. Hein, S. M. 
Pitram, A. A. Tariq, V. M. Burns, R. J. Krom, V. V. Fokin, K. B. Sharpless and J. R. 
Heath, Angew. Chem. Int. Ed. 2009, 48, 4944-4948; b) T. Hirose, T. Sunazuka, A. 
Results and Discussion (paper manuscript) 
62 
Sugawara, A. Endo, K. Iguchi, T. Yamamoto, H. Ui, K. Shiomi, T. Watanabe, K. B. 
Sharpless and S. Omura, J. Antibiot. 2009, 62, 277-282; c) M. Whiting, J. Muldoon, Y. 
C. Lin, S. M. Silverman, W. Lindstrom, A. J. Olson, H. C. Kolb, M. G. Finn, K. B. 
Sharpless, J. H. Elder and V. V. Fokin, Angew. Chem. Int. Ed. 2006, 45, 1435-1439; d) 
A. Krasi!ski, Z. Radi", R. Manetsch, J. Raushel, P. Taylor, K. B. Sharpless and H. C. 
Kolb, J. Am. Chem. Soc. 2005, 127, 6686-6692, e) V. P. Mocharla, B. Colasson, L. V. 
Lee, S. Roper, K. B. Sharpless, C.-H. Wong and H. C. Kolb, Angew. Chem. Int. Ed. 
2005, 44, 116-120; f) R. Manetsch, A. Krasi!ski, Z. Radi", J. Raushel, P. Taylor, K. B. 
Sharpless and H. C. Kolb, J. Am. Chem. Soc. 2004, 126, 12809-12818; g) W. G. Lewis, 
L. G. Green, F. Grynszpan, Z. Radic, P. R. Carlier, P. Taylor, M. G. Finn and K. B. 
Sharpless, Angew. Chem. Int. Ed. 2002, 41, 1053-1057. 
[35] C. W. Tornoe, C. Christensen and M. Meldal, J. Org. Chem. 2002, 67, 3057-3064. 
[36] V. V. Rostovtsev, L. G. Green, V. V. Fokin and K. B. Sharpless, Angew. Chem. Int. Ed. 
2002, 41, 2596-2599. 
[37] S. Sato, M. Mori, Y. Ito and T. Ogawa, Carbohydr. Res. 1986, 155, C6-C10. 
[43] B. Ernst, B. Wagner, G. Baisch, A. Katopodis, T. Winkler and R. Öhrlein, Can. J. 
Chem. 2000, 78, 892-904. 
[43a] a) R. L. Rich and D. G. Myszka, Current Opinion in Biotechnology 2000, 11, 54-61; b) 
T. A. Morton and D. G. Myszka, Methods Enzymol. 1998, 295, 268-294; c) K. Nagata 
and H. Handa, Real-Time Analysis of Biomolecular Interactions: Applications of 
Biacore, Springer-Verlag, Berlin, 2000. 
[44] M. Congreve, R. Carr, C. Murray and H. Jhoti, Drug Discovery Today 2003, 8, 876-
877. 
[45] P. J. Hajduk, E. T. Olejniczak and S. W. Fesik, J. Am. Chem. Soc. 1997, 119, 12257-
12261. 
[46] I. Bertini, C. Luchinat, G. Parigi and R. Pierattelli, ChemBioChem 2005, 6, 1536-1549. 
[47] S. F. Safe in Indole-3-carbinol, diindolylmethane and substituted analogs as 
antiestrogens, Vol. WO9850357 USA, 1998, p. WO9850357. 
[48] R. J. W. Cremlyn, Aust. J. Chem. 1973, 26, 1591-1593. 
[49] R. C. Larock, E. K. Yum and M. D. Refvik, J. Org. Chem. 1998, 63, 7652-7662. 
Results and Discussion (paper manuscript) 
63 
[50] J. A. Gylys, E. H. Ruediger, D. W. Smith, C. Solomon and J. P. Yevich in Antimigraine 
cyclobutenedione derivatives of tryptamines, Vol.  USA, 1995. 
[51] A.-C. Macherey and P. M. Dansette in Chemical mechanisms of toxicity: Basic 
knowledge for designing safer drugs, Vol.  (Ed. W. C. G.), Elsevier Academic Press, 
Amsterdam, 2003, pp. 545-560. 
[52] R. Paulini, K. Müller and F. Diederich, Angew. Chem. Int. Ed. 2005, 44, 1788-1805; b) 
J. M. A. Robinson, D. Philp, K. D. M. Harris and B. M. Kariuki, New J. Chem. 2000, 
24, 799-806; c) M. H. Abraham, P. P. Duce, D. V. Prior, D. G. Barratt, J. J. Morris and 
P. J. Taylor, J. Chem. Soc., Perkin Trans. 2 1989, 1355-1375; d) T. W. Panunto, Z. 
Urbanczyk-Lipkowska, R. Johnson and M. C. Etter, J. Am. Chem. Soc. 1987, 109, 
7786-7797. 
[56] T.-L. Hwang and A.J. Shaka, J. Magn. Reson. A, 1995, 112, 275-279. 
[57] A. Frostell-Karlsson, A. Remaeus, H. Roos, K. Andersson, P. Borg, M. Hamalainen 
and R. Karlsson, J. Med. Chem. 2000, 43, 1986-1992. 
[60] S. Mesch, K. Lemme, H. Koliwer-Brandl, D. S. Strasser, O. Schwardt, S. Kelm and B. 
Ernst, Carbohydr. Res. 2010, 345, 1348-1359. 
[BC1] I. Bertini, M. Fragai, Y.-M. Lee, C. Luchinat and B. Terni, Angew. Chem. Int. Ed. 
2004, 43, 2254-2256. 
[61] a) L. Scheffler, B. Ernst, A. Katopodis, J. L. Magnani, W. T. Wang, R. Weisemann 
and T. Peters, Angew. Chem., Int. Ed. 1995, 34, 1841-1844; b) F. P. C. Binder, K. 
Lemme, R. C. Preston and B. Ernst, Angew. Chem., Int. Ed. 2012, in press. 
 
Results and Discussion (paper manuscript) 
64 
Supporting Information 
 
Nanomolar E-selectin Antagonists: A Fragment-based 
Approach 
 
Jonas Egger, Céline Weckerle, Brian Cutting, Oliver Schwardt, Katrin Lemme, Beat Ernst
*
 
 
Institute of Molecular Pharmacy, Pharmacenter, University of Basel, Klingelbergstrasse 50, 
CH-4056 Basel, Switzerland. 
 
 
 
Contents 
Synthesis 65 
HRMS data for the target compounds 108 
Compound purity 109 
HPLC data for the target compounds 109 
References 110 
 
Results and Discussion (paper manuscript) 
65 
Synthesis: 
General methods: NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) 
spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D methods 
(COSY, HSQC, TOCSY and HMBC). Chemical shifts are expressed in ppm using residual 
CHCl3, CHDCl2, CHD2OD, CHD2S(=O)CD3 and HDO as references. For complex 
molecules, the following prefixes for substructures are used: Cy (cyclohexyl), Fuc (fucose), 
Gal (galactose), Ind (indole), and Lac (lactate). Optical rotations were measured on a Perkin-
Elmer Polarimeter 341. IR spectra were recorded on a Perkin Elmer Spectrum One FT-IR 
spectrometer as KBr pellets or films on NaCl plates. Electron spray ionization mass spectra 
(ESI-MS) were obtained on a Waters micromass ZQ. The LC/HRMS analysis were carried 
out using a Agilent 1100 LC equipped with a photodiode array detector and a Micromass 
QTOF I equipped with a 4 GHz digital-time converter. Gas chromatography was carried out 
on a VARIAN 3600 or CE Intruments 8000Top using a chiral betacyclodextrine DEtTBuSil 
(SE54) column (Brechbühler). Microanalyses were performed at the Department of 
Chemistry, University of Basel, Switzerland. Reactions were monitored by TLC using glass 
plates coated with silica gel 60 F254 (Merck) and visualized by using UV light and/or by 
heating to 140°C for 5 min with aq. KMnO4 solution or a molybdate solution (a 0.02 M 
solution of ammonium cerium sulfate dihydrate and ammonium molybdate tetrahydrate in aq. 
10% H2SO4). Column chromatography was performed on a CombiFlash Companion 
(Teledyne-ISCO, Inc.) using RediSep! normal phase disposable flash columns (silica gel). 
Reversed phase chromatography was performed on LiChroprep!RP-18 (Merck, 40-63 µm). 
LC-MS separations were carried out using Sunfire C18 columns (analytical: 2.1 " 50 mm, 3.5 
!m; preparative: 19 " 150 mm, 5.0 !m) on a Waters 2525 LC, equipped with a Waters 2996 
photodiode array and a Waters micromass ZQ for detection. Hydrogenation reactions were 
performed in a shaking apparatus (Parr Instruments Company, Moline, Illinois, USA) in 250 
mL or 500 mL bottles with 4 bar H2 pressure. Solvents and phosphate buffer solutions were 
purchased from Fluka or Acros. Solvents were dried prior to use where indicated. Methanol 
(MeOH) was dried by refluxing with sodium methoxide and distilled immediately before use. 
Dichloromethane (DCM) was dried by filtration through Al2O3 (Fluka, type 5016 A basic). 
Tetrahydrofurane (THF) was dried by distillation from sodium/benzophenone. N,N-
Dimethylformamide (DMF) was dried by stirring over activated MS 4 Å overnight, followed 
by microfiltration. 
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Methyl (1R,3R,4R,5S)-4-O-(2,3,4-tris-O-benzyl-6-deoxy-!-L-galactopyranosyl)-3,4-
dihydroxy-5-methyl-cyclohexane-1-carboxylate (14). To a solution of 13 (677 mg, 0.942 
mmol) in THF (7 mL), TBAF (1 M, in THF, 3.77 mL, 3.77 mmol) was added. The reaction 
was stirred for 9 h and concentrated in vacuo. The crude product was purified by silica gel 
chromatography (petroleum ether/EtOAc) to afford 14 (533 mg, 76%) as a white solid. [!]D
20 
-43.0 (c 1.09, CHCl3); 
1H NMR (CDCl3, 500 MHz): ! = 1.11 (d, J = 6.4 Hz, 3H, Fuc-H6), 
1.15 (d, J = 6.5 Hz, 3H, Me), 1.23 (m, 1H, H-6a), 1.48 (m, 1H, H-2a), 1.59 (m, 1H, H-5), 
1.92 (m, 1H, H-6b), 2.24 (m, 1H, H-2b), 2.39 (m, 1H, H-1), 2.89 (dd, J = 8.6, 10.0 Hz, 1H, 
H-4), 3.43 (ddd, J = 4.7, 8.4, 11.5 Hz, 1H, H-3), 3.67 (s, 3H, Me), 3.70 (m, 1H, Fuc-H4), 3.96 
(dd, J = 2.7, 10.2 Hz, 1H, Fuc-H3), 4.08-4.12 (m, 2H, Fuc-H2, -H5), 4.65, 4.69, 4.67, 4.78, 
4.85, 4.99 (6 m, 6H, 3 CH2Ph), 4.97 (d, J = 3.8 Hz, 1H, Fuc-H1), 7.26-7.39 (m, 15H, 3 
C6H5); 
13C NMR (CDCl3, 125 MHz): ! = 16.61 (Fuc-C6), 18.35 (Me), 34.77 (C-2), 35.44 (C-
5), 35.84 (C-6), 40.33 (C-1), 51.77 (Me), 67.63 (Fuc-C5), 71.99 (C-3), 72.97, 73.52, 74.86 (3 
CH2Ph), 76.32 (Fuc-C2), 77.38 (Fuc-C4), 78.87 (Fuc-C3), 92.12 (C-4), 98.74 (Fuc-C1), 
127.36, 127.49, 127.63, 127.66, 127.91, 128.23, 128.27, 128.35, 128.38, 138.23, 138.35, 
138.70 (18C, 3 C6H5), 174.89 (CO); IR (KBr): " = 3424 (s, OH), 3031 (vw), 2998 (w), 2952 
(s), 2904 (s), 1737 (vs, C=O), 1497 (w), 1454 (m), 1384 (w), 1344 (s), 1305 (m), 1273 (w), 
1248 (w), 1191 (s), 1138 (s), 1157 (s), 1102 (vs), 1037  (vs), 973 (w), 957 (w), 909 (w), 823 
(vw), 802 (vw), 743 (s), 720 (w), 697 (m) cm-1; elemental analysis: calcd (%) for C36H44O8 
(604.73): C 71.50, H 7.33; found: C 71.51, H 7.36. 
 
{(1R,3R,4R,5S)-4-[(2,3,4-tris-O-benzyl-6-deoxy-!-L-galactopyranosyl)oxy]-1-
methoxycarbonyl-5-methyl-cyclohex-3-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-
benzyloxycarbonyl-2-cyclohexyl-ethyl]-"-D-galactopyranoside (16). A mixture of 
thioglycoside 15[S1] (433 mg, 0.554 mmol), 14 (258 mg, 0.427 mmol), and activated 
molecular sieves (4 Å, 2.5 g) was dissolved in anhydrous DCM (8.5 mL) under argon. A 
suspension of DMTST (331 mg, 1.28 mmol) and activated molecular sieves (4 Å, 1.3 g) in 
DCM (5 mL) was prepared in a second flask. Both suspensions were stirred at rt for 4 h, then 
the DMTST suspension was added via syringe to the other suspension with some additional 
DCM (3.5 mL). After 6 d of stirring at rt, the reaction mixture was filtered through celite. The 
filtrate was successively washed with satd aq. NaHCO3 (40 mL) and water (100 mL). The 
aqueous layers were extracted with DCM (3 ! 60 mL). The combined organic layers were 
dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by 
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silica gel chromatography (petroleum ether/Et2O) to afford 16 (450 mg, 80%) as white foam. 
[!]D
20
 -52.8 (c 1.05, CHCl3); 
1
H NMR (CDCl3, 500 MHz): ! = 0.45-2.23 (m, 18H, CyCH2, 
Cy), 1.07 (d, J = 6.4 Hz, 3H, Me), 1.43 (d, J = 6.4 Hz, 3H, Fuc-H6), 1.51 (m, 1H, H-5), 3.21 
(t, J = 9.5 Hz, 1H, H-4), 3.53-3.56 (m, 5H, H-3, Fuc-H4, Me), 3.81 (dd, J = 3.2, 9.9 Hz, 1H, 
Gal-H3), 3.91 (m, 1H, Gal-H5), 4.00-4.05 (m, 2H, Fuc-H2, Fuc-H3), 4.12 (dd, J = 4.5, 7.9 
Hz, 1H, Lac-H2), 4.24-4.28 (m, 2H, Gal-H6a, CH2Ph), 4.36 (dd, J = 5.6, 11.4 Hz, 1H, Gal-
H6b), 4.51, 4.62, 4.67, 4.74, 4.79 (5 m, 5H, 3 CH2Ph), 4.56 (d, J = 8.2 Hz, 1H, Gal-H1), 4.89 
(m, 1H, Fuc-H5), 5.04 (m, 1H, CH2Ph), 5.04 (m, 1H, Fuc-H1), 5.12 (m, 1H, CH2Ph), 5.61 
(m, 1H, Gal-H2), 5.85 (m, 1H, Gal-H4), 7.19-7.33, 7.42-7.48, 7.53-7.58, 8.04-8.12 (4 m, 
35H, 7 C6H5); 
13
C NMR (CDCl3, 125 MHz): ! = 16.77 (Fuc-C6), 18.51 (Me), 25.46, 25.71, 
26.07, 32.60, 33.19, 33.40, 35.37, 38.04, 40.21, 40.46 (11C, Cy, CH2Cy), 51.68 (Me), 62.50 
(Gal-C6), 66.38 (Fuc-C5), 66.65 (CH2Ph), 70.20 (Gal-C4), 71.60 (Gal-C5), 71.99 (Gal-C2), 
72.05, 74.39, 74.90 (3 CH2Ph), 76.18 (Fuc-C2), 78.02 (Gal-C3), 78.41 (Lac-C2), 79.23 (Fuc-
C4), 79.84 (Fuc-C3), 80.08 (C-3), 80.64 (C-4), 98.11 (Fuc-C1), 100.13 (Gal-C1), 126.91, 
127.05, 127.20, 127.45, 127.71, 128.04, 128.09, 128.12, 128,42, 128.45, 128.52, 
128.56,129.56, 129.65, 129.75, 129.93, 133.09, 133.21, 133.30, 135.40, 138.49, 138.95, 
139.15 (42C, 7 C6H5 ), 164.60, 166.08, 166.15, 172.43, 174.09 (5 CO); IR (KBr): " = 2925 
(s), 1731 (vs, C=O), 1602 (w), 1497 (w), 1452 (m), 1267 (vs), 1176 (m), 1097 (vs), 712 (s) 
cm
-1
; elemental analysis: calcd (%) for C79H86O18 (1323.53): C 71.69, H 6.55; found: C 
71.73, H 6.65. 
 
{(1R,3R,4R,5S)-4-[(!-L-fucopyranosyl)oxy]-1-methoxycarbonyl-5-methyl-cyclohex-3-yl} 
2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-"-D-galactopyranoside (3). A 
mixture of 16 (310 mg, 0.234 mmol), Pd(OH)2/C (115 mg), dioxane (4.8 mL) and water (1.4 
mL) was hydrogenated (70 psi H2) at rt. After 5 h, the mixture was filtered through a PTFE 
membrane filter and evaporated to dryness. The residue was redissolved in anhydrous MeOH 
(5.5 mL) and 0.1 M NaOMe/MeOH (370 "L) was added. After stirring at rt for 16 h the 
reaction was quenched by addition of acetic acid (35 "L). The mixture was concentrated in 
vacuo and purified by preparative HPLC to afford compound 3 (125 mg, 71%) as a white 
solid. [!]D
20
 -85.0 (c 0.57, MeOH);
1
H NMR (CD3OD, 500 MHz): ! = 0.55-0.75 (m, 4H, Cy), 
0.92 (m, 1H, Cy), 1.04-1.15 (m, 2H, H-6a, H-2a), 1.10 (d, J = 6.5 Hz, 3H, CH3), 1.21-1.36 
(m, 5H, Cy), 1.33 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.43 (ddd, J = 3.0, 9.6, 13.9 Hz, 1H, Lac-
H3a), 1.52 (ddd, J = 4.0, 10.0, 14.0 Hz, 1H, Lac-H3b), 1.60 (m, 1H, Cy), 1.64 (m, 1H, H-5), 
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1.76 (m, 1H, H-6b), 2.28 (m, 1H, H-2b), 2.40 (m, 1H, H-1), 3.10 (t, J = 9.6 Hz, 1H, H-4), 
3.56-3.58 (m, 4H, Gal-H5, Me), 3.63-3.68 (m, 2H, Gal-H3, H-3), 3.71-3.79 (m, 4H, Gal-H6, 
Fuc-H2, -H4), 3.85 (dd, J = 3.3, 10.3 Hz, 1H, Fuc-H3), 3.97 (m, 1H, Gal-H4), 4.07 (dd, J = 
3.0, 9.9 Hz, 1H, Lac-H2), 4.69 (d, J = 8.1 Hz, 1H, Gal-H1), 4.94 (d, J = 4.0 Hz, 1H, Fuc-H1), 
4.99 (m, 1H, Fuc-H5), 5.43 (dd, J = 8.2, 9.7 Hz, 1H, Gal-H2), 7.49-7.52, 7.62-7.65, 8.07-8.09 
(3 m, 5H, C6H5); 
13
C NMR (CD3OD, 125 MHz): ! = 16.72 (Fuc-C6), 19.18 (Me), 26.59, 
26.78, 27.32, 33.13, 34.23 (5C, Cy), 34.95 (C-2), 35.12 (Cy), 36.98 (C-6), 39.17 (C-5), 41.40 
(C-1), 42.80 (Lac-C3), 52.27 (Me), 62.68 (Gal-C6), 67.72 (Fuc-C5), 67.78 (Gal-C4), 70.35 
(Fuc-C2), 71.47 (Fuc-C3), 73.11 (Gal-C2), 74.00 (Fuc-C4), 75.92 (Gal-C5), 77.91 (Lac-C2), 
79.97 (C-3), 83.06 (C-4), 83.60 (Gal-C3), 100.53 (Fuc-C1), 100.76 (Gal-C1), 129.71, 130.96, 
131.60, 134.40 (6C, C6H5), 166.88 (COPh), 176.18 (COOMe), 178.81 (COOH); elemental 
analysis: calcd (%) for C37H54O16!H2O (754.82): C 57.50, H 7.30; found: C 57.53, H 7.16; 
HR-MS: m/z: calcd for C37H53O16 [M-H]
-
: 753.3339; found: 753.3331. 
 
(1R,3R,4R,5S)-N-(2-Aminoethyl)-3-[2-O-benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-
ethyl)-(!-D-galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-
cyclohexanecarboxamide (17). Ester 3 (31 mg, 41.1 !mol) was dissolved in ethane-1,2-
diamine (2.5 mL) in a bomb tube and stirred at 65 to 70°C for 2 h. The diamine was removed 
under reduced pressure, and the residue was purified by preparative HPLC-MS (H2O/MeCN 
+ 0.2% HCO2H). To increase solubility, 17 was dissolved in MeOH, 1 equivalent of aq. 
NaOH (101.75 mM, 148 !L) was added, and the solvent was removed in vacuo to yield the 
sodium salt 17B (30 mg, 93%). ["]D
20
 (17B) -77.2 (c 1.13, MeOH); 
1
H NMR (500 MHz, 
CD3OD): ! = 0.42-0.72 (m, 4H, Cy), 0.88 (m, 1H, Cy), 1.05-1.20 (m, 6H, Me, H-2a, Cy, H-
6a), 1.20-1.34 (m, 7H, 4 Cy, Fuc-H6), 1.39 (m, 1H, Lac H-3a), 1.43-1.58 (m, 2H, Lac H-3b, 
Cy), 1.62-1.73 (m, 2H, H-6, H-5), 2.17 (m, 1H, H-2b), 2.35 (m, 1H, H-1), 3.04 (t, J = 6.2 Hz, 
2H, H-2’), 3.15 (t, J = 9.5 Hz, 1H, H-4), 3.34-3.45 (m, 2H, H-1’), 3.63-3.71 (m, 2H, Gal-H5, 
Gal-H3), 3.71-3.84 (m, 5H, Gal-H6, H-3, Fuc-H, -H4), 3.89 (dd, J = 3.3, 10.4 Hz, 1H, Fuc-
H3), 3.93 (dd, J = 2.7, 10.2 Hz, 1H, Lac-H1), 3.99 (d, J = 2.6 Hz, 1H, Gal-H4), 4.75 (d, J = 
8.1 Hz, 1H, Gal-H1), 4.97 (q, J = 6.5 Hz, 1H, Fuc-H5), 5.02 (d, J = 4.0 Hz, 1H, Fuc-H1), 
5.35 (dd, J = 8.5, 9.3 Hz, 1H, Gal-H2), 7.51-7.58, 7.66-7.73, 8.03-8.10 (m, 5H, C6H5); 
13
C 
NMR (17B) (125 MHz, CD3OD/D2O 1:1): ! = 16.54 (Fuc-C6), 18.96 (Me), 26.22, 26.45, 
26.92, 32.53, 34.14, 34.88 (6C, Cy), 35.25 (C-2), 36.66 (C-6), 38.52 (C-5), 40.82 (2C, C-1', 
C-2’), 42.57 (C-1), 43.02 (Lac-C3), 62.85 (Gal-C6), 67.44, 67.69 (Fuc-C5, Gal-C4), 69.54 
Results and Discussion (paper manuscript) 
69 
(Fuc-C2), 70.68 (Lac-C2), 73.04 (Gal-C2), 73.32 (Fuc-C3), 75.61 (Gal-C3), 79.57 (C-3), 
80.11 (Fuc-C4), 82.78 (Gal-C5), 83.21 (C-4), 99.97 (Fuc-C1), 100.12 (Gal-C1), 129.75, 
130.57, 130.73, 134.86 (6C, C6H5), 168.06 (COPh), 178.13 (CONH), 183.36 (COOH); IR 
(KBr): ! = 3430 (vs, OH), 2926 (s), 2852 (w), 1725 (m, C=O), 1651 (m, C=O), 1586 (m), 
1451 (w), 1383 (w), 1272 (s), 1097 (vs), 1075 (vs), 1026 (s), 963 (vw), 801 (vw), 765 (vw), 
711 (w), 678 (vw) cm
-1
; HR-MS: m/z: calcd for C38H58N2O15 [M+H]
+
: 783.3910; found: 
783.3922. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-{2-[2,2,6,6-tetramethyl-1-
oxyl-piperidine-4-carboxamido]ethyl}cyclohexanecarboxamide (18•). HBTU (11.3 mg, 
29.8 !mol), HOBt (9.0 mg, 58.8 !mol) and 4-carboxy-TEMPO (5.8 mg, 29.1 !mol) were 
dissolved in anhydrous DMF (1 mL) in an Eppendorf tube. After shaking for 10 min, the 
solution was transferred to a flask containing amine 17 (11 mg, 0.0137 mmol), and DIPEA 
(10 !L, 58.8 !mol) was added. The solvent was removed under reduced pressure after 1 h, 
and the residue was purified by preparative HPLC-MS (H2O/MeCN + 0.2% HCO2H) giving 
the product 18•  as a reddish solid (6.3 mg, 48%). [!]D
20
 -63.5 (c 0.56, MeOH); HR-MS: m/z: 
calcd for C48H74N3O17
•
 [M+Na]
+
: 987.4910; found: 987.4920. 
 
For obtaining the NMR data, oxyl 18•  (6.3 mg, 6.53 !mol) was reduced to hydroxide 18* by 
treatment with a solution of Na-L-ascorbate (5.8 mg, 29.3 !mol) in MeOH (1 mL) at rt for 1 
h. The solvent was removed under reduced pressure, and the residue was purified by 
preparative HPLC-MS (H2O/MeCN + 0.2% HCO2H) to yield 18* (4.3 mg, 68%) as a 
colorless powder. 
1
H NMR (500 MHz, CD3OD): ! = 0.43-0.68 (m, 4H, Cy), 0.87 (m, 1H, 
Cy), 1.08 (s, 3H, Me), 1.12-1.22 (m, 3H, H-2a, H-6a, Cy), 1.22-1.39 (m, 20H, Cy, TEMPO-
CH3, Fuc-H6, Lac-H3a), 1.45 (m, 1H, Lac-H3b), 1.51-1.68 (m, 3H, Cy, H-6b, H-5), 1.78-
1.88 (m, 4H, TEMPO-H3), 2.10-2.25 (m, 2H, H-2, H-1), 2.72 (dt, J = 7.7, 15.1 Hz, 1H, 
TEMPO-H4), 3.07-3.22 (m, 5H, H-4, H-1', H-2'), 3.49-3.59 (m, 2H, Gal-H3, -H5), 3.62-3.78 
(m, 5H, H-3, Gal-H6, Fuc-H2, -H4), 3.80-3.91 (m, 3H, Fuc-H3, Gal-H4, Lac H-2), 4.66 (d, J 
= 7.8 Hz, 1H, Gal-H1), 4.91-4.97 (m, 2H, Fuc-H1, -H5), 5.41 (t, J = 8.3 Hz, 1H, Gal-H2), 
7.42-7.50, 7.54-7.61, 7.76-7.83 (m, 5H, C6H5); 
13
C NMR (125 MHz, CD3OD): ! = 16.77 
(Fuc-C6), 19.38 (Me), 20.33 (2C, TEMPO-Me), 26.59, 26.78, 27.34 (3C, Cy), 29.66 (2C, 
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TEMPO-Me), 33.19, 34.36 (2C, Cy), 35.16, 35.23 (2C, Cy, C-2), 36.15 (TEMPO-C4), 37.59 
(C-6), 39.36 (C-5), 40.14, 40.22 (C-1', C-2'), 41.57 (2C, TEMPO-C3), 43.05 (2C, C-1, Lac-
C3), 43.20 (Gal-C6), 65.05 (2C, TEMPO-C2), 67.76 (2C, Gal-C4, Fuc-C5), 70.36 (Fuc-C2), 
71.41 (Fuc-C3), 72.99 (Gal-C2), 73.92 (Fuc-C4), 76.07 (Gal-C5), 79.60 (Lac-C3), 79.70 (C-
3), 83.09 (C-4), 83.65 (Gal-C3), 100.49 (Gal-C1), 100.58 (Fuc-C1), 129.71, 130.97, 131.66, 
134.31 (6C, C6H5), 166.83 (COPh), 176.38, 177.32 (2 CONH). 
 
6-(Trimethylsilyl)-hex-5-yn-1-ol (20d). Under argon, hex-5-yn-1-ol (19d, 1.03 g, 10.5 
mmol) was dissolved in anhydrous THF (10 mL) and cooled to -90°C. 
t
BuLi (1.6 M in 
pentane; 14.4 mL, 23.1 mmol) was added over a period of 10 min, which lead to refreezing of 
the reaction mixture. Gradual warming to -10 °C over 15 min led to liquefaction, and after 2 
h of stirring, Me3SiCl (3.0 mL, 23.1 mmol) was added. After 2 h, 1 M aq. HCl (3 mL) was 
added and stirring was continued for another hour. The reaction mixture was extracted with 
Et2O (3 ! 40 mL), the combined organic layers were washed with satd aq. NaHCO3 (20 mL) 
and brine (20 mL). The dried (Na2SO4) organic phases were concentrated in vacuo to give 
20d (2.10 g) as colorless oil, which was used without further purification. 
 
3-(Trimethylsilyl)prop-2-ynyl methanesulfonate (21a). 3-(Trimethylsilyl)prop-2-yn-1-ol 
(20a, 1.56 g, 12.2 mmol) was dissolved in anhydrous DCM (37 mL) under argon. The 
solution was cooled to -78 °C, followed by addition of Et3N (3.37 mL, 24.3 mmol). MeSO2Cl 
(0.948 mL, 12.2 mmol) was added over a period of 10 min, leading to the formation of a 
white precipitate. After stirring at -78 °C for 30 min, the reaction mixture was washed with 
0.5 M aq. HCl (15 mL), satd aq. NaHCO3 (20 mL), and brine (20 mL). After extraction of the 
aqueous layers with DCM (2 ! 30 mL), the combined organic layers were dried over Na2SO4, 
and the solvent was removed in vacuo to give 21a (2.46 g) as a pale yellow liquid, which was 
used without further purification. 
 
4-(Trimethylsilyl)but-3-ynyl methanesulfonate (21b). Following the procedure for 21a, 4-
(trimethylsilyl)but-3-yn-1-ol (20b, 3.12 g, 21.9 mmol) was treated with Et3N (6.07 mL, 43.8 
mmol) and MeSO2Cl (2.05 mL, 26.3 mmol) in DCM (65 mL) for 1.5 h at -15 °C. After 
workup 21b (4.88 g) was obtained as pale yellow oil, which was used without further 
purification. 
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5-(Trimethylsilyl)pent-4-ynyl methanesulfonate (21c). Following the procedure for 21a, 5-
(trimethylsilyl)pent-4-yn-1-ol (20c, 2.29 g, 14.7 mmol) was treated with Et3N (4.07 mL, 29.4 
mmol) and MeSO2Cl (1.37 mL, 17.6 mmol) in DCM (50 mL) for 2 h at -15 °C. After workup 
21c (3.56 g) was obtained as pale yellow oil, which was used without further purification. 
 
6-(Trimethylsilyl)hex-5-ynyl methanesulfonate (21d). MeSO2Cl (0.98 mL, 12.6 mmol) 
was added to a solution of 20d (2.10 g) and Et3N (2.9 mL, 21.0 mmol) in anhydrous DCM 
(35 mL) at -15 °C. The reaction mixture was allowed to warm to rt, and after 1.5 h it was 
washed with 0.5 M aq. HCl (10 mL), satd aq. NaHCO3 (15 mL), and brine (15 mL). After 
extraction of the aqueous layers with DCM (2 ! 30 mL), the combined organic layers were 
dried over Na2SO4, and the solvent was removed in vacuo. The residue was purified by silica 
gel chromatography (petroleum ether/DCM) to afford 21d (2.26 g) as a colorless liquid. 
 
(3-Azidoprop-1-ynyl)trimethylsilane (22a). To a solution of 21a (2.46 g, 11.9 mmol) in 
anhydrous DMF (50 mL) was added NaN3 (870 mg, 13.4 mmol), and the suspension was 
heated to 65 °C with vigorous stirring for 35 min under argon. Then water (30 mL) was 
added, the suspension was filtered through a plug of celite, and the celite was washed with 
Et2O (80 mL). The water-DMF mixture was extracted with Et2O (3 ! 60 mL), and the 
organic layers were thoroughly washed with water (2 ! 40 mL) and brine (40 mL). The 
combined organic layers were dried over Na2SO4 and the solvent was removed in vacuo to 
give 22a (1.82 g) as a yellow liquid, which was used without further purification. 
 
(4-Azidobut-1-ynyl)trimethylsilane (22b). Following the procedure for 22a, mesylate 21b 
(4.88 g, 22.1 mmol) was reacted with NaN3 (1.57 g, 24.1 mmol) in DMF (55 mL) for 3 h. 
After workup 22b (3.35 g) was obtained as a yellow liquid, which was used without further 
purification. 
 
(5-Azidopent-1-ynyl)trimethylsilane (22c). Following the procedure for 22a, mesylate 21c 
(3.56 g, 15.2 mmol) was reacted with NaN3 (1.10 g, 16.9 mmol) in DMF (35 mL) for 2.5 h. 
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After workup 22c (2.62 g) was obtained as a yellow liquid, which was used without further 
purification. 
 
(5-Azidohex-1-ynyl)trimethylsilane (22d). Following the procedure for 22a, mesylate 21d 
(2.26 g, 9.10 mmol) was reacted with NaN3 (716 mg, 11.0 mmol) in DMF (20 mL) for 1 h. 
After workup 22d (1.41 g) was obtained as a yellow liquid, which was used without further 
purification. 
1
H NMR (500 MHz, CDCl3): ! = 0.12 (s, 9H, Si(CH3)3), 1.57-1.66 (m, 2H, H-3), 
1.81-1.89 (m, 2H, H-2), 2.99 (s, 3H, CH3SO2), 4.24 (t, J = 6.4 Hz, 2H, H-1); 
13
C NMR (125 
MHz, CDCl3): ! = 0.18 (Si(CH3)3), 19.32 (C-4), 24.49 (C-3), 28.22 (C-2), 37.49 (CH3SO2), 
69.59 (C-1), 85.52 (C-6), 106.19 (C-5). 
 
3-(Trimethylsilyl)-prop-2-yn-1-amine (23a). To a solution of 22a (1.82 g, 11.9 mmol) in 
THF (50 mL) and water (1 mL) was added PPh3 (3.18 g, 12.2 mmol). The solution was 
stirred at 50 °C for 2 h. After careful removal of the solvents in vacuo (! 200 mbar), the 
reaction mixture was subjected to vacuum distillation (oil bath temperature: 100 °C; approx. 
5 mbar; additional cooling trap with liquid nitrogen) to give 23a (1.29 g, 83% over 3 steps 
from 20a) as a colorless liquid. 
1
H NMR (500 MHz, CDCl3): ! = 0.11 (s, 9H, Si(CH3)3), 1.37 
(s, 2H, NH2), 3.38 (s, 2H, H-1);
 13
C NMR (125 MHz, CDCl3): ! = 0.09 (3C, Si(CH3)3), 32.51 
(C-1), 86.72 (C-2), 107.41 (C-3); IR (film): " = 3375 (s, NH2), 3295 (s, NH2), 3181 (m, NH2), 
2960 (vs), 2900 (s), 2850 (m), 2167 (vs, C"C), 1599 (w, NH2), 1409 (w), 1379 (w), 1332 (s), 
1251 (s, Si(CH3)3), 1074 (m), 998 (s), 955 (m), 908 (m), 842 (m, Si(CH3)3), 760 (m, 
Si(CH3)3), 734 (m), 699 (m), 642 (m), 584 (m) cm
-1
. 
The NMR data were in accordance with previously published values.
[S2]
 
 
4-(Trimethylsilyl)-but-3-yn-1-amine (23b). To a solution of 22b (3.35 g, 20.0 mmol) in 
THF (90 mL) and water (1.8 mL) was added PPh3 (5.76 g, 21.9 mmol). The solution was 
stirred at 50 °C for 1.5 h. After removal of the solvents in vacuo, the reaction mixture was 
subjected to vacuum distillation (oil bath temperature: 120 °C; approx. 0.1 mbar; additional 
cooling trap with liquid nitrogen) to give 23b (2.49 g, 80% over 3 steps from 20b) as a 
colorless liquid. 
1
H NMR (500 MHz, CDCl3): ! = 0.12 (s, 9H, Si(CH3)3), 1.40 (s, 2H, NH2), 
2.34 (t, 2H, H-1), 2.80 (t, 2H, H-2); 
13
C NMR (125 MHz, CDCl3): ! = 0.23 (Si(CH3)3), 25.08 
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(C-2), 41.09 (C-1), 86.29 (C-3), 105.09 (C-4); IR (film): ! = 3373 (m, NH2), 3297 (m, NH2), 
2959 (vs), 2896 (s,), 2868 (s, C-H), 2174 (vs, C!C), 1678 (m, NH2), 1621 (w), 1455 (m), 
1425 (m), 1409 (m), 1383 (m), 1355 (m), 1250 (vs, Si(CH3)3), 1179 (vw), 1157 (vw), 1119 
(vw), 1085 (w), 1034 (s), 979 (m), 908 (s), 844 (vs, Si(CH3)3), 760 (vs, Si(CH3)3), 734 (vs), 
699 (m), 639 (s), 574 (m) cm
-1
. 
The 
1
H NMR data were in accordance with previously published values.
[S3]
 
 
5-(Trimethylsilyl)-pent-4-yn-1-amine (23c). To a solution of 22c (1.30 g, 7.17 mmol) in 
THF (100 mL) and water (1 mL) was added PPh3 (2.24 g, 8.5 mmol). The solution was 
stirred at 50 °C for 4.5 h. After removal of the solvents in vacuo, the reaction mixture was 
subjected to vacuum distillation (oil bath temperature: 120 °C; approx. 0.1 mbar) to give 23c 
(973 mg, 43% over 3 steps from 20c) as colorless oil. 
1
H NMR (500 MHz, CDCl3): ! = 0.12 
(s, 9H, Si(CH3)3), 1.18 (s, 2H, NH2), 1.62 (m, 2H, H-2), 2.27 (t, J = 7.0 Hz, 2H, H-3), 2.77 (t, 
J = 6.9 Hz, 2H, H-1); 
13
C NMR (125 MHz, CDCl3): ! = 0.23 (Si(CH3)3), 17.42 (C-3), 32.42 
(C-2), 41.34 (C-1), 84.95 (C-4), 106.92 (C-5); IR (film): " = 3376 (m, NH2), 3297 (w, NH2), 
3181 (w, NH2), 2955 (vs), 2861 (vs), 2173 (vs, C!C), 1682 (w), 1602 (w, NH2), 1431 (s), 
1408 (m), 1324 (m), 1250 (vs, Si(CH3)3), 1087 (s), 1000 (m), 914 (s), 843 (vs, Si(CH3)3), 760 
(vs, Si(CH3)3), 734 (vs), 698 (s), 640 (s), 579 (w) cm
-1
. 
The spectral data were in accordance with previously published values.
[S4]
 
 
6-(Trimethylsilyl)-hex-5-yn-1-amine (23d). To a solution of 22d (1.41 g, 7.22 mmol) in 
THF (100 mL) and water (1 mL) was added PPh3 (2.27 g, 8.65 mmol). The solution was 
stirred at 50-60 °C for 4.5 h. After removal of the solvents in vacuo, the reaction mixture was 
subjected to vacuum distillation (oil bath temperature: 120 °C; approx. 0.1 mbar) to give 23d 
(1.10 g, 62% over 4 steps from 19d) as colorless oil. 
1
H NMR (500 MHz, CDCl3): ! = 0.43 
(s, 9H, Si(CH3)3), 1.39 (s, 2H, NH2), 1.82-1.87 (m, 4H, H-2, H-3), 2.53 (t, J = 6.6 Hz, 2H, H-
4), 2.98-3.03 (m, 2H, H-1); 
13
C NMR (125 MHz, CDCl3): ! = 0.06 (Si(CH3)3), 19.62 (C-4), 
25.89 (C-3), 32.87 (C-2), 41.65 (C-1), 84.89 (C-6), 107.12 (C-5); IR (film): " = 3371 (s, 
NH2), 3296 (s, NH2), 3181 (m, NH2), 2957 (vs), 2929 (vs), 2901 (vs), 2860 (vs), 2173 (vs, 
C!C), 1596 (m, NH2), 1455 (m), 1431 (m), 1408 (m), 1364 (w), 1326 (m), 1249 (vs, 
Si(CH3)3), 1051 (m), 1027 (m), 998 (w), 937 (m), 842 (vs, Si(CH3)3), 760 (vs, Si(CH3)3), 698 
(s), 639 (s), 619 (vw), 461 (s) cm
-1
. 
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(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-cyclohexanecarboxylic acid 
(24). Ester 3 (268 mg, 0.355 mmol) was dissolved in a 1 M solution of NaOH in H2O/MeOH 
(1:1, 8 mL) and stirred at rt for 3 h. The reaction was quenched by addition of 0.5 M aq. HCl 
(1.6 mL), and the solvents were removed in vacuo. The residue was purified by preparative 
HPLC-MS (H2O/MeCN + 0.2% HCO2H) yielding 24 (207 mg, 79%) as a white powder. The 
starting material was partially recovered (25 mg, 9%). [!]D
20
 -67.2 (c 0.40, MeOH); 
1
H NMR 
(500 MHz, CD3OD): ! = 0.50-0.75 (m, 4H, Cy), 0.92 (m, 1H, Cy), 1.11 (d, J = 6.4 Hz, 3H, 
Me), 1.06-1.16 (m, 2H, H-6a, H-2a), 1.33 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.19-1.38 (m, 5H, 
5Cy), 1.43 (m, 1H, Lac-H3a), 1.52 (m, 1H, Lac-H3b), 1.56-1.72 (m, 2H, Cy, H-5), 1.78 (d, J 
= 12.8 Hz, 1H, H-6), 2.29-2.40 (m, 2H, H-2, H-1), 3.11 (t, J = 9.5 Hz, 1H, H-4), 3.58 (t, J = 
5.6 Hz, 1H, Gal-H5), 3.64-3.80 (m, 6H, Gal-H3, -H6, H-3, Fuc-H2, -H4), 3.85 (dd, J = 3.0, 
10.3 Hz, 1H, Fuc-H3), 3.96 (s, 1H, Gal-H4), 4.03-4.08 (m, 1H, Lac-H2), 4.71 (d, J = 8.1 Hz, 
1H, Gal-H1), 4.95 (m, 1H, Fuc-H1), 4.99 (dd, J = 6.1, 12.6 Hz, 1H, Fuc-H5), 5.44 (t, J = 8.8 
Hz, 1H, Gal-H2), 7.46-7.52, 7.58-7.64, 8.04-8.11 (m, 5H, C6H5); 
13
C NMR (125 MHz, 
CD3OD): ! = 16.70 (Fuc-C6), 19.20 (Me), 26.53, 26.72, 27.28, 33.08, 34.17 (5 Cy), 35.05, 
35.08 (Cy, C-2), 37.10 (C-6), 39.20 (C-5), 41.38 (C-1), 42.78 (Lac-C3), 62.68 (Gal-C6), 
67.70, 67.75 (Gal-C4, Fuc-C5), 70.32 (Fuc-C2), 71.44 (Fuc-C3), 73.01 (Gal-C2), 73.97 (Fuc-
C4), 75.89 (Gal-C5), 77.91 (Lac-C2), 79.95 (C-3), 83.16 (C-4), 83.67 (Gal-C3), 100.49 (Fuc-
C1), 100.61 (Gal-C1), 129.68, 130.92, 131.53, 134.35 (6C, C6H5), 166.94 (COPh), 177.88 
(Cy-COOH), 178.89 (Lac-COOH); IR (KBr): " = 3433 (vs, OH), 2927 (s), 2854 (m) 1720 
(vs, C=O), 1638 (w), 1450 (m), 1339 (m), 1316 (m), 1272 (vs), 1207 (m), 1167 (m), 1111 
(vs), 1079 (vs), 999 (m), 967 (w), 846 (w), 806 (vw), 771 (vw) 712 (s), 677 (w), 628 (w), 559 
(w) cm
-1
; elemental analysis: calcd (%) for C36H52O16!H2O (758.80): C 56.98, H 7.14; found: 
C 57.08, H 6.97. 
 
General procedure A for the synthesis of 25a-d. Dicarboxylic acid 24 (1 eq.) and HOBt (3 
eq.) were dissolved in anhydrous DMF (approx. 0.025 M) under argon. HBTU (1.1-1.2 eq.) 
was added and the solution was stirred at rt for 5 min. An excess of alkyne amine (approx. 
10% v/v) was added, and stirring was continued until no further consumption of starting 
material was observed in MS (after 1.5 to 3 h). The solvent was removed in vacuo, and the 
residue was purified by preparative HPLC-MS (H2O/MeCN + 0.2 % HCO2H), and the 
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desired monoamide was isolated based on its retention time (tR(Cy amide) > tR(Lac amide)). The 
identity of the amide was verified by 2D HMBC NMR (coupling of linker and cyclohexyl 
protons to the amide C=O). 
 
General procedure B for the synthesis of 26a-d. To an approx. 0.03 mM solution of TMS-
protected alkyne amide 25a-d (1 eq.) in anhydrous THF, TBAF (2 eq.; 1 M solution in THF) 
was added at rt under argon. The solution was stirred for 1-2 h, and the solvent was removed 
in vacuo. The residue was purified by RP-18 chromatography (water/MeOH) or preparative 
HPLC-MS (H2O/MeCN + 0.2 % HCO2H). 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-[3-(trimethylsilyl)prop-2-
yn-1-yl]cyclohexanecarboxamide (25a). Following general procedure A, 24 (100 mg, 0.135 
mmol), HOBt (55.2 mg, 0.408 mmol), HBTU (53.6 mg, 0.141 mmol) and 23a (500 !L) were 
stirred at rt for 3 h to afford 25a (41 mg, 35%) as a white solid. The starting material 24 (28 
mg, 28%) was partially recovered. 
1
H NMR (500 MHz, CD3OD): ! = 0.15 (s, 9H, Si(CH3)3), 
0.52-0.75 (m, 4H, Cy), 0.91 (d, J = 12.6 Hz, 1H, Cy), 1.10 (d, J = 6.3 Hz, 3H, Me), 1.14-1.39 
(m, 10H, H-2a, H-6a, 5Cy, Fuc-H6), 1.43 (m, 1H, Lac-H3a), 1.51 (m, 1H, Lac-H3b), 1.55-
1.71 (m, 3H, Cy, H-6b, H-5), 2.15 (m, 1H, H-2b), 2.27 (s, 1H, H-1), 3.14 (t, J = 9.5 Hz, 1H, 
H-4), 3.57 (t, J = 5.7 Hz, 1H, Gal-H5), 3.62-3.81 (m, 6H, Gal-H3, -H6, H-3, Fuc-H2, -H4), 
3.83-3.90 (m, 2H, Fuc-H3, H-1'a), 3.92-3.99 (m, 2H, Gal-H4, H-1'b), 4.04 (dd, J = 2.7, 9.5 
Hz, 1H, Lac-H2), 4.69 (d, J = 8.0 Hz, 1H, Gal-H1), 4.94-5.00 (m, 2H, Fuc-H1, -H5), 5.43 (t, 
J = 8.8 Hz, 1H, Gal-H2), 7.48-7.54, 7.59-7.64, 8.03-8.08 (m, 5H, C6H5); 
13
C NMR (125 
MHz, CD3OD): ! = -0.07 (Si(CH3)3), 16.69 (Fuc-C6), 19.22 (Me), 26.55, 26.68, 27.24 (3 
Cy), 30.37 (C-1'), 33.12, 34.17, 35.02 (3 Cy), 35.31 (C-2), 37.25 (C-6), 39.25 (C-5), 42.73 
(Lac-C3), 42.87 (C-1), 62.71 (Gal-C6), 67.68, 67.77 (Fuc-C5, Gal-C4), 70.30 (Fuc-C2), 
71.43 (Fuc-C3), 72.99 (Gal-C2), 73.94 (Fuc-C4), 75.94 (Gal-C5), 77.99 (Lac-C2), 79.89 (C-
3), 83.02 (C-4), 83.68 (Gal-C3), 87.81 (C-3'), 100.41 (Fuc-C1), 100.54 (Gal-C1), 103.04 (C-
2'), 129.74, 130.87, 131.53, 134.34 (6C, C6H5), 166.84 (COPh), 176.41 (CONH), 178.81 
(COOH); ESI-MS: m/z: calcd for C42H63NO15Si [M-H]
-
: 848.39; found: 848.54. 
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(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-[4-(trimethylsilyl)but-3-
yn-1-yl]cyclohexanecarboxamide (25b). Following general procedure A, 24 (31.7 mg, 42.8 
!mol), HOBt (17.7 mg, 135 !mol), HBTU (19.1 mg, 50.4 !mol) and 23b (200 !L) were 
stirred at rt for 1.5 h to afford 25b (30 mg, 70%) as a white solid. The starting material 24 
(6.5 mg, 18%) was partially recovered. 
1
H NMR (500 MHz, CD3OD): ! = 0.15 (s, 9H, 
Si(CH3)3), 0.52-0.73 (m, 4H, Cy), 0.91 (d, J = 12.1 Hz, 1H, Cy), 1.11 (d, J = 6.4 Hz, 3H, 
Me), 1.14-1.38 (m, 10H, H-2a, H-6a, 5Cy, Fuc-H6), 1.42 (m, 1H, Lac-H3a), 1.47-1.71 (m, 
4H, Lac-H3b, Cy, H-6b, H-5), 2.13 (m, 1H, H-2b), 2.27 (m, 1H, H-1), 2.32-2.38 (m, 2H, H-
2'), 3.11-3.20 (m, 2H, H-4, H-1'a), 3.24 (m, 1H, H-1'b), 3.55 (t, J = 5.8 Hz, 1H, Gal-H5), 3.63 
(dd, J = 2.8, 9.7 Hz, 1H, Gal-H3), 3.66-3.81 (m, 5H, H-3, Fuc-H2, -H4, Gal-H6), 3.86 (dd, J 
= 3.2, 10.3 Hz, 1H, Fuc-H3), 3.97 (d, J = 2.1 Hz, 1H, Gal-H4), 4.05 (dd, J = 2.6, 9.7 Hz, 1H, 
Lac-H2), 4.67 (d, J = 8.1 Hz, 1H, Gal-H1), 4.97-5.02 (m, 2H, Fuc-H1, -H5), 5.44 (dd, J = 
8.5, 9.3 Hz, 1H, Gal-H2), 7.48-7.53, 7.60-7.65 (m 3H, C6H5), 7.94 (t, J = 5.8 Hz, 1H, NH), 
8.04-8.09 (m, 2H, C6H5); 
13
C NMR (125 MHz, CD3OD): ! = 0.30 (Si(CH3)3), 16.70 (Fuc-
C6), 19.26 (Me), 21.02 (C-2'), 26.53, 26.68, 27.23, 33.07, 34.14, 35.02 (6 Cy), 35.51 (C-2), 
37.33 (C-6), 39.24 (C-5), 39.29 (C-1'), 42.72 (Lac-C3), 43.11 (C-1), 62.69 (Gal-C6), 67.66, 
67.73 (Gal-C4, Fuc-C5), 70.26 (Fuc-C2), 71.38 (Fuc-C3), 72.94 (Gal-C2), 73.93 (Fuc-C4), 
75.94 (Gal-C5), 77.93 (Lac-C2), 79.86 (C-3), 82.96 (C-4), 83.62 (Gal-C3), 86.23 (C-4'), 
100.41 (Fuc-C1), 100.56 (Gal-C1), 105.35 (C-3'), 129.73, 130.87, 131.48, 134.37 (6C, C6H5), 
166.78 (COPh), 177.06 (CONH), 178.71 (COOH); ESI-MS: m/z: calcd for C43H65NO15Si 
[M-H]
-
: 862.41; found: 862.38. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-[5-(trimethylsilyl)pent-4-
yn-1-yl]cyclohexanecarboxamide (25c). Following general procedure A, 24 (120 mg, 0.159 
mmol), HOBt (67 mg, 0.496 mmol), HBTU (74 mg, 0.195 mmol) and 23c (520 !L) were 
stirred at rt for 2 h to afford 25c (57 mg, 40%) as a white solid. The starting material 24 (23 
mg, 19%) was partially recovered. [!]D
20
 -61.5 (c 0.79, MeOH); 
1
H NMR (500 MHz, 
CD3OD): ! = 0.13 (s, 9H, Si(CH3)3), 0.57 (m, 1H, Cy), 0.62-0.73 (m, 3H, Cy), 0.91 (m, 1H, 
Cy), 1.11 (d, J = 6.5 Hz, 3H, Me), 1.15-1.38 (m, 10H, H-2a, H-6a, 5 Cy, Fuc-H6), 1.41 (m, 
1H, Lac-H3a), 1.51 (m, 1H, Lac-H3b), 1.55-1.69 (m, 6H, Cy, H-6b, H-5, H-2'), 2.12 (d, J = 
11.1 Hz, 1H, H-2), 2.19-2.25 (m, 3H, H-3', H-1), 3.10-3.24 (m, 3H, H-1', H-4), 3.56 (t, J = 
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5.7 Hz, 1H, Gal-H5), 3.62 (dd, J = 2.9, 9.7 Hz, 1H, Gal-H3), 3.65-3.81 (m, 5H, H-3, Fuc-H2, 
-H4, Gal-H6), 3.87 (dd, J = 3.3, 10.3 Hz, 1H, Fuc-H3), 3.93-3.98 (m, 2H, Lac-H2, Gal-H4), 
4.68 (d, J = 8.1 Hz, 1H, Gal-H1), 4.95-5.02 (m, 2H, Fuc-H1, -H5), 5.43 (dd, J = 8.3, 9.4 Hz, 
1H, Gal-H2), 7.48-7.53, 7.59-7.64 (m, 3H, C6H5), 7.77 (t, J = 5.6 Hz, 1H, NH), 8.04-8.08 (m, 
2H, C6H5); 
13
C NMR (125 MHz, CD3OD): ! = 0.23 (Si(CH3)3), 16.72 (Fuc-C6), 18.03 (C-2'), 
19.22 (Me), 26.56, 26.70, 27.26 (3 Cy), 29.64 (C-3'), 33.09, 34.15, 35.06 (4C, 3 Cy, C-2), 
37.35 (C-6), 39.33 (C-5), 39.43 (C-1'), 42.76 (Lac-C3), 43.34 (C-1), 62.70 (Gal-C6), 67.69, 
67.72 (Gal-H4, Fuc-H5), 70.28 (Fuc-C2), 71.40 (Fuc-C3), 72.96 (Gal-C2), 73.97 (Fuc-C4), 
75.93 (Gal-C5), 77.77 (Lac-C2), 79.90 (C-3), 83.01 (C-4), 83.67 (Gal-C3), 85.42 (C-5'), 
100.49 (Fuc-C1), 100.56 (Gal-C1), 107.62 (C-4'), 129.79, 130.87, 131.56, 134.41 (6C, C6H5), 
166.77 (COPh), 177.12 (CONH), 178.75 (COOH); IR (KBr): ! = 3430 (vs, OH), 2927 (s), 
2854 (m), 2175 (vw), 1726 (s, C=O), 1650 (m, C=O), 1542 (vw), 1535 (vw), 1450 (w), 1369 
(w), 1338 (w), 1315 (w), 1271 (s), 1250 (m), 1166 (w), 1140 (vs), 1079 (vs) 1036 (s), 1001 
(w), 969 (vw), 844 (m, Si(CH3)3), 760 (vw), 709 (w) cm
-1
; ESI-MS: calcd for C44H67NO15Si 
[M-H]
-
: 876.42; found: 862.63. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-[6-(trimethylsilyl)hex-5-
yn-1-yl]cyclohexanecarboxamide (25d). Following general procedure A, 24 (47 mg, 63.4 
"mol), HOBt (26 mg, 192 "mol), HBTU (29 mg, 76.5 "mol) and 23d (200 "L) were stirred 
at rt for 2 h to afford 25d (25 mg, 44%) as a white solid. The starting material 24 (5.5 mg, 
12%) was partially recovered. 
1
H NMR (500 MHz, CD3OD): ! = 0.12 (s, 9H, Si(CH3)3), 
0.51-0.75 (m, 4H, Cy), 0.91 (m, 1H, Cy), 1.11 (d, J = 6.4 Hz, 3H, Me), 1.15-1.28 (m, 3H, H-
6a, H-2a, Cy), 1.27-1.38 (m, 7H, Fuc-H6, 4 Cy), 1.42 (m, 1H, Lac-H3a), 1.45-1.62 (m, 7H, 
Lac-H3b, H-3', H-2', H-6b, 3 Cy), 1.67 (m, 1H, H-5), 2.11 (m, 1H, H-2b), 2.21-2.28 (m, 3H, 
H-4', H-1), 3.08-3.12 (m, 2H, H-1'), 3.15 (t, J = 9.6 Hz, 1H, H-4), 3.56 (t, J = 5.9 Hz, 1H, 
Gal-H5), 3.65 (dd, J = 2.7, 9.8 Hz, 1H, Gal-H3), 3.67-3.81 (m, 5H, H-3, Fuc-H2, Gal-H6), 
3.86 (dd, J = 3.2, 10.3 Hz, 1H, Fuc-H3), 3.96 (d, J = 2.3 Hz, 1H, Gal-H4), 4.06 (dd, J = 2.7, 
9.7 Hz, 1H, Lac-H2), 4.69 (d, J = 8.0 Hz, 1H, Gal-H1), 4.95-5.01 (m, 2H, Fuc-H1, -H5), 5.43 
(t, J = 8.9 Hz, 1H, Gal-H2), 7.48-7.53, 7.60-7.65 (m, 3H, C6H5), 7.77 (t, J = 5.6 Hz, 1H, NH), 
8.05-8.08 (m, 2H, C6H5); 
13
C NMR (125 MHz, CD3OD): ! = 0.28 (Si(CH3)3), 16.71 (Fuc-
C6), 19.25 (Me), 20.07 (C-4'), 26.53, 26.68 (2 Cy), 26.96 (C-3'), 27.24 (Cy), 29.54 (C-2'), 
33.11, 34.15, 35.02 (3 Cy), 35.36 (C-2), 37.51 (C-6), 39.33 (C-5), 39.70 (C-1'), 42.72 (Lac-
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C3), 43.31 (C-1), 62.71 (Gal-C6), 67.69 (Gal-C4), 67.74 (Fuc-C5), 70.27 (Fuc-C2), 71.39 
(Fuc-C3), 72.99 (Gal-C2), 73.95 (Fuc-C4), 75.92 (Gal-C5), 77.85 (Lac-C2), 79.84 (C-3), 
83.00 (C-4), 83.63 (Gal-C3), 85.22 (C-6'), 100.44 (Fuc-C1), 100.52 (Gal-C1), 108.17 (C-5'), 
129.76, 130.85, 131.53, 134.40 (6C, C6H5), 166.78 (COPh), 176.96 (CONH), 178.72 
(COOH). 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(prop-2-yn-1-
yl)cyclohexanecarboxamide (26a). Following general procedure B, 25a (49 mg, 57.6 !mol) 
was reacted with TBAF (115 !L, 115 !mol) in THF (2 mL) to give 26a (36 mg, 80%) as a 
white solid. [!]D
20
 -67.5 (c 1.60, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.52-0.75 (m, 
4H, Cy), 0.91 (m, 1H, Cy), 1.11 (d, J = 6.4 Hz, 3H, Me), 1.14-1.27 (m, 6H, 4 Cy, H-6a, H-
2a), 1.27-1.38 (m, 4H, 4 Cy), 1.34 (d, J = 6.5 Hz, 3H, Fuc-H6a), 1.42 (m, 1H, Lac-H3a), 1.51 
(m, 1H, Lac-H3b), 1.54-1.71 (m, 3H, H-6b, Cy, H-5), 2.15 (m, 1H, H-2b), 2.27 (m, 1H, H-1), 
2.59 (t, J = 2.3 Hz, 1H, H-3'), 3.14 (t, J = 9.5 Hz, 1H, H-4), 3.57 (t, J = 5.9 Hz, Gal-H5), 3.65 
(dd, J = 2.9, 9.8 Hz, 1H, Gal-H3), 3.67-3.92 (m, 8H, H-3, Fuc-H3, -H4, Gal-H6, H-1'), 3.96 
(d, J = 2.2 Hz, 1H, Gal-H4), 4.05 (dd, J = 2.7, 9.6 Hz, 1H, Lac-H2), 4.69 (d, J = 8.0 Hz, 1H, 
Gal-H1), 4.96-5.00 (m, 2H, Fuc-H1, -H5), 5.42-5.45 (m, 1H, Gal-H2), 7.50 (t, J = 7.7 Hz, 
2H, C6H5), 7.62 (t, J = 7.4 Hz, 1H, C6H5), 8.06 (d, J = 7.4 Hz, 2H, C6H5); 
13
C NMR (125 
MHz, CD3OD): ! = 16.70 (Fuc-C6), 19.22 (Me), 26.51, 26.68, 27.25 (3 Cy), 29.39 (C-1'), 
33.12, 34.17, 35.02 (3 Cy), 35.25 (C-2), 37.25 (C-6), 39.26 (C-5), 42.72 (Lac-C3), 42.93 (C-
1), 62.72 (Gal-C6), 67.69, 67.78 (Fuc-C5, Gal-C4), 70.31 (Fuc-C2), 71.42 (Fuc-C3), 72.17 
(C-3'), 72.98 (Gal-C2), 73.95 (Fuc-C4), 75.94 (Gal-C5), 77.96 (Lac-C2), 79.86 (C-3), 80.67 
(C-2'), 83.00 (C-4), 83.65 (Gal-C3), 100.42 (Fuc-C1), 100.55 (Gal-C1), 129.74, 130.86, 
131.51, 134.38 (6C, C6H5), 166.85 (COPh), 176.52 (CONH), 178.75 (COOH); IR (KBr): " = 
3436 (vs, OH), 3308 (s, C"C), 2927 (s), 2851 (m), 1727 (s, C=O), 1651 (m, C=O), 1534 (w), 
1450 (m), 1341 (m), 1314 (m), 1270 (s), 1160 (m), 1111 (vs), 1079 (vs), 1030 (s), 966 (w), 
773 (w), 712 (m), 674 (w), 631 (w) cm
-1
; HR-MS: m/z: calcd for C39H55NO15 [M+Na]
+
: 
800.3464; found: 800.3465. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-N-(but-3-yn-1-yl)-4-[("-L-fucopyranosyl)oxy]-5-methyl- 
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cyclohexanecarboxamide (26b). Following general procedure B, 25b (80 mg, 92.5 !mol) 
was reacted with TBAF (185 !L, 185 !mol) in THF (3.5 mL) to give 26b (68 mg, 93%) as a 
white solid. [!]D
20
 -72.8 (c 1.15, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.53-0.76 (m, 
4H, 4 Cy), 0.91 (m, 1H, Cy), 1.11 (d, J = 6.3 Hz, 3H, Me), 1.14-1.27 (m, 3 H, Cy, H-6a, H-
2a), 1.27-1.38 (m, 4H, 4 Cy), 1.34 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.42 (m, 1H, Lac-H3a), 1.50 
(m, 1H, Lac-H3b), 1.54-1.73 (m, 3H, H-6b, Cy, H-5), 2.13 (d, J = 11.8 Hz, 1H, H-2b), 2.21-
2.32 (m, 4H, H-1, H-2', H-4'), 3.15 (t, J = 9.5 Hz, 1H, H-4), 3.18-3.27 (m, 2H, H-1'), 3.57 (m, 
1H, Gal-H5), 3.63-3.82 (m, 6H, Gal-H3, -H6, H-3, Fuc-H2, -H4), 3.87 (dd, J = 3.1, 10.3 Hz, 
1H, Fuc-H3), 3.96 (d, J = 1.8 Hz, 1H, Gal-H4), 4.05 (dd, J = 2.7, 9.6 Hz, 1H, Lac-H1), 4.68 
(d, J = 8.0 Hz, 1H, Gal-H1), 4.94-5.92 (m, 2H, Fuc-H1, -H5), 5.41-5.45 (m, 1H, Gal-H2), 
7.48-7.51, 7.61-7.64, 8.06-8.07 (m, 5H, C6H5); 
13
C NMR (125 MHz, CD3OD): ! = 16.69 
(Fuc-C6), 19.25 (Me), 19.77 (C2'), 26.50, 26.67, 27.24, 33.13, 34.16, 35.00 (6 Cy), 35.44 (C-
2), 37.36 (C-6), 39.27 (C-5), 39.33 (C-1'), 42.71 (Lac-C3), 43.18 (C-1), 62.72 (Gal-C6), 
67.68, 67.77 (Fuc-C5, Gal-C4), 70.31 (Fuc-C2), 70.78 (C-4'), 71.41 (Fuc-C3), 72.99 (Gal-
C2), 73.94 (Fuc-C4), 75.93 (Gal-C5), 77.96 (Lac-C2), 79.87 (C-3), 82.22 (C-3'), 82.98 (C-4), 
83.61 (Gal-C3), 100.40 (Fuc-C1), 100.56 (Gal-C1), 129.71, 130.86, 131.52, 134.36 (6C, 
C6H5), 166.79 (COPh), 177.12 (CONH), 178.74 (COOH); IR (KBr): " = 3435 (s), 3311(s, 
C"C), 2927 (s), 2853 (m), 2115 (vw), 1727 (s, C=O), 1648 (m, C=O), 1544 (w), 1450 (m), 
1364 (m), 1340 (m), 1315 (m), 1270 (s), 1221 (m), 1166 (m), 1111 (vs), 1073 (vs), 1031 (s), 
999 (m), 966 (m), 901 (vw), 867 (vw), 806 (vw), 770 (w), 712 (m), 675 (w), 632 (w) cm
-1
; 
HR-MS: m/z: calcd for C40H57NO15 [M+Na]
+
: 814.3620; found: 814.3620. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(pent-4-yn-1-
yl)cyclohexanecarboxamide (26c). Following general procedure B, 25c (77 mg, 87.7 !mol) 
was reacted with TBAF (175 !L, 175 !mol) in THF (3.5 mL) to give 26c (69 mg, 98%) as a 
white solid. [!]D
20
 -66.4 (c 2.07, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.56 (m, 1H, 
Cy), 0.61-0.75 (m, 3H, 3 Cy), 0.92 (m, 1H, Cy), 1.11 (d, J = 6.5 Hz, 3H, Me), 1.15-1.26 (m, 
3H, Cy, H-6a, H-2a), 1.27-1.38 (m, 4H, 4 Cy), 1.34 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.44 (m, 
1H, Lac-H3a), 1.51 (m, 1H, Lac-H3b), 1.55-1.61 (m, 2H, Cy, H-6b), 1.61-1.71 (m, 3H, H-2', 
H-5), 2.12 (m, 1H, H-2b), 2.18 (td, J = 2.6, 7.2 Hz, 2H, H-3'), 2.24 (m, 1H, H-1), 2.29 (t, J = 
2.6 Hz, 1H, H-5'), 3.14 (t, J = 7.6 Hz, 1H, H-4), 3.14-3.24 (m, 2H, H-1'), 3.57 (m, 1H, Gal-
H5), 3.64-3.80 (m, 6H, Gal-H3, -H6, H-3, Fuc-H2, -H4), 3.86 (dd, J = 3.2, 10.3 Hz, 1H, Fuc-
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H3), 3.96 (d, J = 2.3 Hz, 1H, Gal-H4), 4.04 (dd, J = 2.6, 9.8 Hz, 1H, Lac-H2), 4.69 (d, J = 8.0 
Hz, 1H, Gal-H1), 4.96 (d, J = 4.0 Hz, 1H, Fuc-H1), 5.00 (m, 1H, Fuc-H5), 5.43 (dd, J = 8.6, 
9.2 Hz, 1H, Gal-H2), 7.50 (t, J = 7.7 Hz, 2H, C6H5), 7.62 (t, J = 7.4 Hz, 1H, C6H5) 7.80 (t, J 
= 5.6 Hz, 1H, NH), 8.05-8.07 (m, 2H, C6H5); 
13
C NMR (125 MHz, CD3OD): ! = 16.66, 
16.71 (C-3', Fuc-C6), 19.23 (Me), 26.53, 26.70, 27.27 (3 Cy), 29.48 (C-2'), 33.11, 34.17 (2 
Cy), 35.06, 35.47 (Cy, C-2), 37.39 (C-6), 39.31, 39.39 (C-1', C-5), 42.79 (Lac-C3), 43.31 (C-
1), 62.75 (Gal-C6), 67.70, 67.74 (Gal-C4, Fuc-C5), 70.10, 70.29 (Fuc-C2, C-5'), 71.40 (Fuc-
C3), 72.99 (Gal-C2), 73.96 (Fuc-C4), 75.95 (Gal-C5), 78.01 (Lac-C2), 79.89 (C-3), 83.00 (C-
4), 83.65 (Gal-C3), 84.23 (C-4'), 100.46 (Fuc-C1), 100.57 (Gal-C1), 129.76, 130.85, 131.54, 
134.42 (6C, C6H5), 166.8 (COPh), 177.10 (CONH), 179.01 (COOH); IR (KBr): " = 3443 (vs, 
OH), 2928 (s, C!C), 2115 (vw), 1726 (s, C=O), 1648 (m, C=O), 1544 (w), 1450 (m), 1270 
(s), 1166 (m), 1111 (s), 1078 (vs), 1031 (s), 966 (s), 712 (m) cm
-1
; HR-MS: m/z: calcd for 
C41H59NO15 [M+Na]
+
: 828.3777; found: 828.3776. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-N-(hex-5-yn-1-yl)-5-methyl- 
cyclohexanecarboxamide (26d). Following general procedure B, 25d (25 mg, 28.0 "mol) 
was reacted with TBAF (84 "L, 84 "mol) in THF (1 mL) to give 26d (20 mg, 87%) as a 
white solid. 
1
H NMR (500 MHz, CD3OD): ! = 0.51-0.75 (m, 4H, 4 Cy), 0.92 (m, 1H, Cy), 
1.11 (d, J = 6.4 Hz, 3H, Me), 1.16-1.27 (m, 3H, H-6a, H-2a, Cy), 1.27-1.38 (m, 7H, Fuc-H6, 
4 Cy), 1.42 (m, 1H, Lac-H3a), 1.46-1.62 (m, 7H, Lac-H3b, H-3', H-2', H-6b, Cy), 1.67 (m, 
1H, H-5), 2.12 (m, 1H, H-2b), 2.16-2.30 (m, 4H, H-4', H-6', H-1), 3.05-3.13 (m, 2H, H-1'), 
3.15 (t, J = 9.5 Hz, 1H, H-4), 3.57 (t, J = 5.8 Hz, 1H, Gal-H5), 3.63-3.82 (m, 6H, H-3, Gal-
H3, -H6, Fuc-H2, -H4), 3.87 (dd, J = 2.9, 10.3 Hz, 1H, Fuc-H3), 3.96 (m, 1H, Gal-H4), 4.05 
(m, 1H, Lac-H2), 4.69 (d, J = 8.0 Hz, 1H, Gal-H1), 4.95-5.03 (m, 2H, Fuc-H1, -H5), 5.44 (t, 
J = 8.9 Hz, 1H, Gal-H2), 7.47-7.53, 7.60-7.65, 8.04-8.09 (m, 5H, C6H5);
 13
C NMR (125 
MHz, CD3OD): ! = 16.71 (Fuc-C6), 18.70 (C-4'), 19.25 (Me), 26.52, 26.68 (2 Cy), 26.90 
(C3'), 27.25 (Cy), 29.46 (C-2'), 33.12, 34.16, 35.04 (3 Cy), 35.36 (C-2), 37.50 (C-6), 39.33 
(C-5), 39.68 (C-1'), 42.77 (Lac-C3), 43.32 (C-1), 62.74 (Gal-C6), 67.69 (Gal-C4), 67.75 
(Fuc-C5), 69.85 (C-6'), 70.29 (Fuc-C2), 71.40 (Fuc-C3), 72.98 (Gal-C2), 73.94 (Fuc-C4), 
75.94 (Gal-C5), 78.02 (Lac-C2), 79.83 (C-3), 83.00 (C-4), 83.64 (Gal-C3), 84.70 (C-5'), 
100.42 (Fuc-C1), 100.51 (Gal-C1), 129.73, 130.85, 131.54, 134.38 (6C, C6H5), 166.79 
(COPh), 176.96 (CONH), 178.99 (COOH); IR (KBr): " = 3436 (s, OH), 2928 (s, C!C), 2868 
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(m), 1731 (s, C=O), 1653 (m), 1550 (w), 1451 (m), 1350 (w), 1298 (m), 1270 (s), 1114 (vs), 
1078 (vs), 1034 (s), 996 (w), 966 (w), 712 (m) cm
-1
; HR-MS: m/z: calcd for C42H61NO15 
[M+Na]
+
: 842.3933; found: 842.3919. 
 
1-(2-Bromoethyl)-5-nitro-1H-indole (27b). 5-Nitro-1H-indole (4, 1.00 g, 6.17 mmol) was 
added to powdered KOH (431 mg, 7.68 mmol) dissolved in DMF (40 mL) at rt. Then, 1,2-
dibromoethane (1.55 mL, 18.5 mmol) was added, and the solution was stirred for 25 h. Water 
(100 mL) was added and the reaction mixture was extracted with Et2O (3 ! 100 mL). The 
organic phases were washed with 0.5 M aq. HCl, satd aq. NaHCO3 and brine (60 mL). The 
organic layer was dried over Na2SO4, and the solvent was removed under reduced pressure. 
Silica gel chromatography (petroleum ether/EtOAc) afforded 27b (198 mg, 19%) as a yellow 
solid. Approximately 600 mg of the starting material 4 was recovered. 
1
H NMR (500 MHz, 
CDCl3): ! = 3.68 (t, J = 6.6 Hz, 2H, H-1'), 4.59 (t, J = 6.6 Hz, 2H, H-2'), 6.73 (m, 1H, H-3), 
7.31 (m, 1H, H-2), 7.38 (m, 1H, H-7), 8.15 (m, 1H, H-6), 8.62 (m, 1H, H-4). 
 
1-(3-Bromopropyl)-5-nitro-1H-indole (27c). 5-Nitro-1H-indole (4, 2.01 g, 12.3 mmol) was 
added to powdered KOH (0.692 g, 12.3 mmol) dissolved in DMF (100 mL) at rt, leading to a 
read solution. Then, 1,3-dibromopropane (3.77 mL, 37.0 mmol) was added, accompanied by 
a color change to yellow. After 40 min, additional dibromopropane (0.5 mL, 4.90 mmol) was 
added, whereupon some precipitation occurred. The reaction mixture was stirred for 17 h at 
rt, then water (200 mL) was added and the suspension was extracted with Et2O (3 ! 200 mL). 
The organic phases were washed with 0.5 M aq. HCl, satd aq. NaHCO3 and brine (100 mL). 
The organic layers were dried over Na2SO4, and the solvent was removed under reduced 
pressure. Silica gel chromatography (petroleum ether/EtOAc) afforded 27c (1.59 g, 46%) as 
yellow crystals. The starting material 4 (565 mg, 28%) was partially recovered. 
1
H NMR 
(500 MHz, CDCl3): ! = 2.33-2.44 (m, 2H, H-2'), 3.28-3.35 (m, 2H, H-3'), 4.40 (t, J = 6.5 Hz, 
2H, H-1'), 6.78 (d, J = 3.1 Hz, 1H, H-3), 7.67 (d, J = 3.2 Hz, 1H, H-2), 7.71 (d, J = 9.1 Hz, 
1H, H-7), 8.04 (dd, J = 2.3, 9.1 Hz, 1H, H-6), 8.58 (d, J = 2.2 Hz, 1H, H-4); 
13
C NMR (125 
MHz, CDCl3): ! = 30.05 (C-3’), 32.70 (C-2’), 44.53 (C-1’), 104.54 (C-3), 109.33 (C-7), 
117.52 (C-6), 118.42 (C-4), 127.92 (C-9), 131.22 (C-2), 138.84 (C-8), 141.79 (C-5); IR 
(KBr): " = 1606 (vw), 1577 (vw), 1511 (s, NO2), 1480 (m), 1459 (m), 1431 (vw), 1404 (w), 
1331 (vs, NO2), 1296 (s), 1253 (m), 1226 (m), 1183 (w), 1157 (w), 1068 (m), 975 (vw), 934 
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(vw), 902 (w), 816 (w), 768 (w), 749 (s) cm
-1
. 
 
1-(4-Bromobutyl)-5-nitro-1H-indole (27d). To a solution of 5-nitro-1H-indole (4, 2.00 g, 
12.3 mmol) in anhydrous EtOAc (20 mL) were added K2CO3 (3.39 g, 24.5 mmol) and TBAB 
(4.76 g, 14.8 mmol). The suspension was stirred at 50 °C for 30 min followed by the addition 
of 1,4-dibromobutane (1.74 mL, 14.8 mmol). Stirring was continued under reflux for 21 h. 
Then, water (20 mL) was added to the reaction mixture, the phases were separated, and the 
aqueous phase was extracted with EtOAc (2 ! 40 mL). The organic layers were washed with 
0.5 M aq. HCl, satd aq. NaHCO3 and brine (20 mL), dried over Na2SO4 and concentrated. 
The residue was purified by silica gel chromatography (petroleum ether/EtOAc) to yield 27d 
(1.67 g, 46%) as a yellow solid. 
1
H NMR (500 MHz, CDCl3): ! = 1.83-1.90 (m, 2H, H-2'), 
2.02-2.09 (m, 2H, H-3'), 3.40 (t, J = 6.4 Hz, 2H, H-4'), 4.22 (t, J = 7.0 Hz, 2H, H-1'), 6.70 (m, 
1H, H-3), 7.25 (m, 1H, H-2), 7.36 (m, 1H, H-7), 8.13 (m, 1H, H-6), 8.60 (m, 1H, H-4). 
 
1-(2-Azidoethyl)-5-nitro-1H-indole (28b). NaN3 (69.6 mg, 1.07 mmol) was added to a 
solution of 27b (198 mg, 0.736 mmol) in DMF (2 mL), and the resulting suspension was 
stirred at 60 °C. After 12 h water (10 mL) was added and the reaction mixture was extracted 
with EtOAc (3 ! 20 mL). The organic layers were washed with water and brine (10 mL) and 
dried over Na2SO4. Silica gel chromatography (petroleum ether/EtOAc) gave 28b (90 mg, 
52%) as a yellow solid. 
1
H NMR (500 MHz, DMSO-d6): ! = 3.76 (t, J = 5.6 Hz, 2H, H-2’), 
4.48 (t, J = 5.6 Hz, 2H, H-1’), 6.80 (d, J = 3.2 Hz, 1H, H-3), 7.68 (d, J = 3.2 Hz, 1H, H-2), 
7.77 (d, J = 9.1 Hz, 1H, H-7), 8.05 (dd, J = 2.2, 9.1 Hz, 1H, H-6), 8.58 (d, J = 2.2 Hz, H-4); 
13
C NMR (125 MHz, DMSO-d6): ! = 45.32 (C-1’), 50.66 (C-2’), 104.18 (C-3), 110.51 (C-7), 
116.53 (C-6), 117.59 (C-4), 127.50 (C-9), 132.56 (C-2), 138.95 (C-8), 140.86 (C-5); IR 
(KBr): " = 2122 (m, N3), 2102 (m, N3), 1611 (w), 1515 (s, NO2), 1478 (w), 1453 (w), 1494 
(w), 1338 (vs, NO2), 1292 (s), 1227 (w), 1068 (m), 745 (s) cm
-1
. 
 
1-(3-Azidopropyl)-5-nitro-1H-indole (28c). NaN3 (434 mg, 6.68 mmol) was added to a 
solution of 27c (1.34 g, 4.73 mmol) in DMF (10 mL), and the resulting suspension was 
stirred at 55 °C. After 12 h water (20 mL) was added and the reaction mixture was extracted 
with EtOAc (3 ! 30 mL). The organic layers were washed with water and brine (20 mL) and 
dried over Na2SO4. Silica gel chromatography (petroleum ether/EtOAc) gave 28c (950 mg, 
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82%) as a yellow solid. 
1
H NMR (500 MHz, DMSO-d6): ! = 2.03 (p, J = 6.8 Hz, 2H, H-2'), 
3.32 (t, J = 6.7 Hz, 2H, H-3'), 4.34 (t, J = 7.0 Hz, 2H, H-1'), 6.78 (d, J = 3.1 Hz, 1H, H-3), 
7.67 (d, J = 3.2 Hz, 1H, H-2), 7.71 (d, J = 9.1 Hz, 1H, H-7), 8.04 (dd, J = 2.3, 9.1 Hz, 1H, H-
6), 8.58 (d, J = 2.2 Hz, 1H, H-4); 
13
C NMR (125 MHz, DMSO-d6): ! = 28.97 (C-2'), 43.30 
(C-1'), 48.00 (C-3'), 103.91 (C-3), 110.32 (C-7), 116.46 (C-6), 117.64 (C-4), 127.36 (C-9), 
132.50 (C-2), 138.68 (C-5), 140.73 (C-5); IR (KBr): " = 2128 (m), 2101 (s, N3), 2073 (m), 
1613 (w), 1513 (m, NO2), 1483 (w), 1455 (w), 1404 (w), 1331 (vs, NO2), 1315 (s), 1302 (s), 
1267 (m), 1176 (w), 1068 (m), 741 (s) cm
-1
; elemental analysis: calcd (%) for C11H11N5O2 
(245.24): C 53.87, H 4.52, N 28.56; found: C 53.77, H 4.65, N 28.32. 
 
1-(4-Azidobutyl)-5-nitro-1H-indole (28d). NaN3 (531 mg, 8.17 mmol) was added to a 
solution of 27d (1.60 g, 5.38 mmol) in DMF (5 mL), and the resulting suspension was stirred 
at 55 °C. After 14 h, water (10 mL) was added, and the reaction mixture was extracted with 
EtOAc (3 ! 20 mL). The organic layers were washed with water and brine (10 mL) and dried 
over Na2SO4. Silica gel chromatography (petroleum ether/EtOAc) gave 28d (1.10 g, 79%) as 
a yellow solid. 
1
H NMR (500 MHz, DMSO-d6): ! = 1.43-1.50 (m, 2H, H-3’), 1.78-1.85 (m, 
2H, H-2’), 3.31-3.38 (m, 2H, H-4’), 4.30 (t, J = 7.0 Hz, 2H, H-1’), 6.76 (d, J = 3.1 Hz, H-3), 
7.68 (d, J = 3.2 Hz, H-2), 7.73 (d, J = 9.1 Hz, 1H, H-7), 8.03 (dd, J = 2.3, 9.1 Hz, 1H, H-6), 
8.57 (d, J = 2.2 Hz, 1H, H-4); 
13
C NMR (125 MHz, DMSO-d6): ! = 25.63 (C-3’), 27.10 (C-
2’), 45.44 (C-1’), 50.15 (C-4’), 103.70 (C-3), 110.40 (C-7), 116.37 (C-6), 117.64 (C-4), 
127.32 (C-9), 132.55 (C-2), 138.67 (C-8), 140.66 (C-5); IR (KBr): " = 2089 (vs, N3), 1514 (s, 
NO2), 1479 (m), 1466 (w), 1453 (vw), 1402 (w), 1334 (vs, NO2), 1319 (s), 1306 (s), 1267 
(m), 1249 (m), 1233 (w), 1221 (vw), 1169 (vw), 1091 (vw), 1066 (m), 891 (m), 748 (vs) 
cm
-1
; elemental analysis: calcd (%) for C12H13N5O2 (259.26): C 55.59, H 5.05, N 27.01; 
found C 55.66, H 5.20, N 26.81. 
 
(5-Nitro-1H-indol-1-yl)methanol (29). 5-Nitro-1H-indole (4, 995 mg, 6.14 mmol) and 
K2CO3 (396 mg, 2.87 mmol) were dissolved in EtOH in a bomb tube. The solution was 
stirred at 60 °C for 5 min, then freshly prepared aq. methanal (8 mL, approx. 30%, 
preparation: 3.00 g paraformaldehyde and 0.901 g of K2CO3 were suspended in 10 mL H2O 
and stirred at 60 °C until complete dissolution of the paraformaldehyde) were added. Stirring 
was continued at 60 °C for another 20 min. After concentration, the remains were redissolved 
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in EtOAc and adsorbed on silica gel. The adsorbed material was subjected to silica gel 
chromatography (petroleum ether/EtOAc) to afford 29 (784 mg, 66%) as a yellow solid. 
1
H 
NMR (500 MHz, CD3OD): ! = 5.62 (s, 2H, H-1'), 6.70 (d, J = 2.7 Hz, 1H, H-3), 7.50 (d, J = 
3.3 Hz, 1H, H-2), 7.63 (d, J = 9.1 Hz, 1H, H-7), 8.08 (dd, J = 2.2, 9.1 Hz, 1H, H-6), 8.52 (d, J 
= 2.2 Hz, 1H, H-4); 
13
C NMR (125 MHz, CD3OD): ! = 70.45 (C-1'), 105.21 (C-3), 111.17 
(C-7), 117.95 (C-6), 118.54 (C-4), 129.92 (C-9), 132.41 (C-2), 140.12 (C-8), 143.16 (C-5); 
IR (KBr): " = 3486 (vs, OH), 1609 (w), 1580 (vw), 1512 (s, NO2), 1466 (m), 1399 (w), 1331 
(vs, NO2), 1279 (s), 1206 (w), 1147 (vw), 1100 (w), 1073 (w), 1040 (s), 988 (vw), 894 (vw), 
814 (vw), 763 (vw), 744 (s), 722 (vw) cm
-1
; elemental analysis: calcd (%) for C9H8N2O3 
(192.17): C 56.25, H H 4.20, N 14.58; found: C 56.14; H 4.21; N 14.60. 
 
1-(Azidomethyl)-5-nitro-1H-indole (28a). To a solution of 29 (770 mg, 4.01 mmol) in 
anhydrous THF (13 mL) were added MeSO2Cl (0.312 mL, 4.01 mmol) and Et3N (1.1 mL, 
8.02 mmol) at -15 °C under argon. After 10 min, the ice bath was removed and stirring was 
continued for 1 h. Then 15-crown-5 (0.397 mL, 2.01 mmol) and NaN3 (521 mg, 8.02 mmol) 
were added to the solution. After another 5 h, the solvent was removed and the crude mixture 
was dissolved in EtOAc (75 mL) and H2O (50 mL). The two phases were separated, and the 
organic phase was washed with brine (50 mL). The aqueous phase was extracted with EtOAc 
(2 ! 50 mL). The combined organic layers were dried over Na2SO4, and the solvent was 
removed under reduced pressure. Silica gel chromatography (petroleum ether/EtOAc) gave 
28a (297 mg, 34%) as yellow crystals. 
1
H NMR (500 MHz, CDCl3): ! = 5.51 (s, 2H, H-1'), 
6.77 (d, J = 3.3 Hz, 1H, H-3), 7.34 (d, J = 3.3 Hz, 1H, H-2), 7.49 (d, J = 9.0 Hz, 1H, H-7), 
8.20 (dd, J = 2.2, 9.1 Hz, 1H, H-6), 8.61 (d, J = 2.1 Hz, 1H, H-4); 
13
C NMR (125 MHz, 
CDCl3): ! = 61.56 (C-1'), 106.03 (C-3), 109.68 (C-7), 118.43 (C-6), 118.50 (C-4), 128.73 (C-
9), 130.71 (C-2), 138.88 (C-8), 142.84 (C-5); IR (KBr): " = 3101 (vw), 2924 (vw), 2118 (m, 
N3), 2092 (m, N3), 1612 (w), 1583 (vw), 1509 (s, NO2), 1480 (m), 1451 (m), 1401 (vw), 1336 
(vs, NO2/N3), 1287 (vs, N3), 1266 (m), 1231 (m), 1208 (w), 1179 (m), 1147 (w), 1076 (w), 
1065 (w), 1029 (vw), 934 (vw), 906 (w), 876 (w), 821 (w), 745 (s) cm
-1
; elemental analysis: 
calcd (%) for C9H7N5O2 (217.18): C 49.77, H 3.25, N 32.25; found: C 49.59; H 3.28; N 
32.46. 
 
3-(Azidomethyl)-5-nitro-1H-indole (32a). To a suspension of 31
[S5]
 (752 mg, 3.91 mmol) in 
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toluene (10 mL) were added diphenyl phosphoryl azide (1.0 mL, 4.69 mmol) and dropwise at 
-10 °C DBU (0.7 mL, 4.69 mmol) under argon. The mixture was allowed to warm to rt, and 5 
mL THF were added leading to the formation of two phases. The reaction was continued 
under vigorous stirring for 18 h. After removal of the THF in vacuo, EtOAc (80 mL) was 
added to the reaction mixture, and the organic phases were washed with satd aq. NaHCO3 (2 
! 40 mL), 0.5 M aq. HCl (40 mL), satd aq. NaHCO3 (40 mL) and brine (40 mL). The 
aqueous layers were extracted with EtOAc (2 ! 80 mL), and the organic phase was dried over 
Na2SO4. Silica gel chromatography (DCM) and subsequent crystallization from DCM 
afforded 32a as yellow crystals (658 mg, 78%). 
1
H NMR (500 MHz, DMSO-d6): ! = 4.70 (s, 
2H, H-1'), 7.60 (d, J = 9.0 Hz, 1H, H-7), 7.75 (s, 1H, H-2), 8.05 (dd, J = 1.8, 8.9 Hz, 1H, H-
6), 8.65 (s, 1H, H-4), 11.90 (s, 1H, NH); 
13
C NMR (125 MHz, DMSO-d6): ! = 45.16 (C-1'), 
111.57 (C-3), 112.38 (C-7), 115.76 (C-4), 117.07 (C-6), 125.88 (C-9), 129.50 C-2), 139.53 
(C-8), 140.88 (C-5); IR (KBr): " = 3257 (m, NH), 2117 (vs, N3), 1625 (w), 1580 (w), 1551 
(m), 1515 (s, NO2), 1472 (m), 1456 (m), 1436 (m), 1376 (w), 1331 (vs, N3/ NO2), 1261 (m), 
1224 (m), 1196 (m), 1128 (w), 1113 (m), 1102 (m), 1045 (w), 976 (w), 939 (vw), 920 (vw), 
894 (m), 863 (w), 836 (m), 816 (m), 782 (w), 769 (w), 751 (m), 735 (m), 686 (m), 631 (m), 
613 (w), 563 (m), 559 (m) cm
-1
; elemental analysis: calcd (%) for C9H7N5O2 (217.18): C 
49.77, H 3.25, N 32.25; found: C 49.73, H 3.27, N 32.14. 
 
General procedure C for the synthesis of triazoles. Alkyne (1.0 eq.) and azide (1.3 eq.) 
were dissolved in 
t
BuOH/H2O/THF (1:1:1, approx. 0.015 M) under argon, and the solution 
was degassed in an ultrasound bath for 20 min. Degassed 0.1 M aq. Na-L-ascorbate (0.5 eq.) 
and 0.1 M aq. CuSO4!5 H2O (0.25 eq.) were added, and the mixture was stirred at rt for 1-4 h 
until full conversion as indicated by MS. The solvent was removed in vacuo, the residue was 
redissolved in H2O/MeCN (1:1 + 1-2 drops of Et3N), filtrated (PTFE membrane filter) and 
purified by preparative HPLC-MS (H2O/MeCN + 0.1% HCO2H). All triazoles were isolated 
as yellow solids. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-({1-[(6-nitro-1H-indol-3-
yl)methyl]-1H-1,2,3-triazol-4-yl}methyl)cyclohexanecarboxamide (33). Prepared 
according to general procedure C from 26a (8.4 mg, 10.8 "mol), 28a (3.6 mg, 16.6 "mol), 
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Na-L-ascorbate (54 !L, 5.4 !mol) and CuSO4"5 H2O (27 !L, 2.7 !mol). Yield: 10.1 mg 
(94%). [#]D
20
 -58.0 (c 0.32, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.55 (m, 1H, Cy), 
0.61-0.73 (m, 3H, Cy), 0.91 (m, 1H, Cy), 1.06 (d, J = 6.4 Hz, 3H, Me), 1.10-1.27 (m, 3H, Cy, 
H-6a, H-2a), 1.26-1.45 (m, 8H, Fuc-H6, 4Cy, Lac-H3a), 1.46-1.65 (m, 4H, Lac-H3b, H-6b, 
Cy, H-5), 2.11 (m, 1H, H-2b), 2.22 (m, 1H, H-1), 3.10 (t, J = 9.6 Hz, 1H, H-4), 3.54 (t, J = 
5.8 Hz, 1H, Gal-H5), 3.59-3.68 (m, 2H, Gal-H3, H-3), 3.68-3.80 (m, 4H, Fuc-H2, -H4, Gal-
H6), 3.85 (dd, J = 3.2, 10.3 Hz, 1H, Fuc-H3), 3.95 (m, 1H, Gal-H4), 4.02 (m, 1H, Lac-H2), 
4.30 (t, J = 5.3 Hz, 2H, H-1'), 4.64 (d, J = 8.0 Hz, 1H, Gal-H1), 4.92-5.00 (m, 2H, Fuc-H1, -
H5), 5.42 (t, J = 8.9 Hz, 1H, Gal-H2), 6.79 (d, J = 3.3 Hz, 1H, Ind-H3), 6.84, 6.88 (A, B of 
AB, J = 14.8 Hz, 1H, H-1''), 7.40 (t, J = 7.7 Hz, 2H, C6H5), 7.55 (t, J = 7.4 Hz, 1H, C6H5), 
7.72 (d, J = 3.3 Hz, 1H, Ind-H2), 7.88 (d, J = 9.1 Hz, 1H, Ind-H7), 8.02 (s, 3H, C6H5, H-3'), 
8.14 (dd, J = 2.1, 9.1 Hz, 1H, Ind-H6), 8.19 (t, J = 5.4 Hz, 1H, NH), 8.54 (d, J = 2.0 Hz, 1H, 
Ind-H4); 
13
C NMR (125 MHz, CD3OD): ! = 16.73 (Fuc-C6), 19.22 (Me), 26.55, 26.72, 
27.29, 33.10, 34.19, 35.00 (6 Cy), 35.09 (C-2), 35.45 (C-1'), 37.48 (C-6), 39.31 (C-5), 42.84 
(Lac-C3), 42.95 (C-1), 59.70 (C-1''), 62.76 (Gal-C6), 67.71 (2C, Gal-C4, Fuc-C5), 70.28 
(Fuc-C2), 71.39 (Fuc-C3), 72.98 (Gal-C2), 73.95 (Fuc-C4), 75.95 (Gal-C5), 78.25 (Lac-C2), 
79.70 (C-3), 83.00 (C-4), 83.69 (Gal-C3), 100.44 (Fuc-C1), 100.47 (Gal-C1), 106.81 (Ind-
C3), 111.48 (Ind-C7), 118.74 (Ind-C6), 118.78 (Ind-C4), 123.94 (C-3'), 129.69 (2C, C6H5), 
130.10 (Ind-C9), 130.86, 131.52 (3C, C6H5), 132.58 (Ind-C2), 134.33 (C6H5), 140.07 (Ind-
C8), 143.86 (Ind-C5), 146.95 (C-2'), 166.85 (COPh), 176.93 (CONH), 179.38 (COOH); IR 
(KBr): " = 3430 (vs, OH), 2927 (s), 2846 (w), 1723 (s, C=O), 1648 (m, C=O), 1616 (w), 
1584 (vw), 1520 (m), 1476 (vw), 1450 (m), 1403 (w), 1337 (vs, NO2), 1314 (m), 1273 (s), 
1226 (w), 1170 (w), 1114 (s), 1092 (s), 1073 (vs), 1040 (s), 999 (w), 966 (vw), 766 (w), 746 
(w), 713 (m) cm
-1
; HR-MS: m/z: calcd for C48H62N6O17 [M+Na]
+
: 1017.4064; found: 
1017.4067. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(2-{1-[(6-nitro-1H-indol-
3-yl)methyl]-1H-1,2,3-triazol-4-yl}ethyl)cyclohexanecarboxamide (34). Prepared 
according to general procedure C from 26b (10.4 mg, 13.1 !mol), 28a (4.3 mg, 19.8 !mol), 
Na-L-ascorbate (66 !L, 6.6 !mol) and CuSO4"5 H2O (33 !L, 3.3 !mol). Yield: 8.8 mg 
(66%). [#]D
20
 -67.5 (c 0.23, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.54 (m, 1H, Cy), 
0.59-0.71 (m, 3H, Cy), 0.85-0.99 (m, 2H, Cy, H-6a), 1.02 (d, J = 6.5 Hz, 3H, Me), 1.09 (m, 
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1H, H-2a), 1.17-1.37 (m, 8H, Fuc-H6, 5 Cy), 1.37-1.45 (m, 2H, Lac-H3a, H-6b), 1.46-1.62 
(m, 3H, Lac-H3b, H-5, Cy), 2.06-2.12 (m, 2H, H-2, H-1), 2.76 (t, J = 7.0 Hz, 2H, H-2'), 3.08 
(t, J = 9.5 Hz, 1H, H-4), 3.55 (t, J = 5.8 Hz, 1H, Gal-H5), 3.59-3.66 (m, 2H, Gal-H3, H-3), 
3.69-3.81 (m, 4H, Fuc-H2, -H4, Gal-H6), 3.86 (dd, J = 3.2, 10.3 Hz, 1H, Fuc-H3), 3.96 (m, 
1H, Gal-H4), 4.01 (m, 1H, Lac-H2), 4.66 (d, J = 8.0 Hz, 1H, Gal-H1), 4.93-5.01 (m, 2H, 
Fuc-H1, -H5), 5.43 (t, J = 8.9 Hz, 1H, Gal-H2), 6.78 (A of AB, J = 14.8 Hz, 1H, H-1''a), 6.81 
(d, J = 3.3 Hz, 1H, Ind-H3), 6.85 (B of AB, J = 14.7 Hz, 1H, H-1''b), 7.44 (t, J = 7.7 Hz, 2H, 
C6H5), 7.53 (t, J = 7.4 Hz, 1H, C6H5), 7.67 (d, J = 3.4 Hz, 1H, Ind-H2), 7.84 (s, 1H, H-4'), 
7.88 (d, J = 9.1 Hz, 1H, Ind-H7), 8.05 (d, J = 7.7 Hz, 2H, C6H5), 8.16 (dd, J = 2.0, 9.1 Hz, 
1H, Ind-H6), 8.57 (d, J = 2.0 Hz, 1H, Ind-H4); 
13
C NMR (125 MHz, CD3OD): ! = 16.74 
(Fuc-C6), 19.18 (Me), 26.41, 26.54, 26.72 (2 Cy, C-2'), 27.28, 33.11, 34.21 35.10 (4 Cy), 
35.35 (C-2'), 37.26 (C-6), 39.24 (C-5), 39.66 (C-1'), 42.88, 43.08 (Lac-C3, C-1), 59.63 (C-
1''), 62.78 (Gal-C6), 67.71 (Gal-C4, Fuc-C5), 70.31 (Fuc-C2), 71.42 (Fuc-C3), 73.05 (Gal-
C2), 73.98 (Fuc-C4), 76.00 (Gal-C5), 78.33 (Lac-C2), 79.87 (C-3), 82.91 (C-4), 83.69 (Gal-
C3), 100.44 (Fuc-C1), 100.62 (Gal-C1), 106.92 (Ind-C3), 111.49 (Ind-C7), 118.78 (Ind-C6), 
118.84 (Ind-C4), 123.30 (C-4'), 129.73 (2C, C6H5), 130.06 (Ind-C9), 130.93, 131.62 (3C, 
C6H5), 132.52 (Ind-C2), 134.36 (C6H5), 140.09 (Ind-C8), 143.89 (Ind-C5), 147.06 (C-3'), 
166.81 (COPh), 176.99 (CONH), 179.82 (COOH); IR (KBr): " = 3429 (vs, OH), 2927 (s), 
2853 (w), 1722 (s, C=O), 1648 (m, C=O), 1616 (w), 1584 (vw), 1520 (m), 1476 (vw), 1450 
(m), 1403 (w), 1337 (vs, NO2), 1317 (s), 1273 (s), 1224 (w), 1169 (w), 1114 (s), 1095 (s), 
1073 (vs), 1034 (s), 1000 (vw), 966 (vw), 760 (vw), 746 (w), 713 (m) cm
-1
; HR-MS: m/z: 
calcd for C49H64N6O17 [M+Na]
+
: 1031.4220; found: 1031.4218. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(3-{1-[(5-nitro-1H-indol-
1-yl)methyl]-1H-1,2,3-triazol-4-yl}propyl)cyclohexanecarboxamide (35). Prepared 
according to general procedure C from 26c (9.7 mg, 12.0 !mol), 28a (3.9 mg, 18.0 !mol), 
Na-L-ascorbate (60 !L, 6.0 !mol) and CuSO4"5 H2O (30 !L, 3.0 !mol). Yield: 7.5 mg 
(61%). [#]D
20
 -42.3 (c 0.72, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.54 (m, 1H, Cy), 
0.59-0.71 (m, 4H, 4 Cy), 0.90 (m, 1H, Cy), 1.09 (d, J = 6.5 Hz, 3H, Me), 1.11-1.25 (m, 3H, 
Cy, H-6a, H-2a), 1.25-1.36 (m, 7H, 4 Cy, Fuc-H6), 1.41 (m, 1H, Lac-H3a), 1.45-1.60 (m, 3H, 
Lac-H3b, Cy, H-6b), 1.64 (m, 1H, H-5), 1.67-1.74 (m, 2H, H-2'), 2.10 (m, 1H, H-2b), 2.21 
(m, 1H, H-1), 2.60 (t, J = 7.5 Hz, 2H, H-3'), 3.04-3.10 (m, 2H, H-1'), 3.13 (t, J = 9.6 Hz, 1H, 
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H-4), 3.56 (t, J = 5.9 Hz, 1H, Gal-H5), 3.62-3.81 (m, 6H, Gal-H3, -H6, H-3, Fuc-H2, -H4), 
3.86 (dd, J = 3.2, 10.3 Hz, 1H, Fuc-H3), 3.96 (d, J = 2.5 Hz, 1H, Gal-H4), 4.02 (d, J = 6.9 
Hz, 1H, Lac-H2), 4.66 (d, J = 8.0 Hz, 1H, Gal-H1), 4.95-5.00 (m, 2H, Fuc-H1, -H5), 5.42 (m, 
1H, Gal-H2), 6.81 (m, 1H, Ind-H3), 6.85 (s, 2H, H-1''), 7.24-7.29, 7.30-7.35 (m, 3H, C6H5), 
7.69-7.76 (m, 2H, NH, Ind-H2), 7.90 (m, 1H, Ind-H7), 7.94 (s, 1H, H-5'), 7.96-7.99 (m, 2H, 
C6H5), 8.15 (m, 1H, Ind-H6), 8.56 (m, 1H, Ind-H4); 
13
C NMR (125 MHz, CD3OD): ! = 16.70 
(Fuc-C6), 19.24 (Me), 23.46 (C-3'), 26.52, 26.70, 27.26 (3 Cy), 30.12 (C-2'), 33.12, 34.19, 
35.05 (3 Cy), 35.52 (C-2), 37.38 (C-6), 39.30, 39.42 (C-5, C-1'), 42.78 (Lac-C3), 43.37 (C-
1), 59.70 (C-1''), 62.77 (Gal-C6), 67.71, 67.76 (Gal-C4, Fuc-C5), 70.33 (Fuc-C2), 71.42 
(Fuc-C3), 73.04 (Gal-C2), 73.97 (Fuc-C4), 75.99 (Gal-C5), 78.28 (Lac-C2), 79.91 (C-3), 
82.98 (C-4), 83.61 (Gal-C3), 100.45 (Fuc-C1), 100.63 (Gal-C1), 106.81 (Ind-C3), 111.47 
(Ind-C7), 118.80, 118.81 (Ind-C4, -C6), 123.10 (C-5'), 129.58 (Ind-C9), 130.11, 130.76, 
131.48 (5C, C6H5), 132.58 (Ind-C2), 134.21 (C6H5), 140.11 (Ind-C8), 143.89 (Ind-C5), 
149.16 (C-4'), 166.76 (COPh), 177.05 (CONH); HR-MS: m/z: calcd for C50H66N6O17 
[M+Na]
+
: 1045.4377; found: 1045.4376. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(4-{1-[(6-nitro-1H-indol-
3-yl)methyl]-1H-1,2,3-triazol-4-yl}butyl)cyclohexanecarboxamide (36). Prepared 
according to general procedure C from 26d (10.6 mg, 13.4 !mol), 28a (4.4 mg, 20.3 !mol), 
Na-L-ascorbate (67 !L, 6.7 !mol) and CuSO4"5 H2O (34 !L, 3.4 !mol). Yield: 11.3 mg 
(81%). [#]D
20
 -53.2 (c 1.13, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.47-0.70 (m, 4H, 4 
Cy), 0.89 (m, 1H, Cy), 1.08 (d, J = 6.4 Hz, 3H, Me), 1.11-1.24 (m, 3H, Cy, H-6a, H-2a), 
1.25-1.32 (m, 4H, 4 Cy), 1.34 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.37-1.68 (m, 9H, Lac-H3, H-2', 
H-6, H-3', H-5, Cy), 2.10 (m, 1H, H-2b), 2.20 (m, 1H, H-1), 2.66 (t, J = 7.5 Hz, 2H, H-4'), 
3.06 (t, J = 7.0 Hz, 2H, H-1'), 3.13 (t, J = 9.6 Hz, 1H, H-4), 3.58 (t, J = 5.9 Hz, 1H, Gal-H5), 
3.63-3.70 (m, 2H, Gal-H3, H-3), 3.75 (s, 4H, Fuc-H2, -H4, Gal-H6), 3.86 (dd, J = 3.2, 10.3 
Hz, 1H, Fuc-H3), 3.96 (d, J = 2.0 Hz, 1H, Gal-H4), 4.02 (dd, J = 2.5, 9.7 Hz, 1H, Lac-H2), 
4.69 (d, J = 8.0 Hz, 1H, Gal-H1), 4.95-5.02 (m, 2H, Fuc-H1, -H5), 5.43 (t, J = 8.9 Hz, 1H, 
Gal-H2), 6.79 (d, J = 3.3 Hz, 1H, Ind-H3), 6.83 (s, 2H, H-1''), 7.36-7.41, 7.51-7.56 (m, 3H, 
C6H5), 7.72 (d, J = 3.4 Hz, 1H, Ind-H2), 7.88 (d, J = 9.1 Hz, 1H, Ind-H7), 7.95 (s, 1H, H-6'), 
7.99-8.03 (m, 2H, C6H5), 8.14 (dd, J = 2.1, 9.1 Hz, 1H, Ind-H6), 8.55 (d, J = 2.1 Hz, 1H, Ind-
H4); 
13
C NMR (125 MHz, CD3OD): ! = 16.74 (Fuc-C6), 19.24 (Me), 25.67 (C-4'), 26.51, 
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26.67, 27.24 (3 Cy), 27.43 (C-3'), 29.67 (C-2'), 33.08, 34.13, 35.03 (3 Cy), 35.38 (C-2), 37.46 
(C-6), 39.32 (C-5), 39.75 (C-1'), 42.75 (Lac-C3), 43.31 (C-1), 59.65 (C-1''), 62.73 (Gal-C6), 
67.70, 67.75 (Gal-C4, Fuc-C5), 70.30 (Fuc-C2), 71.41 (Fuc-C3), 73.00 (Gal-C2), 73.96 (Fuc-
C4), 75.95 (Gal-C5), 77.96 (Lac-C2), 79.82 (C-3), 83.02 (C-4), 83.63 (Gal-C3), 100.45 (Fuc-
C1), 100.50 (Gal-C1), 106.78 (Ind-C3), 111.43 (Ind-C7), 118.77 (Ind-C6), 118.82 (Ind-C4), 
122.98 (C-6'), 129.65 (2C, C6H5), 130.07 (Ind-C9), 130.84, 131.52 (3C, C6H5), 132.59 (Ind-
C2), 134.34 (C6H5), 140.07 (Ind-C8), 143.83 (Ind-C5), 149.56 (C-5'), 166.79 (COPh), 176.95 
(CONH), 178.88 (COOH); IR (KBr): ! = 3436 (vs, OH), 2927 (s), 2852 (w), 1725 (m, C=O), 
1647 (m, C=O), 1616 (w), 1583 (vw), 1520 (m), 1476 (vw), 1450 (m), 1402 (w), 1384 (w), 
1336 (s, NO2), 1315 (m), 1271 (m), 1223 (w), 1167 (w), 1114 (m), 1072 (s), 1040 (s), 999 
(w), 966 (vw), 763 (vw), 746 (w), 712 (w) cm
-1
; HR-MS: m/z: calcd for C51H68N6O17 
[M+Na]
+
: 1059.4533; found: 1059.4531. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-({1-[2-(5-nitro-1H-indol-
1-yl)ethyl]-1H-1,2,3-triazol-4-yl}methyl)cyclohexanecarboxamide (37). Prepared 
according to general procedure C from 26a (15.0 mg, 19.3 !mol), 28b (5.5 mg, 23.8 !mol), 
Na-L-ascorbate (96 !L, 9.6 !mol) and CuSO4"5 H2O (76 !L, 7.6 !mol). Yield: 12.9 mg 
(66%). [#]D
20
 -53.0 (c 1.09, MeOH); 
1
H NMR (500 MHz, CD3OD): " = 0.55 (m, 1H, Cy), 
0.61-0.72 (m, 3H, Cy), 0.91 (d, J = 11.6 Hz, 1H, Me), 1.12-1.25 (m, 3H, Cy, H-6a, H-2a), 
1.25-1.37 (m, 7H, Fuc-H6, 4 Cy), 1.41 (m, 1H, Lac-H3a), 1.45-1.61 (m, 3H, Lac-H3b, H-6b, 
Cy), 1.66 (m, 1H, H-5), 2.10 (m, 1H, H-2b), 2.20 (m, 1H, H-1), 3.14 (t, J = 9.6 Hz, 1H, H-4), 
3.59 (t, J = 6.0 Hz, 1H, Gal-H5), 3.64 (dd, J = 2.9, 9.7 Hz, 1H, Gal-H3), 3.66-3.82 (m, 5H, 
H-3, Fuc-H2, -H4, Gal-H6), 3.87 (dd, J = 3.3, 10.3 Hz, 1H, Fuc-H3), 3.94-4.01 (m, 2H, Gal-
H4, Lac-H2), 4.15-4.18 (m, 2H, H-1'), 4.70 (d, J = 8.1 Hz, 1H, Gal-H1), 4.75 (t, J = 5.3 Hz, 
2H, H-2''), 4.78-4.83 (m, 2H, H-1''), 4.97 (t, J = 5.1 Hz, 2H, Fuc-H1, -H5), 5.43 (dd, J = 8.3, 
9.5 Hz, 1H, Gal-H2), 6.68 (d, J = 2.9 Hz, Ind-H3), 7.19 (d, J = 9.1 Hz, Ind-H7), 7.23 (d, J = 
3.3 Hz, 1H, Ind-H2), 7.37 (s, 1H, H-3'), 7.38-7.44, 7.54-7.60 (m, 3H, C6H5), 7.96-8.03 (m, 
3H, Ind-H6, C6H5), 8.06 (t, J = 5.3 Hz, 1H, NH), 8.50-8.54 (m, 1H, Ind-H4); 
13
C NMR (125 
MHz, CD3OD): " = 16.74 (Fuc-C6), 19.25 (Me), 26.54, 26.69, 27.27, 33.11, 34.17 (5 Cy), 
35.05 (C-2), 35.09 (C-1'), 35.32 (Cy), 37.51 (C-6), 39.31 (C-5), 42.81 (Lac-C3), 42.91 (C-1), 
47.53 (C-2''), 51.43 (C-1''), 62.74 (Gal-C6), 67.72 (2C, Gal-C4, Fuc-C5), 70.32 (Fuc-C2), 
71.41 (Fuc-C3), 72.99 (Gal-C2), 73.97 (Fuc-C4), 75.95 (Gal-C5), 78.09 (Lac-C2), 79.78 (C-
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3), 83.01 (C-4), 83.73 (Gal-C3), 100.46 (Fuc-C1), 100.52 (Gal-C1), 105.73 (Ind-C3), 110.25 
(Ind-C7), 117.99 (Ind-C6), 118.71 (Ind-C4), 124.91 (C-3'), 129.18 (Ind-C9), 129.70, 130.88, 
131.54 (5C, C6H5), 132.55 (Ind-C2), 134.32 (C6H5), 140.46 (Ind-C8), 142.89 (Ind-C5), 
146.55 (C-2'), 166.84 (COPh), 176.74 (CONH), 179.18 (COOH); IR (KBr): ! = 3435 (vs, 
OH), 2927 (m), 2852 (w), 1721 (m, C=O), 1643 (m, C=O), 1583 (w), 1516 (w), 1449 (w), 
1402 (w), 1383 (w), 1335 (s, NO2), 1272 (m). 1215 (vw), 1166 (w), 1111 (m), 1095 (m), 
1073 (s), 1032 (m), 966 (vw), 897 (vw), 804 (vw), 776 (vw), 765 (vw), 744 (w), 713 (w) cm
-
1
; HR-MS: m/z: calcd for C49H64N6O17 [M+Na]
+
: 1031.4220; found: 1031.4222. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(2-{1-[2-(5-nitro-1H-
indol-1-yl)ethyl]-1H-1,2,3-triazol-4-yl}ethyl)cyclohexanecarboxamide (38). Prepared 
according to general procedure C from 26b (15.3 mg, 19.3 !mol), 28b (5.8 mg, 25.0 !mol), 
Na-L-ascorbate (116 !L, 11.6 !mol) and CuSO4"5 H2O (52 !L, 5.2 !mol). Yield: 15.7 mg 
(79%). [#]D
20
 -88.2 (c 0.29, MeOH);
 1
H NMR (500 MHz, CD3OD): " = 0.55 (m, 1H, Cy), 
0.61-0.73 (m, 3H, 3 Cy), 0.90 (m, 1H, Cy), 1.09 (d, J = 6.5 Hz, 3H, Me), 1.11-1.26 (m, 3H, 
H-2a, H-6a, Cy), 1.26-1.37 (m, 8H, 5 Cy, Fuc-H6), 1.42 (m, 1H, Lac-H3a), 1.45-1.61 (m, 3H, 
Lac-H3b, H-6, Cy), 1.65 (m, 1H, H-5), 2.10 (m, 1H, H-2), 2.18 (m, 1H, H-1), 2.61 (t, J = 7.4 
Hz, 2H, H-2'), 3.09-3.19 (m, 3H, H-1', H-4), 3.56 (m, 1H, Gal-H5), 3.59-3.83 (m, 6H, Gal-
H3, -H6, H-3, Fuc-H2, -H4), 3.87 (dd, J = 3.3, 10.3 Hz, 1H, Fuc-H3), 3.91-4.00 (m, 2H, Gal-
H4, Lac-H2), 4.68 (d, J = 8.0 Hz, 1H, Gal-H1), 4.73-4.78 (m, 2H, H-2''), 4.78-4.82 (m, 2H, 
H-1''), 4.92-5.01 (m, 2H, Fuc-H1, -H5), 5.43 (m, 1H, Gal-H2), 6.70 (d, J = 3.2 Hz, 1H, Ind-
H3), 7.24-7.28 (m, 2H, Ind-H2, -H7), 7.29 (s, 1H, H-4'), 7.40-7.46 (m, 2H, C6H5), 7.51-7.55 
(m, J = 7.4 Hz, 1H, C6H5), 7.67 (t, J = 5.8 Hz, 1H, NH), 8.00 (dd, J = 2.2, 9.1 Hz, 1H, Ind-
H6), 8.02-8.06 (m, 2H, C6H5), 8.52 (m, 1H, Ind-H4); 
13
C NMR (125 MHz, CD3OD): " = 
16.72 (Fuc-C6), 19.25 (Me), 26.35 (C-2'), 26.53, 26.70, 27.27, 33.15, 34.22, 35.07 (6 Cy), 
35.31 (C-2), 37.38 (C-6), 39.29 (C-5), 40.03 (C-1'), 42.82 (Lac-C3), 43.20 (C-1), 47.50 (C-
2''), 51.30 (C-1''), 62.78 (Gal-C6), 67.71, 67.77 (Gal-C4, Fuc-C5), 70.33 (Fuc-C2), 71.43 
(Fuc-C3), 73.04 (Gal-C2), 73.96 (Fuc-C4), 76.00 (Gal-C5), 79.84 (C-3), 82.99 (C-4), 83.66 
(Gal-C3), 100.41 (Fuc-C1), 100.57 (Gal-C1), 105.73 (Ind-C3), 110.26 (Ind-C7), 117.96 (Ind-
C6), 118.74 (Ind-C4), 124.34 (C-4'), 129.20 (Ind-C9), 129.69, 129.74, 130.89 (5C, C6H5), 
132.54 (Ind-C2), 134.32 (C6H5), 140.44 (Ind-C8), 142.97 (Ind-C5), 146.47 (C-3'), 166.82 
(COPh), 176.94 (CONH); IR (KBr): ! = 3418 (s, OH), 2926 (s), 2853 (m), 1722 (s, C=O), 
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1648 (m, C=O), 1619 (m), 1583 (w), 1517 (s), 1479 (w), 1451 (m), 1404 (w), 1334 (vs, 
NO2), 1290 (m), 1271 (w), 1223 (w), 1166 (m), 1112 (s), 1095 (s), 1071 (vs), 1032 (s), 967 
(w), 999 (m), 935 (vw), 897 (vw), 809 (vw), 778 (w), 766 (w), 747 (m), 712 (s), 677 (w), 593 
(w) cm
-1
; HR-MS: m/z: calcd for C50H66N6O17 [M-H+2Na]
+
: 1067.4202; found: 1067.4207. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(3-{1-[2-(5-nitro-1H-
indol-1-yl)ethyl]-1H-1,2,3-triazol-4-yl}propyl)cyclohexanecarboxamide (39). Prepared 
according to general procedure C from 26c (14.6 mg, 18.1 !mol), 28b (5.5 mg, 23.8 !mol), 
Na-L-ascorbate (91 !L, 9.1 !mol) and CuSO4"5 H2O (45 !L, 4.5 !mol). Yield: 12.8 mg 
(68%). [#]D -51.0 (c 0.89, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.54 (m, 1H, Cy), 
0.59-0.70 (m, 3H, 3 Cy), 0.89 (m, 1H, Cy), 1.11 (d, J = 6.5 Hz, 3H, Me), 1.14-1.36 (m, 10H, 
5 Cy, H-6a, H-2a, Fuc-H6), 1.40 (m, 1H, Lac-H3a), 1.44-1.54 (m, 3H, Lac-H3b, H-2'), 1.54-
1.62 (m, 2H, Cy, H-6b), 1.67 (m, 1H, H-5), 2.15 (m, 1H, H-2b), 2.23 (m, 1H, H-1), 2.47 (t, J 
= 7.4 Hz, 2H, H-3'), 2.86-2.93 (m, 2H, H-1'), 3.15 (t, J = 9.6 Hz, 1H, H-4), 3.59 (t, J = 5.8 
Hz, 1H, Gal-H5), 3.65 (dd, J = 2.7, 9.7 Hz, 1H, Gal-H3), 3.67-3.82 (m, 5H, H-3, Fuc-H2, -
H4, Gal-H6), 3.88 (dd, J = 3.3, 10.3 Hz, 1H, Fuc-H3), 3.94-3.99 (m, 2H, Gal-H4, Lac-H2), 
4.72-4.78 (m, 3H, Gal-H1, H-2''), 4.79-4.83 (m, 2H, H-1''), 4.95-5.02 (m, 2H, Fuc-H1, -H5), 
5.43 (dd, J = 8.4, 9.3 Hz, 1H, Gal-H2), 6.70 (d, J = 3.1 Hz, 1H, Ind-H3), 7.17 (d, J = 9.1 Hz, 
Ind-H7), 7.21 (s, 1H, H-5'), 7.33 (d, J = 3.3 Hz, 1H, Ind-H2), 7.49-7.54, 7.49-7.54 (m, 3H, 
C6H5), 7.96 (m, 1H, Ind-H6), 8.01-8.04 (m, 2H, C6H5), 8.50 (d, J = 2.2 Hz, 1H, Ind-H4); 
13
C 
NMR (125 MHz, CD3OD): ! = 16.73 (Fuc-C6), 19.27 (Me), 23.28 (C-3'), 26.54, 26.71, 27.30 
(3 Cy), 30.26 (C-2'), 33.11, 34.24, 35.13 (3 Cy), 35.38 (C-2), 37.49 (C-6), 39.31, 39.36 (C-5, 
C-1'), 42.98 (Lac-C3), 43.32 (C-1), 47.51 (C-2''), 51.46 (C-1''), 62.87 (Gal-C6), 67.73, 67.76 
(Gal-C4, Fuc-C5), 70.34 (Fuc-C2), 71.42 (Fuc-C3), 73.02 (Gal-C2), 73.97 (Fuc-C4), 76.03 
(Gal-C5), 78.78 (Lac-C2)
‡
, 79.85 (C-3), 83.05 (C-4), 83.72 (Gal-C3), 100.44 (Fuc-C1), 
100.56 (Gal-C1), 105.87 (Ind-C3), 110.18 (Ind-C7), 117.98 (Ind-C6), 118.73 (Ind-C4), 
124.12 (C-5'), 129.11 (Ind-C9), 129.65, 130.85, 131.62 (5C, C6H5), 132.46 (Ind-C2), 134.25 
(C6H5), 140.57 (Ind-C8), 142.88 (Ind-C5), 148.44 (C-4'), 166.82 (COPh), 176.99 (CONH), 
180.71 (COOH); IR (KBr): " = 3421 (s, OH), 2927 (m), 2852 (w), 1718 (m, C=O), 1646 (m, 
C=O), 1638 (m), 1620 (m), 1580 (w), 1517 (m), 1476 (w), 1429 (w), 1402 (w), 1383 (w), 
1336 (vs, NO2), 1270 (m), 1218 (w), 1166 (w), 1095 (s), 1070 (s), 1029 (s), 996 (m), 966 (w), 
933 (vw), 894 (vw), 826 (vw), 809 (vw), 779 (vw), 771 (vw), 746 (w), 712 (w), 675 (vw), 
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589 (vw) cm
-1
; HR-MS: m/z: calcd for C51H68N6O17 [M+H]
+
: 1037.4714; found: 1037.4711. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(4-{1-[2-(6-nitro-1H-
indol-3-yl)ethyl]-1H-1,2,3-triazol-4-yl}butyl)cyclohexanecarboxamide (40). Prepared 
according to general procedure C from 26d (10.2 mg, 12.9 !mol), 28b (4.5 mg, 19.5 !mol), 
Na-L-ascorbate (64 !L, 6.4 !mol) and CuSO4"5 H2O (32 !L, 3.2 !mol). Yield: 11.5 mg 
(85%). [#]D
20
 -47.8 (c 1.10, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.54 (m, 1H, Cy), 
0.59-0.71 (m, 3H, 3 Cy), 0.90 (m, 1H, Cy), 1.10 (d, J = 6.5 Hz, 3H, Me), 1.14-1.24 (m, 3H, 
Cy, H-6a, H-2a), 1.24-1.36 (m, 9H, Fuc-H6, 4 Cy, H-2'), 1.36-1.61 (m, 6H, H-3', Lac-H3b, 
H-6b, Cy), 1.66 (m, 1H, H-5), 2.13 (m, 1H, H-2), 2.24 (m, 1H, H-1), 2.50 (t, J = 7.3 Hz, 2H, 
H-4'), 2.96-3.07 (m, 2H, H-1'), 3.14 (t, J = 9.6 Hz, 1H, H-4), 3.57 (t, J = 5.7 Hz, 1H, Gal-H5), 
3.64 (dd, J = 2.5, 9.7 Hz, 1H, Gal-H3), 3.66-3.82 (m, 5H, H-3, Fuc-H2, -H4, Gal-H6), 3.87 
(dd, J = 3.2, 10.3 Hz, 1H, Fuc-H3), 3.96 (m, 1H, Gal-H4), 4.03 (m, 1H, Lac-H2), 4.71 (d, J = 
8.0 Hz, 1H, Gal-H1), 4.74-4.78 (m, 2H, H-2''), 4.79-4.83 (m, 2H, H-1''), 4.95-5.01 (m, 2H, 
Fuc-H1, -H5), 5.43 (m, 1H, Gal-H2), 6.70 (d, J = 3.2 Hz, 1H, Ind-H3), 7.21 (d, J = 9.0 Hz, 
1H, Ind-H7), 7.22 (s, 1H, H-6'), 7.29 (d, J = 3.2 Hz, 1H, Ind-H2), 7.43 (t, J = 7.7 Hz, 2H, 
C6H5), 7.58 (t, J = 7.4 Hz, 1H, C6H5), 7.97 (dd, J = 2.1, 9.1 Hz, 1H, Ind-H6), 8.02 (d, J = 7.6 
Hz, 2H, C6H5), 8.52 (d, J = 2.1 Hz, 1H, Ind-H4); 
13
C NMR (125 MHz, CD3OD): ! = 16.72 
(Fuc-C6), 19.24 (Me), 25.46 (C-4'), 26.49, 26.66, 27.24 (3 Cy), 27.59 (C-3'), 29.51 (C-2'), 
33.08, 34.13, 35.02 (3 Cy), 35.32 (C-2), 37.52 (C-6), 39.34 (C-5), 39.79 (C-1'), 42.76 (Lac-
C3), 43.27 (C-1), 47.49 (C-2''), 51.34 (C-1''), 62.72 (Gal-C6), 67.68 (Gal-C4), 67.73 (Fuc-
C5), 70.29 (Fuc-C2), 71.39 (Fuc-C3), 72.95 (Gal-C2), 73.94 (Fuc-C4), 75.94 (Gal-C5), 77.98 
(Lac-C2), 79.81 (C-3), 83.03 (C-4), 83.65 (Gal-C3), 100.44 (Fuc-C1), 100.47 (Gal-C1), 
105.76 (Ind-C3), 110.21 (Ind-C7), 117.97 (Ind-C6), 118.69 82 (Ind-C4), 123.96 (C-6'), 
129.12 (Ind-C9), 129.68, 130.84, 131.51 (5C, C6H5), 132.46 (Ind-C2), 134.34 (C6H5), 140.49 
(Ind-C8), 142.87 (Ind-C5), 148.89 (C-5'), 166.79 (COPh), 176.92 (CONH), 178.93 (COOH); 
IR (KBr): " = 3436 (vs, OH), 2927 (m), 2852 (w), 1725 (m, C=O), 1638 (m, C=O), 1584 
(vw), 1516 (w), 1479 (vw), 1450 (w), 1383 (vw), 1335 (s, NO2), 1269 (s), 1218 (w), 1166 
(w), 1114 (m), 1071 (s), 1032 (m), 998 (w), 966 (vw), 746 (vw), 712 (w) cm
-1
; HR-MS: m/z: 
calcd for C52H70N6O17 [M+H]
+
: 1051.4870; found: 1051.4872. 
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(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-({1-[3-(5-nitro-1H-indol-
1-yl)propyl]-1H-1,2,3-triazol-4-yl}methyl)cyclohexanecarboxamide (41). Prepared 
according to general procedure C from 26a (12.0 mg, 15.4 !mol), 28c (5.7 mg, 23.2 !mol), 
Na-L-ascorbate (77 !L, 7.7 !mol) and CuSO4"5 H2O (39 !L, 3.9 !mol). Yield: 13.5 mg 
(85%). [#]D
20
 -51.9 (c 1.15, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.50-0.72 (m, 4H, 
Cy), 0.90 (m, 1H, Cy), 1.08 (d, J = 6.4 Hz, 3H, Me), 1.13-1.25 (m, 3H, Cy, H-6a, H-2a), 
1.24-1.37 (m, 7H, 4 Cy, Fuc-H6), 1.41 (m, 1H, Lac-H3a), 1.45-1.58 (m, 2H, Lac-H3b, Cy), 
1.58-1.71 (m, 2H, H-6b, H-5), 2.16 (m, 1H, H-2b), 2.29 (m, 1H, H-1), 2.47 (p, J = 6.8 Hz, 
2H, H-2''), 3.13 (t, J = 9.5 Hz, 1H, H-4), 3.56 (t, J = 5.8 Hz, 1H, Gal-H5), 3.61 (dd, J = 2.5, 
9.7 Hz, 1H, Gal-H3), 3.65-3.82 (m, 5H, H-3, Fuc-H2, -H4, Gal-H6), 3.86 (dd, J = 3.3, 10.3 
Hz, 1H, Fuc-H3), 3.95 (s, 1H, Gal-H4), 4.01 (d, J = 7.9 Hz, 1H, Lac-H2), 4.31 (t, J = 7.0 Hz, 
2H, H-3''), 4.33 (s, 2H, H-1'), 4.39 (t, J = 6.7 Hz, 2H, H-1''), 4.67 (d, J = 8.0 Hz, 1H, Gal-H1), 
4.93-4.99 (m, 2H, Fuc-H1, -H5), 5.43 (m, 1H, Gal-H2), 6.74 (d, J = 3.1 Hz, 1H, Ind-H3), 
7.38-7.45 (m, 3H, Ind-H7, C6H5), 7.48 (d, J = 3.2 Hz, 1H, Ind-H2), 7.56 (m, 1H, C6H5), 7.75 
(s, 1H, H-3'), 7.99-8.02 (m, 2H, C6H5), 8.07 (dd, J = 2.2, 9.1 Hz, 1H, Ind-H6), 8.20-8.24 (m, 
1H, NH), 8.56 (d, J = 2.2 Hz, 1H, Ind-H4); 
13
C NMR (125 MHz, CD3OD): ! = 16.73 (Fuc-
C6), 19.24 (Me), 26.53, 26.68, 27.26 (3 Cy), 31.48 (C-2''), 33.12, 34.18 (2 Cy), 35.04, 35.09 
(Cy, C-2), 35.64 (C-1'), 37.51 (C-6), 39.34 (C-5), 42.77 (Lac-C3), 43.03 (C-1), 44.50 (C-3''), 
49.85 (C-1''), 62.76 (Gal-C6), 67.72, 67.75 (Gal-C4, Fuc-C5), 70.31 (Fuc-C2), 71.41 (Fuc-
C3), 72.98 (Gal-C2), 73.95 (Fuc-C4), 75.99 (Gal-C5), 77.98 (Lac-C2), 79.75 (C-3), 83.03 (C-
4), 83.71 (Gal-C3), 100.43 (Fuc-C1), 100.47 (Gal-C1), 105.24 (Ind-C3), 110.69 (Ind-C7), 
117.94 (Ind-C6), 118.84 (Ind-C4), 124.44 (C-3'), 129.36 (Ind-C9), 129.68, 130.87, 131.55 
(5C, C6H5), 132.79 (Ind-C2), 134.30 (C6H5), 140.24 (Ind-C8), 142.85 (Ind-C5), 166.82 
(COPh), 176.96 (CONH); IR (KBr): " = 3429 (vs, OH), 2928 (m), 2852 (w), 1723 (m, C=O), 
1643 (m, C=O), 1580 (vw), 1516 (m), 1479 (w), 1449 (w), 1402 (w), 1380 (w), 1335 (s, 
NO2), 1269 (m), 1210 (w), 1163 (w), 1111 (m), 1070 (s), 1032 (m), 963 (w), 894 (vw), 768 
(vw), 745 (w), 712 (w), 672 (w) cm
-1
; HR-MS: m/z: calcd for C50H66N6O17 [M+H]
+
: 
1023.4557; found: 1023.4561. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(2-{1-[3-(5-nitro-1H-
indol-1-yl)propyl]-1H-1,2,3-triazol-4-yl}ethyl)cyclohexanecarboxamide (42). Prepared 
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according to general procedure C from 26b (17.3 mg, 21.8 !mol), 28c (7.0 mg, 28.5 !mol), 
Na-L-ascorbate (110 !L, 11.0 !mol) and CuSO4"5 H2O (55 !L, 5.5 !mol). Yield: 14.4 mg 
(63%). [#]D
20
 -60.4 (c 0.32 , MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.49-0.74 (m, 4H, 4 
Cy), 0.90 (m, 1H, Cy), 1.05 (d, J = 6.5 Hz, 3H, Me), 1.07-1.25 (m, 3H, H-2a, H-6a, Cy), 
1.26-1.37 (m, 7H, Fuc-H6, 4 Cy), 1.41 (m, 1H, Lac-H3a), 1.45-1.58 (m, 3H, Lac-H3b, H-6b, 
Cy), 1.64 (m, 1H, H-5), 2.11 (m, 1H, H-2b), 2.22 (m, 1H, H-1), 2.46 (p, J = 6.6 Hz, 2H, H-
2''), 2.79 (t, J = 7.1 Hz, 2H, H-2'), 3.11 (t, J = 9.6 Hz, 1H, H-4), 3.32-3.41 (m, 2H, H-1'), 3.54 
(t, J = 6.1 Hz, 1H, Gal-H5), 3.61 (dd, J = 2.8, 9.8 Hz, 1H, Gal-H3), 3.63-3.82 (m, 6H, H-3, 
Fuc-H1, -H4, Gal-H6), 3.85 (dd, J = 3.3, 10.3 Hz, 1H, Fuc-H3), 3.95 (d, J = 2.5 Hz, 1H, Gal-
H4), 4.00 (m, 1H, Lac-H2), 4.30 (t, J = 6.9 Hz, 2H, H-3''), 4.37 (t, J = 6.8 Hz, 2H, H-1''), 4.66 
(d, J = 8.0 Hz, 1H, Gal-H1), 4.93-5.00 (m, 2H, Fuc-H1, -H5), 5.42 (dd, J = 8.2, 9.5 Hz, 1H, 
Gal-H2), 6.73 (d, J = 3.0 Hz, 1H, Ind-H3), 7.41-7.53 (m, 4H, C6H5, Ind-H2, -H7), 7.58 (m, 
1H, C6H5), 7.68 (s, 1H, H-4'), 7.81 (t, J = 5.3 Hz, 1H, NH), 8.02-8.06 (m, 2H, C6H5), 8.05 (d, 
J = 7.2 Hz, 1H, Ind-H6), 8.56 (d, J = 2.2 Hz, 1H, Ind-H4); 
13
C NMR (125 MHz, CD3OD): ! 
= 16.72 (Fuc-C6), 19.24 (Me), 26.53, 26.62, 26.71 (2 Cy, C-2'), 27.27 (Cy), 31.48 (C-2''), 
33.15, 34.22, 35.07 (3 Cy), 35.26 (C-2), 37.52 (C-6), 39.31 (C-5), 39.94 (C-1'), 42.84 (Lac-
C3), 43.23 (C-1), 44.60 (C-3''), 48.16 (C-1''), 62.80 (Gal-C6), 67.72, 67.77 (Gal-C4, Fuc-C5), 
70.33 (Fuc-C2), 71.42 (Fuc-C3), 73.04 (Gal-C2), 73.96 (Fuc-C4), 76.01 (Gal-C5), 77.78 
(Lac-C1), 79.77 (C-3), 82.98 (C-4), 83.69 (Gal-C3), 100.40 (Fuc-C1), 100.52 (Gal-C1), 
105.21 (Ind-C3), 110.75 (Ind-C7), 117.92 (Ind-C6), 118.83 (Ind-C4), 123.83 (C-4'), 129.39 
(Ind-C9), 129.72, 130.90, 131.62 (5C, C6H5), 132.84 (Ind-C2), 134.34 (C6H5), 140.25 (Ind-
C8), 142.90 (Ind-C5), 146.71 (C-3'), 166.81 (COPh), 177.01 (CONH); IR (KBr): " = 3431 
(vs, OH), 2927 (s), 2852 (w), 1724 (s, C=O), 1644 (m,C=O), 1578 (w), 1516 (m), 1476 (w), 
1451 (m), 1404 (w), 1334 (vs, NO2), 1271 (s), 1220 (w), 1163 (m), 1109 (s), 1071 (vs), 1032 
(s), 967 (w), 899 (vw), 807 (vw), 765 (w), 746 (m), 713 (m), 593 (w) cm
-1
; HR-MS: m/z: 
calcd for C51H68N6O17 [M-H+2Na]
+
: 1081.4358; found: 1081.4360. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(3-{1-[3-(5-nitro-1H-
indol-1-yl)propyl]-1H-1,2,3-triazol-4-yl}propyl)cyclohexanecarboxamide (43). Prepared 
according to general procedure C from 26c (106 mg, 132 !mol), 28c (48.0 mg, 196 !mol), 
Na-L-ascorbate (658 !L, 65.8 !mol) and CuSO4"5 H2O (329 !L, 32.9 !mol). Yield: 125 mg 
(91%). [#]D
20
 -53.1 (c 0.99, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.46-0.70 (m, 4H, 4 
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Cy), 0.87 (m, 1H, Cy), 1.11 (d, J = 6.5 Hz, 3H, Me), 1.14-1.36 (m, 10H, H-2a, H-6a, 5 Cy, 
Fuc-H6), 1.40 (m, 1H, Lac-H3a), 1.47 (m, 1H, Lac-H3b), 1.54 (m, 1H, Cy), 1.60 (dd, J = 2.5, 
13.2 Hz, 1H, H-6b), 1.67 (m, 1H, H-5), 1.71-1.81 (m, 2H, H-2'), 2.15 (m, 1H, H-2b), 2.25 
(ddd, J = 3.2, 8.0, 12.7 Hz, 1H, H-1), 2.49 (p, J = 6.8 Hz, 2H, H-2''), 2.65 (t, J = 7.4 Hz, 2H, 
H-3'), 3.05-3.19 (m, 3H, H-1', H-4), 3.57 (t, J = 6.1 Hz, 1H, Gal-H5), 3.64 (dd, J = 3.0, 9.7 
Hz, 1H, Gal-H3), 3.66-3.83 (m, 5H, H-3, Fuc-H2, -H4, Gal-H6), 3.87 (dd, J = 3.3, 10.3 Hz, 
1H, Fuc-H3), 3.96 (d, J = 2.4 Hz, 1H, Gal-H4), 4.00 (dd, J = 2.9, 9.8 Hz, 1H, Lac-H2), 4.32 
(t, J = 6.9 Hz, 2H, H-3''), 4.40 (t, J = 6.7 Hz, 2H, H-1''), 4.70 (d, J = 8.1 Hz, 1H, Gal-H1), 
4.95-5.01 (m, 2H, Fuc-H1, -H5), 5.43 (dd, J = 8.2, 9.6 Hz, 1H, Gal-H2), 6.72 (d, J = 2.9 Hz, 
1H, Ind-H3), 7.34-7.38 (m, 2H, C6H5), 7.44-7.52 (m, 3H, Ind-H2, -H7, C6H5), 7.65 (s, 1H, H-
5'), 7.98-8.02 (m, 2H, C6H5), 8.06 (dd, J = 2.2, 9.1 Hz, 1H, Ind-H6), 8.56 (d, J = 2.2 Hz, Ind-
H4); 
13
C NMR (125 MHz, CD3OD): ! = 16.73 (Fuc-C6), 19.26 (Me), 23.54 (C-3'), 26.50, 
26.67, 27.25 (3 Cy), 30.22 (C-2'), 31.41 (C-2''), 33.11, 34.18, 35.04 (3 Cy), 35.42 (C-2), 
37.50 (C-6), 39.35, 39.48 (C-5, C-1'), 42.82 (Lac-C3), 43.35 (C-1), 44.64 (C-3''), 48.56 (C-
1''), 62.79 (Gal-C6), 67.71, 67.77 (Gal-C4, Fuc-C5), 70.33 (Fuc-C2), 71.42 (Fuc-C3), 73.00 
(Gal-C2), 73.96 (Fuc-C4), 75.99 (Gal-C5), 78.32 (Lac-C2), 79.85 (C-3), 83.03 (C-4), 83.67 
(Gal-C3), 100.45 (Fuc-C1), 100.54 (Gal-C1), 105.21 (Ind-C3), 110.70 (Ind-C7), 117.90 (Ind-
C6), 118.83 (Ind-C4), 123.54 (C-5'), 129.36 (Ind-C9), 129.65, 130.83, 131.56 (5C, C6H5), 
132.81 (Ind-C2), 134.26 (C6H5), 140.24 (Ind-C8), 142.83 (Ind-C5), 148.51 (C-4'), 166.78 
(COPh), 177.04 (CONH), 179.26 (COOH); IR (KBr): " = 3433 (vs, OH), 2926 (m), 2852 
(w), 1725 (m, C=O), 1638 (m, C=O), 1514 (w), 1449 (w), 1402 (w), 1383 (w), 1334 (m, 
NO2), 1268 (m), 1213 (w), 1163 (w), 1111 (m), 1070 (s), 1032 (m), 996 (w), 963 (vw), 933 
(vw), 897 (vw), 807 (vw), 777 (vw), 744 (w), 712 (w) cm
-1
; HR-MS: m/z: calcd for 
C52H70N6O17 [M+Na]
+
: 1073.4690; found: 1073.4684. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-({1-[4-(5-nitro-1H-indol-
1-yl)butyl]-1H-1,2,3-triazol-4-yl}methyl)cyclohexanecarboxamide (44). Prepared 
according to general procedure C from 26a (9.7 mg, 12.5 !mol), 28d (4.2 mg, 16.2 !mol), 
Na-L-ascorbate (124 !L, 12.4 !mol) and CuSO4"5 H2O (62 !L, 6.2 !mol). Yield: 6.4 mg 
(49%). [#]D
20
 -57.0 (c 0.62, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.50-0.73 (m, 4H, 
Cy), 0.91 (m, 1H, Cy), 1.07 (d, J = 6.4 Hz, 3H, Me), 1.17 (m, 3H, Cy, H-6a, H-2a), 1.32 (m, 
7H, 4 Cy, Fuc-H6), 1.42 (m, 1H, Lac-H3a), 1.50 (m, 1H, Lac-H3b), 1.54-1.69 (m, 3H, Cy, H-
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6, H-5), 1.77-1.93 (m, 4H, H-3'', H-2''), 2.15 (m, 1H, H-2), 2.26 (m, 1H, H-1), 3.12 (t, J = 9.5 
Hz, 1H, H-4), 3.55 (t, J = 5.8 Hz, 1H, Gal-H5), 3.62 (dd, J = 2.9, 9.7 Hz, 1H, Gal-H3), 3.64-
3.82 (m, 5H, H-3, Fuc-H2, -H4, Gal-H6), 3.86 (dd, J = 3.3, 10.3 Hz, 1H, Fuc-H3), 3.96 (m, 
1H, Gal-H4), 4.01 (dd, J = 2.5, 9.6 Hz, 1H, Lac-H2), 4.26 (t, J = 6.8 Hz, 2H, H-4''), 4.31 (s, 
2H, H-1'), 4.39 (t, J = 6.6 Hz, 2H, H-1''), 4.67 (d, J = 8.1 Hz, 1H, Gal-H1), 4.94-4.99 (m, 2H, 
Fuc-H1, -H5), 5.43 (m, 1H, Gal-H2), 6.71 (d, J = 3.2 Hz, 1H, Ind-H3), 7.41-7.47 (m, 3H, 
Ind-H7, C6H5), 7.52 (d, J = 9.1 Hz, 1H, Ind-H2), 7.58 (m, 1H, C6H5), 7.72 (s, 1H, H-3'), 8.02-
8.05 (m, 2H, C6H5), 8.07 (dd, J = 2.2, 9.1 Hz, 1H, Ind-H6), 8.55 (d, J = 2.1 Hz, 1H, Ind-H4); 
13
C NMR (125 MHz, CD3OD): ! = 16.73 (Fuc-C6), 19.23 (Me), 26.54, 26.70, 27.28 (3 Cy), 
28.16, 28.48 (C-2'', C-3''), 33.13, 34.20 (2 Cy), 35.06, 35.10 (Cy, C-2), 35.58 (C-1'), 37.44 
(C-6), 39.31 (C-5), 42.83 (Lac-C3), 42.97 (C-1), 46.81 (C-4''), 50.70 (C-1''), 62.78 (Gal-C6), 
67.72, 67.76 (Gal-C4, Fuc-C5), 70.31 (Fuc-C2), 71.41 (Fuc-C3), 73.00 (Gal-C2), 73.96 (Fuc-
C4), 75.99 (Gal-C5), 78.29 (Lac-C2), 79.76 (C-3), 83.00 (C-4), 83.72 (Gal-C3), 100.43 (Fuc-
C1), 100.50 (Gal-C1), 104.94 (Ind-C3), 110.76 (Ind-C7), 117.80 (Ind-C6), 118.81 (Ind-C4), 
124.19 (C-3'), 129.27 (Ind-C9), 129.71, 130.89, 131.59 (5C, C6H5), 132.79 (Ind-C2), 134.33 
(C6H5), 140.27 (Ind-C8), 142.72 (Ind-C5), 146.16 (C-2'), 166.85 (COPh), 176.90 (CONH), 
179.31 (COOH); IR (KBr): " = 3431 (vs, OH), 2927 (m), 2852 (m), 1725 (m, C=O), 1639 
(m, C=O), 1580 (w), 1516 (m), 1479 (w), 1448 (w), 1402 (w), 1383 (w), 1334 (s, NO2), 1271 
(m), 1111 (m), 1071 (s), 1032 (m), 999 (vw), 966 (vw), 933 (vw), 897 (vw), 837 (vw), 804 
(vw), 768 (vw), 746 (vw), 713 (w), 667 (vw), 593 (vw) cm
-1
; HR-MS: m/z: calcd for 
C51H68N6O17 [M-H+2Na]
+
: 1081.4353; found: 1081.4342. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(2-{1-[4-(5-nitro-1H-
indol-1-yl)butyl]-1H-1,2,3-triazol-4-yl}ethyl)cyclohexanecarboxamide (45). Prepared 
according to general procedure C from 26b (14.0 mg, 17.7 !mol), 28d (6.1 mg, 23.5 !mol), 
Na-L-ascorbate (252 !L, 25.2 !mol) and CuSO4"5 H2O (125 !L, 12.5 !mol). Yield: 9.3 mg 
(50%). [#]D
20
 -60.1 (c 0.86, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.49-0.72 (m, 4H, 4 
Cy), 0.90 (m, 1H, Cy), 1.06 (d, J = 6.5 Hz, 3H, Me), 1.08-1.26 (m, 3H, Cy, H-6a, H-2a), 
1.26-1.36 (m, 7H, 4 Cy, H-6), 1.40 (m, 1H, Lac-H3), 1.46-1.59 (m, 3H, Lac-H3, H-6b, Cy), 
1.63 (m, 1H, H-5), 1.77-1.91 (m, 4H, H-3'', H-2''), 2.12 (m, 1H, H-2b), 2.19 (m, 1H, H-1), 
2.76 (t, J = 7.2 Hz, 2H, H-2'), 3.11 (t, J = 9.6 Hz, 1H, H-4), 3.32 (m, 1H, H-1') 3.56 (m, 1H, 
Gal-H5), 3.61-3.81 (m, 6H, Gal-H3, -H6, H-3, Fuc-H2, -H4), 3.86 (dd, J = 3.3, 10.3 Hz, 1H, 
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Fuc-H3), 3.95 (d, J = 2.3 Hz, 1H, Gal-H4), 4.03 (dd, J = 2.8, 9.8 Hz, 1H, Lac-H1), 4.27 (t, J 
= 6.7 Hz, 2H, H-1''), 4.36 (t, J = 6.4 Hz, 2H, H-1''), 4.68 (d, J = 8.1 Hz, 1H, Gal-H1), 4.94 (d, 
J = 4.0 Hz, 1H, Fuc-H1), 4.98 (m, 1H, Fuc-H5), 5.43 (dd, J = 8.3, 9.5 Hz, 1H, Gal-H2), 6.71 
(dd, J = 0.5, 3.2 Hz, 1H, Ind-H3), 7.43-7.47 (m, 3H, C6H5, Ind-H2), 7.52-7.58 (m, 2H, Ind-
H7, C6H5), 7.64 (s, 1H, H-4'), 8.03-8.09 (m, 3H, C6H5, Ind-H6), 8.56 (d, J = 2.2 Hz, 1H, Ind-
H4); 
13
C NMR (125 MHz, CD3OD): ! = 16.74 (Fuc-C6), 19.24 (Me), 26.53, 26.59, 26.70 
(3C, 2 Cy, C-2'), 27.27 (Cy), 28.11 (C-3''), 28.50 (C-2''), 33.12, 34.18, 35.05 (3 Cy), 35.27 
(C-2), 37.46 (C-6), 39.31 (C-5), 39.97 (C-1'), 42.80 (Lac-C3), 43.22 (C-1), 46.85 (C-2''), 
50.61 (C-1''), 62.75 (Gal-C6), 67.70, 67.74 (Gal-C4, Fuc-C5), 70.31 (Fuc-C2), 71.42 (Fuc-
C3), 73.02 (Gal-C2), 73.96 (Fuc-C4), 75.98 (Gal-C5), 78.07 (Lac-C2), 79.79 (C-3), 83.00 (C-
4), 83.68 (Gal-C3), 100.43 (Fuc-C1), 100.51 (Gal-C1), 104.93 (Ind-C3), 110.78 (Ind-C7), 
117.79 (Ind-C6), 118.84 (Ind-C4), 123.58 (C-4'), 129.29 (Ind-C9), 129.73, 130.91, 131.58 
(5C, C6H5), 132.88 (Ind-C2), 134.36 (C6H5), 140.24 (Ind-C8), 142.72 (Ind-C5), 146.35 (C-
3'), 166.81 (COPh), 176.99 (CONH), 179.14 (COOH); IR (KBr): " = 3414 (vs, OH), 2927 
(s), 2852 (m), 1722 (s, C=O), 1648 (m, C=O), 1610 (w), 1580 (w), 1515 (m), 1479 (w), 1450 
(m), 1404 (w), 1334 (vs), 1272 (s), 1215 (w), 1163 (m), 1112 (s), 1072 (vs), 1032 (s, NO2), 
967 (w), 897 (vw), 807 (vw), 768 (w), 747 (m), 713 (m), 675 (w), 628 (w), 593 (w) cm
-1
; 
HR-MS: m/z: calcd for C52H70N6O17 [M+H]
+
: 1051.4870; found: 1051.4868. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(3-{1-[4-(5-nitro-1H-
indol-1-yl)butyl]-1H-1,2,3-triazol-4-yl}propyl)cyclohexanecarboxamide (46). Prepared 
according to general procedure C from 26c (12.0 mg, 14.9 !mol), 28d (5.8 mg, 22.4 !mol), 
Na-L-ascorbate (74 !L, 7.4 !mol) and CuSO4"5 H2O (37 !L, 3.7 !mol). Yield: 9.4 mg 
(59%). [#]D
20
 -53.1 (c 0.82, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.49-0.70 (m, 4H, 4 
Cy), 0.89 (m, 1H, Cy), 1.10 (d, J = 6.4 Hz, 3H, Me), 1.14-1.37 (m, 10H, H-2a, H-6a, 5 Cy, 
Fuc-H6), 1.40 (dd, J = 9.1, 11.8 Hz, 1H, Lac-H3a), 1.45-1.62 (m, 3H, Lac-H3b, Cy, H-6b), 
1.66 (m, 1H, H-5), 1.70-1.78 (m, 2H, H-2'), 1.78-1.93 (m, 4H, H-3'', H-2''), 2.15 (m, 1H, H-
2b), 2.25 (m, 1H, H-1), 2.63 (t, J = 7.4 Hz, 2H, H-3'), 3.03-3.19 (m, 3H, H-1', H-4), 3.57 (t, J 
= 5.9 Hz, 1H, Gal-H5), 3.64 (dd, J = 2.8, 9.7 Hz, 1H, Gal-H3), 3.66-3.83 (m, 5H, H-3, Fuc-
H2, -H4, Gal-H6), 3.87 (dd, J = 3.2, 10.3 Hz, 1H, Fuc-H3), 3.95-4.03 (m, 2H, Gal-H4, Lac-
H2), 4.28 (t, J = 6.8 Hz, 2H, H-4''), 4.38 (t, J = 6.6 Hz, 2H, H-1''), 4.70 (d, J = 8.0 Hz, 1H, 
Gal-H1), 4.95-5.02 (m, 2H, Fuc-H1, -H5), 5.43 (m, 1H, Gal-H2), 6.70 (d, J = 2.8 Hz, 1H, 
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Ind-H3), 7.33-7.40 (m, 2H, C6H5), 7.44 (d, J = 3.2 Hz, 1H, Ind-H2), 7.46-7.54 (m, 2H, C6H5, 
Ind-H7), 7.63 (s, 1H, H-5'), 7.98-8.04 (m, 2H, C6H5), 8.06 (dd, J = 2.2, 9.1 Hz, 1H, Ind-H6), 
8.55 (d, J = 2.2 Hz, 1H, Ind-H4); 
13
C NMR (125 MHz, CD3OD): ! = 16.73 (Fuc-C6), 19.26 
(Me), 23.53 (C-3'), 26.52, 26.69, 27.27 (3 Cy), 28.11, 28.47 (C-2'', C-3''), 30.23 (C-2'), 33.12, 
34.20, 35.07 (3 Cy), 35.44 (C-2), 37.48 (C-6), 39.34, 39.45 (C-5, C-1'), 42.86 (Lac-C3), 
43.34 (C-1), 46.87 (C-2''), 50.61 (C-1''), 62.81 (Gal-C6), 67.71, 67.76 (Gal-C4, Fuc-C5), 
70.33 (Fuc-C2), 71.42 (Fuc-C3), 73.02 (Gal-C2), 73.97 (Fuc-C4), 76.00 (Gal-C5), 78.36 
(Lac-C2), 79.87 (C-3), 83.01 (C-4), 83.67 (Gal-C3), 100.44 (Fuc-C1), 100.58 (Gal-C1), 
104.90 (Ind-C3), 110.78 (Ind-C7), 117.78 (Ind-C6), 118.82 (Ind-C4), 123.35 (C-5'), 129.31 
(Ind-C9), 129.65, 130.83, 131.57 (5C, C6H5), 132.89 (Ind-C2), 134.26 (C6H5), 140.26 (Ind-
C8), 142.71 (Ind-C5), 148.45 (C-4'), 166.78 (COPh), 177.03 (CONH), 179.61 (COOH); IR 
(KBr): " = 3436 (vs, OH), 2926 (w), 2852 (vw), 1723 (w, C=O), 1632 (m, C=O), 1512 (w), 
1451 (w), 1383 (w), 1334 (m, NO2), 1270 (m), 1210 (vw), 1166 (vw), 1111 (m), 1070 (m), 
1032 (m), 996 (vw), 966 (vw), 744 (w), 711 (w) cm
-1
; HR-MS: m/z: calcd for C53H72N6O17 
[M+Na]
+
: 1087.4846; found: 1087.4848. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-({1-[2-(6-nitro-1H-indol-
3-yl)ethyl]-1H-1,2,3-triazol-4-yl}methyl)cyclohexanecarboxamide (47). Prepared 
according to general procedure C from 26a (9.2 mg, 11.8 !mol), 32b (3.6 mg, 15.6 !mol), 
Na-L-ascorbate (118 !L, 11.8 !mol) and CuSO4"5 H2O (59 !L, 5.9 !mol). Yield: 2.5 mg 
(21%). [#]D
20
 -62.7 (c 0.26, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.48-0.71 (m, 4H, 4 
Cy), 0.90 (m, 1H, Cy), 1.10 (t, J = 7.0 Hz, 3H, Me), 1.13-1.24 (m, 3H, H-2a, H-6a, Cy), 1.24-
1.36 (m, 7H, 4 Cy, Fuc-H6), 1.41 (m, 1H, Lac-H3a), 1.49 (m, 1H, Lac-H3b), 1.53-1.61 (m, 
2H, Cy, H-6b), 1.65 (m, 1H, H-5), 2.15 (m, 1H, H-2b), 2.25 (m, 1H, H-1), 3.14 (t, J = 9.6 Hz, 
1H, H-4), 3.41 (t, J = 6.7 Hz, 2H, H-2''), 3.57 (t, J = 5.9 Hz, 1H, Gal-H5), 3.61 (dd, J = 2.9, 
9.7 Hz, 1H, Gal-H3), 3.65-3.82 (m, 5H, H-3, Fuc-H2, -H4, Gal-H6), 3.87 (dd, J = 3.3, 10.3 
Hz, 1H, Fuc-H3), 3.93-3.98 (m, 2H, Gal-H4, Lac-H2), 4.27 (s, 2H, H-1'), 4.66-4.71 (m, 3H, 
H-1'', Gal-H1), 4.94-5.00 (m, 2H, Fuc-H1, -H5), 5.42 (dd, J = 8.2, 9.6 Hz, 1H, Gal-H2), 7.21 
(s, 1H, Ind-H2), 7.41-7.46 (m, 3H, C6H5, Ind-H7), 7.57 (m, 1H, C6H5), 7.66 (s, 1H, H-3'), 
8.01-8.05 (m, 3H, Ind-H6, C6H5), 8.30 (d, J = 2.1 Hz, 1H, Ind-H4); 
13
C NMR (125 MHz, 
CD3OD): ! = 16.72 (Fuc-C6), 19.26 (Me), 26.54, 26.72, 27.09 (3 Cy), 27.30 (C-2''), 33.12, 
34.24 (2 Cy), 35.12, 35.16 (Cy, C-2), 35.54 (C-1'), 37.39 (C-6), 39.32 (C-5), 42.95, 42.98 (C-
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1, Lac-C3), 52.36 (C-1''), 62.85 (Gal-C6), 67.74, 67.75 (Gal-C4, Fuc-C5), 70.33 (Fuc-C2), 
71.41 (Fuc-C3), 73.02 (Gal-C2), 73.96 (Fuc-C4), 76.03 (Gal-C5), 79.11 (Lac-C2), 79.79 (C-
3), 83.03 (C-4), 83.75 (Gal-C3), 100.44 (Fuc-C1), 100.54 (Gal-C1), 112.57 (Ind-C7), 114.78 
(Ind-C3), 116.40 (Ind-C4), 117.99 (Ind-C6), 124.51 (C-3'), 127.90, 127.98 (Ind-C2, -C9), 
129.69, 130.89, 131.60, 134.30 (6C, C6H5), 141.03 (Ind-C8), 142.51 (Ind-C5), 146.17 (C-2'), 
166.86 (COPh), 176.85 (CONH); IR (KBr): ! = 3435 (vs, OH), 2925 (w), 2852 (vw), 1720 
(w, C=O), 1632 (m, C=O), 1517 (vw), 1451 (vw), 1383 (w), 1333 (m), 1268 (w), 1163 (w), 
1076 (m), 1032 (m, NO2), 966 (vw), 711 (vw), 675 (vw), 587 (vw) cm
-1
; HR-MS: m/z: calcd 
for C49H64N6O17 [M+Na]
+
: 1031.4220; found: 1031.4223. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(2-{1-[2-(6-nitro-1H-
indol-3-yl)ethyl]-1H-1,2,3-triazol-4-yl}ethyl)cyclohexanecarboxamide (48). Prepared 
according to general procedure C from 26b (15.2 mg, 19.2 !mol), 32b (5.9 mg, 25.5 !mol), 
Na-L-ascorbate (96 !L, 9.6 !mol) and CuSO4"5 H2O (48 !L, 4.8 !mol). Yield: 13.7 mg 
(70%). [#]D
20
 -53.9 (c 1.04, MeOH); 
1
H NMR (500 MHz, CD3OD): " = 0.50-0.73 (m, 4H, 4 
Cy), 0.90 (m, 1H, Cy), 1.08 (d, J = 6.5 Hz, 3H, Me), 1.10-1.26 (m, 3H, H-6a, H-2a, Cy), 
1.26-1.37 (m, 8H, 5 Cy, Fuc-H6), 1.41 (m, 1H, Lac-H3a), 1.46-1.58 (m, 3H, Lac-H3b, Cy, H-
6b), 1.64 (m, 1H, H-5), 2.11 (m, 1H, H-2), 2.20 (m, 1H, H-1), 2.72 (t, J = 7.2 Hz, 2H, H-2'), 
3.12 (t, J = 9.6 Hz, 1H, H-4), 3.24-3.29 (m, 2H, H-1'), 3.41 (t, J = 6.7 Hz, 2H, H-2''), 3.54 (t, 
J = 5.9 Hz, 1H, Gal-H5), 3.61 (dd, J = 3.0, 9.7 Hz, 1H, Gal-H3), 3.67 (ddd, J = 4.7, 9.3, 11.6 
Hz, 1H, H-3), 3.70-3.81 (m, 4H, Fuc-H2, -H4, Gal-H6), 3.86 (dd, J = 3.3, 10.3 Hz, 1H, Fuc-
H3), 3.94 (d, J = 2.4 Hz, 1H, Gal-H4), 4.01 (dd, J = 3.1, 9.7 Hz, 1H, Lac-H2), 4.64-4.69 (m, 
3H, Gal-H1, H-1''), 4.93-4.99 (m, 2H, Fuc-H1, -H5), 5.42 (dd, J = 8.2, 9.6 Hz, 1H, Gal-H2), 
7.22 (s, 1H, Ind-H2), 7.41-7.48 (m, 3H, Ind-H7, C6H5), 7.54 (m, 1H, C6H5), 7.60 (s, 1H, H-
4'), 7.99-8.05 (m, 3H, Ind-H6, C6H5), 8.09 (s, 1H, NH), 8.30 (d, J = 2.2 Hz, 1H, Ind-H4); 
13
C 
NMR (125 MHz, CD3OD): " = 16.71 (Fuc-C6), 19.24 (Me), 26.47, 26.53, 26.70 (2 Cy, C-2'), 
27.12, 27.26 (Cy, C-2''), 33.14, 34.18, 35.04 (3 Cy), 35.29 (C-2), 37.43 (C-6), 39.31 (C-5), 
39.96 (C-1'), 42.77 (Lac-C3), 43.22 (C-1), 52.34 (C-1''), 62.76 (Gal-C6), 67.71, 67.77 (Gal-
C4, Fuc-C5), 70.32 (Fuc-C2), 71.42 (Fuc-C3), 73.02 (Gal-C2), 73.96 (Fuc-C4), 75.97 (Gal-
C5), 78.06 (Lac-C2), 79.83 (C-3), 83.01 (C-4), 83.67 (Gal-C3), 100.42 (Fuc-C1), 100.53 
(Gal-C1), 112.58 (Ind-C7), 114.82 (Ind-C3), 116.36 (Ind-C4), 117.99 (Ind-C6), 124.01 (C-
4'), 127.93, 127.95 (Ind-C2, -C9), 129.73, 130.88, 131.55, 134.37 (6C, C6H5), 140.99 (Ind-
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C8), 142.53 (Ind-C5), 146.19 (C-3'), 166.83 (COPh), 176.99 (CONH), 178.96 (COOH); IR 
(KBr): ! = 3431 (vs, OH), 2927 (m), 2852 (w), 1721 (m, C=O), 1647 (m, C=O), 1545 (w), 
1522 (w), 1471 (w), 1450 (w), 1380 (w), 1334 (s, NO2), 1272 (m), 1221 (w), 1163 (w), 1097 
(s), 1079 (s), 1029 (m), 999 (w), 963 (vw), 809 (vw), 785 (vw), 741 (vw), 712 (w), 678 (w) 
cm
-1
; HR-MS: m/z: calcd for C50H66N6O17 [M+Na]
+
: 1045.4377; found: 1045.4375. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(3-{1-[2-(6-nitro-1H-
indol-3-yl)ethyl]-1H-1,2,3-triazol-4-yl}propyl)cyclohexanecarboxamide (49). Prepared 
according to general procedure C from 26c (14.5 mg, 18.0 !mol), 32b (6.3 mg, 27.2 !mol), 
Na-L-ascorbate (90 !L, 9.0 !mol) and CuSO4"5 H2O (45 !L, 4.5 !mol). Yield: 10.3 mg 
(55%). [#]D
20
 -32.3 (c 0.31, MeOH); 
1
H NMR (500 MHz, CD3OD): " = 0.46-0.71 (m, 4H, 4 
Cy), 0.88 (m, 1H, Cy), 1.11 (d, J = 6.5 Hz, 3H, Me), 1.14-1.37 (m, 10H, H-2a, H-6a, 5 Cy, 
Fuc-H6), 1.41 (m, 1H, Lac-H3a), 1.45-1.56 (m, 2H, Lac-H3b, Cy), 1.60 (m, 1H, H-6b), 1.62-
1.74 (m, 3H, H-5, H-2'), 2.15 (m, 1H, H-2b), 2.25 (m, 1H, H-1), 2.53-2.64 (m, 2H, H-3'), 
2.95-3.11 (m, 2H, H-1'), 3.15 (t, J = 9.4 Hz, 1H, H-4), 3.41 (t, J = 6.5 Hz, 2H, H-2''), 3.55-
3.65 (m, 2H, Gal-H3, -H5), 3.66-3.83 (m, 5H, H-3, Fuc-H2, -H4, Gal-H6), 3.87 (dd, J = 2.8, 
10.3 Hz, 1H, Fuc-H3), 3.90-4.04 (m, 2H, Gal-H4 Lac-H2), 4.61-4.74 (m, 3H, Gal-H1, H-1''), 
4.95-5.01 (m, 2H, Fuc-H1, -H5), 5.43 (m, 1H, Gal-H2), 7.23 (s, 1H, Ind-H2,), 7.35-7.45 (m, 
3H, Ind-H7, C6H5), 7.51 (m, 1H, C6H5), 7.58 (s, 1H, H-5'), 7.99-8.05 (m, 3H, Ind-H6, C6H5), 
8.23 (d, J = 2.1 Hz, 1H, Ind-H4); 
13
C NMR (125 MHz, CD3OD): " = 16.72 (Fuc-C6), 19.28 
(Me), 23.50 (C-3'), 26.50, 26.71 (2 Cy), 27.09 (C-2''), 27.28 (Cy), 30.12 (C-2'), 33.12, 34.38, 
35.13 (3 Cy), 35.41 (C-2), 37.45 (C-6), 39.34, 39.40 (C-1', C-5), 43.33 (2C, Lac-C3, C-1), 
52.54 (C-1''), 62.88 (Gal-C5), 67.73 (2C, Fuc-C5, Gal-C4), 70.33 (Fuc-C2), 71.41 (Fuc-C3), 
73.08 (Gal-C2), 73.97 (Fuc-C4), 76.26 (Lac-C2), 79.84 (C-3), 83.03 (C-4), 83.70 (Gal-C3), 
100.43 (Fuc-C1), 100.59 (Gal-C1), 112.55 (Ind-C7), 114.91 (Ind-C3), 116.35 (Ind-C4), 
117.93 (Ind-C6), 123.98 (C-5'), 127.99 (2C, Ind-C2, -C9), 129.66, 130.85, 131.59, 134.27 
(6C, C6H5), 140.96 (Ind-C8), 142.49 (Ind-C5), 148.09 (C-4'), 166.82 (COPh), 177.03 
(CONH); IR (KBr): ! = 3434 (vs, OH), 2926 (m), 282 (w), 1720 (w, C=O), 1631 (m, C=O), 
1547 (w), 1520 (w), 1468 (w), 1449 (w), 1380 (w), 1333 (m, NO2), 1268 (m), 1169 (w), 1161 
(w), 1097 (m), 1074 (m), 1032 (m), 999 (w), 712 (w) cm
-1
; HR-MS: m/z: calcd for 
C51H68N6O17 [M+Na]
+
: 1059.4533; found: 1059.4528. 
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(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-({1-[3-(6-nitro-1H-indol-
3-yl)propyl]-1H-1,2,3-triazol-4-yl}methyl)cyclohexanecarboxamide (50). Prepared 
according to general procedure C from 26a (14.4 mg, 11.8 !mol), 32c (6.8 mg, 27.7 !mol), 
Na-L-ascorbate (186 !L, 18.6 !mol) and CuSO4"5 H2O (92 !L, 9.2 !mol). Yield: 12.9 mg 
(68%). [#]D
20
 -54.1 (c 0.3, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.47-0.71 (m, 4H, 4 
Cy), 0.88 (m, 1H, Cy), 1.09 (d, J = 6.4 Hz, 3H, Me), 1.12-1.44 (m, 11 H, H-2a, H-6a, 5 Cy, 
Lac-H3a), 1.49 (m, 1H, Lac-H3b), 1.52-1.70 (m, 4H, 2 Cy, H-6b, H-5), 2.16 (m, 1H, H-2b), 
2.26-2.36 (m, 3H, H-1, H-2''), 2.82 (t, J = 7.5 Hz, 2H, H-3''), 3.13 (t, J = 9.5 Hz, 1H, H-4), 
3.53-3.58 (m, 2H, Gal-H3, -H5), 3.65-3.81 (m, 5H, H-3, Fuc-H2, -H4, Gal-H6), 3.84-3.90 
(m, 2H, Fuc-H3, Gal-H4), 3.94 (s, 1H, Lac-H2), 4.31-4.41 (m, 2H, H-1'), 4.46 (t, J = 6.8 Hz, 
2H, H-1''), 4.65 (d, J = 8.1 Hz, 1H, Gal-H1), 4.93-4.98 (m, 2H, Fuc-H1, -H5), 5.41 (dd, J = 
8.5, 9.3 Hz, 1H, Gal-H2), 7.30 (s, 1H, Ind-H2), 7.38-7.44 (m, 2H, C6H5), 7.46 (d, J = 9.0 Hz, 
1H, Ind-H7), 7.55 (m, 1H, C6H5), 7.82 (s, 1H, H-3'), 7.98-8.02 (m, 2H, C6H5), 8.04 (dd, J = 
2.2, 9.0 Hz, 1H, Ind-H6), 8.47 (d, J = 2.1 Hz, 1H, Ind-H4); 
13
C NMR (125 MHz, CD3OD): ! 
= 16.72 (Fuc-C6), 19.24 (Me), 22.56 (C3''), 26.53, 26.74, 27.33 (3 Cy), 31.89 (C-2''), 33.10, 
34.29 (3C, 3 Cy), 35.14, 35.20 (Cy, C-2), 35.63 (C-1'), 37.49 (C-6), 39.33 (C-5), 43.04 (Lac-
C3), 43.14 (C-1), 50.86 (C-1''), 62.92 (Gal-C6), 67.71, 67.74 (Gal-C4, Fuc-C5), 70.33 (Fuc-
C2), 71.40 (Fuc-C3), 72.99 (Gal-C2), 73.96 (Fuc-C4), 76.01 (Gal-C5), 79.76 (C-3), 83.02 (C-
4), 83.76 (Gal-C3), 100.41 (Fuc-C1), 100.55 (Gal-C1), 112.53 (Ind-C7), 116.55 (Ind-C4), 
117.68 (Ind-C3), 117.93 (Ind-C6), 124.35 (C-3'), 127.11 (Ind-C2), 127.95 (Ind-C9), 129.66, 
130.87, 131.65, 134.24 (6C, C6H5), 141.25 (Ind-C8), 142.29 (Ind-C5), 166.84 (COPh), 
176.98 (CONH); IR (KBr): " = 3433 (vs, OH), 2925 (m), 2852 (w), 1722 (m, C=O), 1631 (m, 
C=O), 1520 (w), 1468 (w), 1451 (w), 1383 (w), 1333 (m, NO2), 1270 (m), 1210 (w), 1163 
(w), 1108 (m), 1074 (m), 1029 (m), 966 (vw), 892 (vw), 807 (vw), 776 (vw), 738 (vw), 712 
(w), 672 (vw) cm
-1
; HR-MS: m/z: calcd for C50H66N6O17 [M+Na]
+
: 1045.4377; found: 
1045.4381. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(2-{1-[3-(6-nitro-1H-
indol-3-yl)propyl]-1H-1,2,3-triazol-4-yl}ethyl)cyclohexanecarboxamide (51). Prepared 
according to general procedure C from 26b (15.8 mg, 20.0 !mol), 32c (6.9 mg, 28.1 !mol), 
Na-L-ascorbate (100 !L, 10.0 !mol) and CuSO4"5 H2O (50 !L, 5.0 !mol). Yield: 14.1 mg 
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(68%). [!]D
20
 -59.7 (c 1.22, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.50-0.72 (m, 4H, 4 
Cy), 0.89 (m, 1H, Cy), 1.00 (d, J = 6.5 Hz, 3H, Me), 1.04-1.25 (m, 3H, H-2a, H-6a, Cy), 
1.26-1.36 (m, 7H, 4 Cy, Fuc-H6), 1.40 (m, 1H, Lac-H3a), 1.45-1.62 (m, 4H, Lac-H3b, Cy, H-
6b, H-5), 2.12 (m, 1H, H-2b), 2.20 (tt, J = 3.2, 12.7 Hz, 1H, H-1), 2.24-2.34 (m, 2H, H-2''), 
2.77-2.85 (m, 4H, H-2', H-3''), 3.06 (t, J = 9.6 Hz, 1H, H-4), 3.39 (t, J = 7.0 Hz, 2H, H-1'), 
3.52 (t, J = 6.0 Hz, 1H, Gal-H5), 3.59 (dd, J = 2.8, 9.7 Hz, 1H, Gal-H3), 3.64 (ddd, J = 4.6, 
9.1, 11.6 Hz, 1H, H-3), 3.69-3.81 (m, 4H, Fuc-H2, -H4, Gal-H6), 3.85 (dd, J = 3.3, 10.3 Hz, 
1H, Fuc-H3), 3.93 (d, J = 2.1 Hz, 1H, Gal-H4), 3.98 (dd, J = 2.5, 9.6 Hz, 1H, Lac-H2), 4.36-
4.47 (m, 2H, H-1''), 4.64 (d, J = 8.1 Hz, 1H, Gal-H1), 4.92 (m, 1H, Fuc-H1), 4.96 (q, J = 6.4 
Hz, 1H, Fuc-H5), 5.42 (dd, J = 8.2, 9.6 Hz, 1H, Gal-H2), 7.30 (s, 1H, Ind-H2), 7.43-7.50 (m, 
3H, Ind-H7, C6H5), 7.58 (m, 1H, C6H5), 7.70 (s, 1H, H-4'), 8.01-8.09 (m, 3H, C6H5, Ind-H6), 
8.49 (d, J = 2.1 Hz, 1H, Ind-H4); 
13
C NMR (125 MHz, CD3OD): ! = 16.73 (Fuc-C6), 19.17 
(Me), 22.58 (C-3''), 26.53, 26.55, 26.71 (2 Cy, C-2'), 27.29 (Cy), 31.85 (C-2''), 33.12, 34.24, 
35.12 (3 Cy), 35.30 (C-2), 37.43 (C-6), 39.25 (C-5), 39.87 (C-1'), 42.95 (Lac-C3), 43.17 (C-
1), 50.75 (C-1''), 62.84 (Gal-C6), 67.72, 67.73 (Gal-C4, Fuc-C5), 70.31 (Fuc-C2), 71.41 
(Fuc-C3), 73.03 (Gal-C2), 73.95 (Fuc-C4), 75.97 (Gal-C5), 78.36 (Lac-C2), 79.77 (C-3), 
83.01 (C-4), 83.72 (Gal-C3), 100.39 (Fuc-C1), 100.54 (Gal-C1), 112.53 (Ind-C7), 116.59 
(Ind-C4), 117.69 (Ind-C3), 117.93 (Ind-C6), 123.79 (C-4'), 127.12 (Ind-C2), 127.94 (Ind-
C9), 129.74, 130.91, 131.63, 134.36 (6C, C6H5), 141.23 (Ind-C8), 142.30 (Ind-C5), 146.29 
(C-3'), 166.84 (COPh), 177.00 (CONH); IR (KBr): " = 3430 (vs, OH), 2927 (m), 2852 (w), 
1720 (m, C=O), 1647 (m, C=O), 1547 (w), 1520 (w), 1471 (w), 1450 (w), 1333 (s, NO2), 
1272 (m), 1221 (w), 1163 (w), 1097 (s), 1078 (s), 1029 (m), 999 (w), 966 (vw), 809 (vw), 
778 (vw), 738 (vw), 712 (w), 678 (vw) cm
-1
; HR-MS: m/z: calcd for C51H68N6O17 [M+H]
+
: 
1037.4714; found: 1037.4714. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(3-{1-[3-(6-nitro-1H-
indol-3-yl)propyl]-1H-1,2,3-triazol-4-yl}propyl)cyclohexanecarboxamide (52). Prepared 
according to general procedure C from 26c (11.6 mg, 14.4 "mol), 32c (5.3 mg, 21.6 "mol), 
Na-L-ascorbate (72 "L, 7.2 "mol) and CuSO4#5 H2O (36 "L, 3.6 "mol). Yield: 9.5 mg 
(63%). [!]D
20
 -47.6 (c 0.87, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.46-0.67 (m, 4H, 4 
Cy), 0.85 (m, 1H, Cy), 1.10 (d, J = 6.4 Hz, 3H, Me), 1.13-1.44 (m, 11H, H-2a, H-6a, 5 Cy, 
Fuc-H6, Lac-H3a), 1.50 (m, 1H, Lac-H3b), 1.58 (m, 1H, H-6b), 1.66 (m, 1H, H-5), 1.75-1.84 
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(m, 2H, H-2'), 2.15 (m, 1H, H-2b), 2.25 (dd, J = 3.5, 13.0 Hz, 1H, H-1), 2.29-2.39 (m, 2H, H-
2''), 2.66-2.72 (m, 2H, H-3'), 2.82 (t, J = 7.4 Hz, 2H, H-3''), 3.06-3.23 (m, 3H, H-1', H-4), 
3.55-3.65 (m, 2H, Gal-H3, -H5), 3.65-3.84 (m, 5H, H-3, Fuc-H2, -H4, Gal-H6), 3.87 (dd, J = 
3.2, 10.3 Hz, 1H, Fuc-H3), 3.96 (s, 2H, Lac-H2, Gal-H4), 4.45 (t, J = 6.8 Hz, 2H, H-1''), 4.69 
(d, J = 8.0 Hz, 1H, Gal-H1), 4.92-5.03 (m, 2H, Fuc-H1, -H5), 5.42 (m, 1H, Gal-H2), 7.30 (s, 
1H, Ind-H2), 7.34-7.38 (m, 2H, C6H5), 7.45 (d, J = 9.0 Hz, 1H, Ind-H7), 7.50 (m, 1H, C6H5), 
7.74 (s, 1H, H-5'), 7.98-8.02 (m, 2H, C6H5), 8.04 (dd, J = 2.1, 9.0 Hz, 1H, Ind-H6), 8.47 (m, 
1H, Ind-H4); 
13
C NMR (125 MHz, CD3OD): ! = 16.72 (Fuc-C6), 19.25 (Me), 22.55 (C-3''), 
23.63 (C-3'), 26.46, 26.67, 27.25 (3 Cy), 30.31 (C-2'), 31.86 (C-2''), 33.08, 34.19, 35.07 (3 
Cy), 35.47 (C-2), 37.41 (C-6), 39.32 (C-5), 39.54 (C-1'), 42.88 (Lac-C3), 43.36 (C-1), 50.80 
(C-1''), 62.82 (Gal-C6), 67.71, 67.73 (Gal-C4, Fuc-C5), 70.34 (Fuc-C2), 71.42 (Fuc-C3), 
72.99 (Gal-C2), 73.97 (Fuc-C4), 75.99 (Gal-C5), 78.69 (Lac-C2), 79.89 (C-3), 83.03 (C-4), 
83.70 (Gal-C3), 100.44 (Fuc-C1), 100.58 (Gal-C1), 112.51 (Ind-C7), 116.55 (Ind-C4), 
117.69 (Ind-C3), 117.89 (Ind-C6), 123.54 (C-5'), 127.11 (Ind-C2), 127.96 (Ind-C9), 129.64, 
130.83, 131.55, 134.27 (6C, C6H5), 141.22 (Ind-C8), 142.25 (Ind-C5), 148.53 (C-4'), 166.79 
(COPh), 177.05 (CONH); IR (KBr): " = 3431 (vs, OH), 2927 (m), 2852 (w), 1720 (s, C=O), 
1631 (m, C=O), 1547 (w), 1517 (w), 1471 (w), 1450 (w), 1383 (w), 1332 (s, NO2), 1270 (m), 
1213 (w), 1166 (w), 1106 (s), 1073 (s), 1032 (m), 996 (w), 963 (vw), 807 (vw), 774 (vw), 
741 (vw), 712 (w), 669 (vw) cm
-1
; HR-MS: m/z: calcd for C52H70N6O17 [M+H]
+
: 1051.4870; 
found: 1051.4870. 
 
tert-Butyl N-[1-(3-bromopropyl)-1H-indol-5-yl]carbamate (53). Nitroindole 27c (700 mg, 
2.50 mmol) and PtO2 (35 mg, 5% w/w) were suspended in a solution of Boc2O (1.76 g, 8.06 
mmol) in EtOH (23 mL) under argon. The flask was flushed with H2, and the solution was 
stirred under H2 (1 atm) at rt for 45 min. Then another 35 mg of PtO2 was added and stirring 
was continued for 30 min. The mixture was filtrated (PTFE membrane filter) and the solvent 
was removed in vacuo. The residue was dissolved in EtOAc (100 mL) and washed with 0.5 
M aq. HCl (50 mL), satd aq. NaHCO3 (50 mL) and brine (50 mL). The organic layer was 
dried over Na2SO4, and the solvent was removed under reduced pressure. After purification 
by silica gel chromatography (petroleum ether/EtOAc), 53 (637 mg, 72%) was obtained as a 
pale yellow oil, which eventually crystallized and turned pink after 24 h at -18 °C. 
1
H NMR 
(500 MHz, CD3OD): ! = 1.50 (s, 9H, C(CH3)3), 2.28 (p, J = 6.4 Hz, 2H, H-2’), 3.28 (m, 2H, 
H-3’), 4.27 (t, J = 6.5 Hz, 2H, H-1’), 6.35 (dd, J = 0.6, 3.1 Hz, 1H, H-3), 7.10 (dd, J = 1.3, 
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8.7 Hz, 1H, H-6), 7.16 (d, J = 3.1 Hz, 1H, H-2), 7.30 (d, J = 8.8 Hz, 1H, H-7), 7.57 (bs, 1H, 
H-4); 
13
C NMR (125 MHz, CD3OD): ! = 28.80 (C(CH3)3), 31.16 (C-3’), 34.31 (C-2’), 45.05 
(C-1’), 80.44 (C(CH3)3), 102.08 (H-3), 110.37 (C-7), 112.84 (C-6), 116.67 (C-4), 129.81 (C-
2), 130.26 (C-9), 132.41 (C-8), 134.36 (C-5), 156.27 (CO); IR (KBr): " = 2972 (w) 2932 (w), 
1695 (vs, C=O), 1625 (vw), 1584 (m), 1532 (s), 1509 (m), 1490 (s), 1447 (m), 1441 (m), 
1392 (m), 1367 (s), 1334 (m), 1312 (vw), 1295 (m), 1287 (m), 1261 (m), 1232 (s), 1163 (vs), 
1092 (vw), 1053 (m), 1027 (vw), 889 (vw), 863 (vw), 825 (vw), 802 (vw), 756 (w), 726 (w), 
623 (vw), 563 (vw) cm
-1
; elemental analysis: calcd (%) for C16H21BrN2O2 (353.25): C 54.40, 
H 5.99, N 7.93; found: C 54.29, H 5.97, N 7.86. 
 
tert-Butyl N-[1-(3-azidopropyl)-1H-indol-5-yl]carbamate (54). To a solution of 53 (570 
mg, 1.61 mmol) in anhydrous DMF (15 mL), NaN3 (528 mg, 8.12 mmol) was added at rt. 
After 2 h, H2O (50 mL) was added to the reaction mixture, and the aqueous layer was 
extracted with EtOAc (100 mL). The organic layer was washed with satd aq NaHCO3 and 
brine, and dried over Na2SO4. After removal of the solvent under reduced pressure, the crude 
product was purified by silica gel chromatography (petroleum ether/EtOAc) to afford 54 (458 
mg, 90%) as yellowish crystals. 
1
H NMR (500 MHz, CD3OD): ! = 1.52 (s, 9H, C(CH3)3), 
2.02 (p, J = 6.6 Hz, 2H, H-2’), 3.22 (t, J = 6.5 Hz, 2H, H-3’), 4.22 (t, J = 6.7 Hz, 2H, H-1’), 
6.37 (d, J = 3.1 Hz, 1H, H-3), 7.13 (dd, J = 1.4, 8.7 Hz, 1H, H-6), 7.16 (d, J = 3.0 Hz, 1H, H-
2), 7.30 (d, J = 8.8 Hz, 1H, H-7), 7.59 (bs, 1H, H-4); 
13
C NMR (125 MHz, CD3OD): ! = 
28.80 (C(CH3)3), 30.51 (C-2’), 44.02 (C-1’), 49.54 (C-3’), 80.40 (C(CH3)3), 102.01 (H-3), 
110.27 (C-7), 112.79 (C-6), 116.63 (C-4), 129.72 (C-2), 130.20 (C-9), 132.32 (C-8), 134.38 
(C-5), 156.24 (CO); IR (KBr): " = 2976 (w), 2930 (w), 2873 (vw), 2099 (vs, N3), 1697 (s, 
C=O), 1625 (vw), 1584 (w), 1529 (m), 1510 (m), 1489 (s), 1450 (m), 1440 (m), 1392 (w), 
1366 (m), 1334 (w), 1286 (m), 1236 (m), 1159 (s), 1096 (vw), 1085 (vw), 1051 (w), 1051 
(m), 1026 (w) cm
-1
; elemental analysis: calcd (%) for C16H21N5O2 (315.37): C 60.94, H 6.71, 
N 22.21; found: C 61.04, H 6.70, N 22.17. 
 
1-(3-Azidopropyl)-1H-indol-5-amine (55). A solution of 54 (408 mg, 1.29 mmol) in DCM 
(40 mL) was treated with trifluoroacetic acid (3 mL) at rt for 30 min. Then, the solvent was 
removed in vacuo, and the mixture was co-evaporated with toluene. The residue was 
dissolved in EtOAc (50 mL), the organic layer was washed with satd aq. NaHCO3 and brine 
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(30 mL), and the aqueous layers were extracted with EtOAc (50 mL). The combined organic 
phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by silica gel chromatography (DCM/MeOH, 10:1) to give 55 (239 mg, 86%) as a 
mixture with inseparable by-products. 
1
H NMR (500 MHz, CD3OD): ! = 1.93-1.99 (m, 3H, 
H-2'), 3.15 (t, J = 6.4 Hz, 3H, H-3'), 4.08 (t, J = 6.6 Hz, 2H, H-1'), 6.24 (d, J = 3.0 Hz, 1H, H-
3), 6.62 (dd, J = 2.1, 8.6 Hz, 1H, H-6), 6.86 (d, J = 1.9 Hz, 1H, H-4), 6.92 (d, J = 3.0 Hz, 1H, 
H-2), 7.07 (d, J = 8.6 Hz, 1H, H-7). 
 
N-[1-(3-Azidopropyl)-1H-indol-5-yl]acetamide (56). To a solution of 55 (43 mg, 0.200 
mmol) in DCM (2 mL) were added Et3N (28 !L, 0.200 mmol) and Ac2O (18 !L, 0.200 
mmol), and the solution was stirred for 3 h. The solvents were removed in vacuo and the 
residue was purified by silica gel chromatography (DCM/EtOAc) to give 56 (44 mg, 86%) as 
a mixture with inseparable by-products. 
1
H NMR (500 MHz, CDCl3): ! = 1.92-1.96 (m, 2H, 
H-2’), 2.07 (s, 3H, Ac), 3.12 (t, J = 6.3 Hz, 2H, H-3’), 4.09 (t, J = 6.6 Hz, 2H, H-1’), 6.35 (d, 
J = 3.1 Hz, 1H, H-3), 6.98 (d, J = 3.1 Hz, 1H, H-2), 7.14-7.16 (m, 2H, H-6, H-7), 7.70 (s, 1H, 
H-4); 
13
C NMR (125 MHz, CDCl3): ! = 24.38 (Ac), 29.35 (C-2’), 43.14 (C-1’), 48.33 (C-3’), 
101.72 (C-3), 109.33 (C-7), 113.41 (C-4), 116.48 (C-6), 128.71, 128.72 (C-2, C-9), 130.38 
(C-8), 133.42 (C-5), 168.85 (CO); ESI-MS: m/z: calcd for C13H15N5O [M+Na]
+
: 280.12; 
found: 280.20. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(3-{1-[3-(5-acetamido-
1H-indol-1-yl)propyl]-1H-1,2,3-triazol-4-yl}propyl)cyclohexanecarboxamide (57). 
Prepared according to general procedure C from 26c (11.6 mg, 14.4 !mol), 56 (13 mg, 22.3 
!mol), Na-L-ascorbate (72 !L, 7.2 !mol) and CuSO4"5 H2O (36 !L, 3.6 !mol). Yield: 11.0 
mg (73%). [#]D
20
 -49.4 (c 0.83, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.52 (m, 1H, Cy), 
0.57-0.70 (m, 3H, 3 Cy), 0.88 (m, 1H, Cy), 1.10 (d, J = 6.4 Hz, 3H, Me), 1.13-1.36 (m, 8H, 
H-2a, H-6a, 5 Cy, Fuc-H6), 1.40 (m, 1H, Lac-H3a), 1.48 (m, 1H, Lac-H3b), 1.51-1.61 (m, 
2H, H-6b, Cy), 1.66 (m, 1H, H-5), 1.73-1.80 (m, 2H, H-2'), 2.10-2.15 (m, 4H, H-2b, Ac), 
2.25 (m, 1H, H-1), 2.42 (p, J = 6.7 Hz, 2H, H-2''), 2.65 (t, J = 7.5 Hz, 2H, H-3'), 3.06-3.18 
(m, 3H, H-1', H-4), 3.55 (m, 1H, Gal-H5), 3.60 (dd, J = 2.8, 9.7 Hz, 1H, Gal-H3), 3.65-3.81 
(m, 5H, H-3, Fuc-H2, -H4, Gal-H6), 3.86 (dd, J = 3.2, 10.3 Hz, 1H, Fuc-H3), 3.94 (d, J = 2.1 
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Hz, 1H, Gal-H4), 4.00 (dd, J = 2.3, 9.6 Hz, 1H, Lac-H2), 4.20 (t, J = 6.7 Hz, 2H, H-3''), 4.32 
(t, J = 6.8 Hz, 2H, H-1''), 4.67 (d, J = 8.0 Hz, 1H, Gal-H1), 4.94-5.01 (m, 2H, Fuc-H1, -H5), 
5.42 (m, 1H, Gal-H2), 6.42 (m, 1H, Ind-H3), 7.18-7.28 (m, 3H, Ind-H2, -H6, -H7), 7.33-7.41, 
7.47-7.52 (m, 3H, C6H5), 7.60 (s, 1H, H-5’), 7.77 (m, 1H, Ind-H4), 7.99-8.03 (m, 2H, C6H5); 
13
C NMR (125 MHz, CD3OD): ! = 16.74 (Fuc-C6), 19.25 (Me), 23.54 (Ac), 23.67 (C-3’), 
26.50, 26.68, 27.25 (3 Cy), 30.23 (C-2'), 31.61 (C-2''), 33.07, 34.14, 35.05 (3 Cy), 35.43 (C-
2), 37.43 (C-6), 39.33, 39.47 (C-5, C-1'), 42.81 (Lac-C3), 43.30 (C-1), 44.14 (C-3''), 48.66 
(C-1''), 62.76 (Gal-C6), 67.70 (2C, Gal-C4, Fuc-C5), 70.28 (Fuc-C2), 71.39 (Fuc-C3), 72.95 
(Gal-C2), 73.96 (Fuc-C4), 75.95 (Gal-C5), 78.15 (Lac-C2), 79.80 (C-3), 83.03 (C-4), 83.65 
(Gal-C3), 100.47 (Fuc-C1), 100.50 (Gal-C1), 102.48 (Ind-C3), 110.34 (Ind-C7), 114.12 (Ind-
C4), 117.20 (Ind-C6), 123.59 (C-5'), 129.68 (2C, C6H5), 129.97 (Ind-C9), 130.11 (Ind-C2), 
130.83 (2C, C6H5), 131.52, 131.94 (Ind-C5, C6H5), 134.32 (C6H5), 134.78 (Ind-C8), 147.95 
(C-4’), 166.76 (COPh), 171.50 (COCH3), 177.04 (CONH), 178.70 (COOH); IR (KBr): " = 
3422 (vs, OH), 2927 (s), 2853 (m), 1725 (s, C=O), 1651 (s, C=O), 1603 (m), 1587 (m), 1548 
(m), 1488 (m), 1450 (m), 1401 (w), 1373 (m), 1337 (m), 1316 (m), 1271 (vs), 1113 (vs), 
1076 (vs), 1033 (s), 1000 (w), 874 (vw), 804 (w), 762 (w), 762 (w), 713 (m), 675 (w) cm
-1
; 
HR-MS: m/z: calcd for C54H74N6O16 [M+H]
+
: 1063.5234; found: 1063.5234. 
 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(3-{1-[3-(5-amino-1H-
indol-1-yl)propyl]-1H-1,2,3-triazol-4-yl}propyl)cyclohexanecarboxamide (58). A mixture 
of nitroindole 43 (8.5 mg, 8.1 !mol), PtO2 (2 mg, cat.) and morpholine (5 !L) in MeOH was 
stirred at rt under an H2 atmosphere (1 atm). Completion of the reaction was indicated by 
discoloration of the solution and confirmed by MS after 30 min. The catalyst was removed 
via filtration through a PTFE membrane filter, and the solution was concentrated in vacuo. 
Purification by preparative HPLC-MS (H2O/MeCN + 0.1% HCO2H) gave 58 (4.5 mg, 54%) 
as a colorless solid. ["]D
20
 -59.1 (c 0.45, MeOH); 
1
H NMR (500 MHz, CD3OD): ! = 0.39-
0.65 (m, 4H, 4 Cy), 0.82 (m, 1H, Cy), 1.04 (d, J = 5.8 Hz, 3H, Me), 1.09-1.36 (m, 11H, H-2a, 
H-6a, 5 Cy, Fuc-H6, Lac-H3a), 1.43 (t, J = 11.9 Hz, 1H, Lac-H3b), 1.47-1.55 (m, 2H, H-6b, 
Cy), 1.60 (m, 1H, H-5), 1.70-1.78 (m, 2H, H-2'), 2.09 (m, 1H, H-2), 2.19 (t, J = 11.8 Hz, 1H, 
H-1), 2.35-2.44 (m, 2H, H-2''), 2.62 (t, J = 7.0 Hz, 2H, H-3'), 3.02-3.16 (m, 3H, H-1', H-4), 
3.47-3.54 (m, 2H, Gal-H3, -H5), 3.60-3.80 (m, 6H, H-3, Fuc-H2, -H4, Gal-H6, Lac-H2), 3.83 
(m, 1H, Fuc-H3), 3.89 (s, 1H, Gal-H4), 4.20 (t, J = 6.5 Hz, 2H, H-3''), 4.30 (t, J = 6.3 Hz, 2H, 
Results and Discussion (paper manuscript) 
107 
H-1''), 4.62 (d, J = 8.1 Hz, 1H, Gal-H1), 4.89-4.97 (m, 2H, Fuc-H1, -H5), 5.37 (t, J = 8.7 Hz, 
1H, Gal-H2), 6.41 (s, 1H, Ind-H3), 6.95 (m, 1H, Ind-H6), 7.27 (s, 1H, Ind-H2), 7.29-7.37 (m, 
4H, C6H5, Ind-H4, -H7), 7.44 (t, J = 7.1 Hz, 1H, C6H5), 7.60 (s, 1H, H-5’), 7.97 (d, J = 7.5 
Hz, 2H, C6H5); 
13
C NMR (125 MHz, CD3OD): ! = 16.75 (Fuc-C6), 19.26 (Me), 23.54 (C-3'), 
26.53, 26.77, 27.34 (3 Cy), 30.15 (C-2'), 31.60 (C-2''), 33.05, 34.33, 35.26 (3 Cy), 35.50 (C-
2), 37.39 (C-6), 39.26 (C-5), 39.41 (C-1'), 43.27 (2C, Lac-C3, C-1), 44.28 (C-3''), 48.66 (C-
1''), 63.02 (Gal-C6), 67.70, 67.78 (Gal-C4, Fuc-C5), 70.28 (Fuc-C2), 71.36 (Fuc-C3), 73.07 
(Gal-C2), 73.94 (Fuc-C4), 76.10 (Gal-C5), 79.74 (C-3), 79.89 (Lac-C2), 83.02 (C-4), 83.66 
(Gal-C3), 100.46 (Fuc-C1), 100.62 (Gal-C1), 102.22 (Ind-C3), 111.54 (Ind-C4), 112.92 (Ind-
C6), 115.87 (Ind-C7), 123.58 (C-5'), 129.63 (2C, C6H5), 130.84, 130.87 (C6H5, Ind-H2), 
131.68 (Ind-C8), 134.19 (C6H5), 135.30 (Ind-C5), 148.45 (C-4'), 166.78 (COPh), 177.05 
(CONH), 181.91 (COOH); IR (KBr): " = 3431 (vs, OH), 2926 (m), 2853 (w), 1722 (w), 1643 
(m), 1603 (m), 1584 (m), 1555 (w), 1492 (w), 1451 (w), 1406 (w), 1384 (w), 1365 (w), 1348 
(w), 1316 (w), 1273 (m), 1222 (vw), 1167 (w), 1118 (m), 1096 (m), 1079 (s), 1031 (m), 1000 
(w), 967 (vw), 804 (vw), 768 (vw), 713 (m) cm
-1
; HR-MS: m/z: calcd for C52H72N6O15 
[M+H]
+
: 1021.5128; found: 1021.5159. 
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HRMS data for the target compounds: 
 
Table S1. HRMS data for the target compounds.  
 
Compound Formula HRMS [m/z] 
  calcd found 
3 C37H53O16 753.3339 [M-H]
-
 753.3331 [M-H]
-
 
18•  C48H74N3O17
•
 987.4910 [M+Na]
+
 987.4920 [M+Na]
+
 
26b C40H57NO15 814.3620 [M+Na]
+
 814.3620 [M+Na]
+
 
33 C48H62N6O17 1017.4064 [M+Na]
+
 1017.4067 [M+Na]
+
 
34 C49H64N6O17 1031.4220 [M+Na]
+
 1031.4218 [M+Na]
+
 
35 C50H66N6O17 1045.4377 [M+Na]
+
 1045.4376 [M+Na]
+
 
36 C51H68N6O17 1059.4533 [M+Na]
+
 1059.4531 [M+Na]
+
 
37 C49H64N6O17 1031.4220 [M+Na]
+
 1031.4222 [M+Na]
+
 
38 C50H66N6O17 1067.4202 [M-H+2Na]
+
 1067.4207 [M-H+2Na]
+
 
39 C51H68N6O17 1037.4714 [M+H]
+
 1037.4711 [M+H]
+
 
40 C52H70N6O17 1051.4870 [M+H]
+
 1051.4872 [M+H]
+
 
41 C50H66N6O17 1023.4557 [M+H]
+
 1023.4561 [M+H]
+
 
42 C51H68N6O17 1081.4358 [M-H+2Na]
+
 1081.4360 [M-H+2Na]
+
 
43 C52H70N6O17 1073.4690 [M+Na]
+
 1073.4684 [M+Na]
+
 
44 C51H68N6O17 1081.4353 [M-H+2Na]
+
 1081.4342 [M-H+2Na]
+
 
45 C52H70N6O17 1051.4870 [M+H]
+
 1051.4868 [M+H]
+
 
46 C53H72N6O17 1087.4846 [M+Na]
+
 1087.4848 [M+Na]
+
 
47 C49H64N6O17 1031.4220 [M+Na]
+
 1031.4223 [M+Na]
+
 
48 C50H66N6O17 1045.4377 [M+Na]
+
 1045.4375 [M+Na]
+
 
49 C51H68N6O17 1059.4533 [M+Na]
+
 1059.4528 [M+Na]
+
 
50 C50H66N6O17 1045.4377 [M+Na]
+
 1045.4381 [M+Na]
+
 
51 C51H68N6O17 1037.4714 [M+H]
+
 1037.4714 [M+H]
+
 
52 C52H70N6O17 1051.4870 [M+H]
+
 1051.4870 [M+H]
+
 
57 C54H74N6O16 1063.5234 [M+H]
+
 1063.5234 [M+H]
+
 
58 C52H72N6O15 1021.5128 [M+H]
+
 1021.5159 [M+H]
+
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Compound purity: 
Compound purity was determined on an Agilent 1100 HPLC apparatus with UV detection 
(190-410 nm). A linear gradient (5% B ! 95% B over 25 min; A: Water + 0.1% formic acid; 
B: acetonitrile + 0.1% formic acid) was used, and the absorption was measured at a 
wavelength of 250 or 350 nm. Column: Waters Atlantis dC18, 3 "m, 4.6 ! 75 mm. 
 
Table S2. HPLC data for the target compounds  
 
Compound Formula Retention [min] Detection [nm] Purity [%] 
33 C48H62N6O17 14.150 350 95.3 
34 C49H64N6O17 14.000 350 95.4 
35 C50H66N6O17 14.017 350 94.5 
36 C51H68N6O17 14.367 350 95.5 
37 C49H64N6O17 14.483 350 97.2 
38 C50H66N6O17 14.500 350 96.2 
39 C51H68N6O17 14.583 350 96.3 
40 C52H70N6O17 14.000 350 97.0 
41 C50H66N6O17 14.317 350 96.1 
42 C51H68N6O17 15.033 350 95.1 
43 C52H70N6O17 14.267 350 97.3 
44 C51H68N6O17 14.633 350 95.1 
45 C52H70N6O17 15.283 350 96.5 
46 C53H72N6O17 14.517 350 98.9 
47 C49H64N6O17 13.517 350 99.4 
48 C50H66N6O17 13.550 350 > 99.5 
49 C51H68N6O17 13.617 350 95.0 
50 C50H66N6O17 13.883 350 98.9 
51 C51H68N6O17 13.717 350 > 99.5 
52 C52H70N6O17 13.767 350 96.1 
57 C54H74N6O16 12.483 250 95.2 
58 C52H72N6O15 11.117 250 95.8 
Results and Discussion (paper manuscript) 
110 
References 
[S1] B. Ernst, B. Wagner, G. Baisch, A. Katopodis, T. Winkler and R. Öhrlein, Can. J. 
Chem. 2000, 78, 892-904. 
[S2] I. MacInnes, J. C. Walton, J. Chem. Soc., Perkin Trans. 2 1987, 8, 1077-1082. 
[S3] M. Pullagurla, M. Dukat, B. L. Roth, V. Setola, B. A. Glennon, Med. Chem. Res. 2005, 
14, 1-18. 
[S4] (a) Y. W. Li, T. J. Marks, J. Am. Chem. Soc. 1996, 118, 9295-9306; (b) Y. Li, P.-F. Fu, 
T. J. Marks, Organometallics 1994, 13, 439-440. 
[S5] S. Shelke, B. Cutting, X. Jiang, H. Koliwer-Brandl, D. S. Strasser, S. Kelm, O. 
Schwardt, B. Ernst, Angew. Chem. Int. Ed. 2010, 49, 5721-5725. 
 
Results and Discussion (continued) 
111 
3. Results and Discussion (continued) 
For a simple representation of the linker pattern and the nitroindole attachment point, the 
naming convention shown in Figure 3-1 is used in the following sections. 
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Figure 3-1. Naming convention for the linker pattern of triazole–nitroindole antagonists. 
3.1. Failed approaches to the synthesis of alkyne amides 
As mentioned in Section 2, the synthesis of alkyne amides via direct aminolysis suffered 
from low yields caused by low reaction rate and excessive byproduct formation. Before the 
eventual discovery that the cHex carboxyl group of diacid P24 can be selectively activated, 
different reaction conditions and synthetic strategies had been evaluated unsuccessfully. 
Here, an overview of the different attempts is given. 
3.1.1. Stability of alkyne amines 
The direct aminolysis approach mainly suffered from the low stability and reactivity of the 
alkyne amines. The low stability furthermore aggravated the synthesis of these amines and 
required careful adaption of the reaction conditions. Generally, unprotected alkyne amines 
were found to be very unstable even at room temperature, which was indicated by coloration 
of the originally colorless solutions. For unprotected alkyne amines, the stability appeared to 
decrease with increasing chain length, while an inverse relationship was observed for TMS-
protected alkyne amines. Here, stability was lowest for the propargyl amine derivative, which 
had to be stored at -80 °C to delay its decomposition. 
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Figure 3-2. Stability of alkyne amines with respect to chain length. 
3.1.2. Direct aminolysis via TMS-protected alkyne amines 
Different catalysts or activators were tested for their ability to accelerate the direct aminolysis 
(Figure 3-3). DMAP and cyanide (194) were used as nucleophilic catalysts. Also 
tetraethyleneglcole (TEG), which was described as a catalyst stabilizing the transition state of 
the aminolysis reaction (195), was investigated. Furthermore, amines can be converted to 
dimethylaluminium amides (! Weinreb reagent) (196), which increases their 
nucleophilicity. In this work, a relatively stable DABCO-(AlMe3)2 ("DABAL-Me3") (197) 
complex was used as a source of trimethylaluminium.  
However, the reaction rate was not sufficiently increased by any of the conditions, and the 
desired amides could only be obtained with low yields. 
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Figure 3-3. Catalysts and activators used in the direct aminolysis of the methyl ester P3 to the 
corresponding alkyne amides. 
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Table 3-1. Illustrative examples of reaction conditions used for the direct aminolysis. 
catalyst/activator conditions n R yield 
DMAP amine as solvent, !w: 120 °C, 3 h 1 H traces 
cyanide amine excess, DMF, !w: 100 °C, 6 h 2 TMS approx. 8% 
TEG/DMAP amine/TEG 3:1, !w: 100 °C, 8 h 2 TMS 
2% 
diamide: 24% 
TEG/DMAP amine/TEG 3:1, 70 °C, 48 h 2 TMS < 18% 
DABAL-Me3 amine excess, THF, !w: 100-130 °C, 2.5 h 2 TMS traces 
     
3.1.3. Direct aminolysis via (1-(2-(5-nitro-1H-indol-1-yl)ethyl)-1H-1,2,3-triazol-4-
yl)methanamine 
To circumvent the inherent instability and low reactivity of alkyne amines, an alternative 
route for direct aminolysis was investigated (Scheme 3-1). Besides the increased stability, 
amine 32 was also expected to be more nucleophilic due to the absence of the electron-
withdrawing alkyne group. However, the solubility of 32 was limited, and it could not be 
used in as large an excess like the liquid alkyne amines. Thus, product P37 was formed only 
in trace amounts under various reaction conditions. 
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Scheme 3-1. a) Di-tert-butyldicarbonate, DMAP, Et3N, CH2Cl2, 0 °C, 3 h, 46%; b) Na-L-ascorbate, 
CuSO4"5H2O, tBuOH/H2O/MeCN 9:2:2, r.t., 15 h, 100%; c) TFA, 30 min, 96%; d) DABAL-Me3, 
THF, !W: 100 °C, 30 min, < 2%; e) DABAL-Me3, THF/DMF 4:1, !W: 70-90 °C, 6 h; f) NaH, 
THF/DMF 1:1, 70 °C, 6 h. 
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3.1.4. Alkyne ethers as a possible alternative for alkyne amides 
As shown in Scheme 3-2, an alternative synthetic strategy for the synthesis of alkyne ethers 
instead of amides was suggested. However, test reactions revealed similar stability and 
reactivity problems as encountered in the direct aminolysis approach. Furthermore, some 
uncertainty was associated with the benzyl–pivaloate protecting group exchange on the 
sterically restricted fucose. Thus, this alternative was not considered any further. 
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Scheme 3-2. Alternative approach for the synthesis of alkyne ethers. 
3.2. Studies on physicochemical parameters 
3.2.1. Observation of micelle formation in ITC and Biacore assays 
The triazole–nitroindole antagonists are comprised of a polar carbohydrate-mimetic and a 
hydrophobic linker part (Figure 3-4A), i.e. they have an amphiphilic structure. This property 
became first evident during the preparation of these antagonists, where the compounds 
formed opalescent films on aqueous surfaces or tended to form aggregates in aqueous 
solutions. Also in biological assays, the unusual properties of the triazole–nitroindole 
antagonists were recognized: Figure 3-4B shows Biacore sensorgrams of sequential blank 
injections, which were carried out after a single injection of P38 at a concentration of 
62.5 !M. The intensity and characteristic shape of the signal (up to 40 resonance units) 
indicated that significant amounts of the compound had remained within the instrument after 
the first injection. Furthermore, in an isothermal titration calorimentry (ITC) experiment with 
Results and Discussion (continued) 
115 
P38 (Figure 3-4C), an endothermic process was superimposed on the exothermic ligand 
binding process. 
 
Figure 3-4. A) P38; blue: hydrophilic carbohydrate-mimetic part; yellow: hydrophobic linker part. B) 
Biacorre soensorgrams; 1-3: serial blank injections after one injection of P38 at a concentration of 
62.5 !M. Experiment performed by Céline Weckerle. C) ITC enthalpogram of P38 (ligand 1.6 mM 
titrated into E-selectin/IgG 84 !M) showing an exothermic binding process. Experiment performed by 
Katrin Lemme. 
Amphiphilic properties are common to many drugs. Apart from the effects in biological 
assays as described above, amphiphilicity is of considerable importance in vivo. Drug 
toxicity, for example, may arise from the incorporation of amphiphilic molecules into 
membranes, where they can lead to membrane disruption or alteration of other membrane 
properties (198, 199). Besides toxicity, gastrointestinal absoprtion (200), blood–brain barrier 
permeation (201), and P-glycoprotein substrate avidity (202) correlate with amphiphilicity. 
Based on these considerations and given the difficulties encountered during compound 
characterization, it was decided to investigate the physicochemical properties of the triazole–
nitroindole antagonists and derivatives thereof. 
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3.2.2. Chemical modifications to reduce surface activity 
P43, the most potent antagonist identified by Biacore (Section 2) was chosen for the 
investigation of structural modifications, which are summarized in Figure 3-5. 
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Figure 3-5. Modifications to P43 for lowering the CMC. 
3.2.2.1. Modifications of the nitro group 
As described in Section 2, amine and acetamide derivatives of P43 were synthesized to 
elucidate the effect of these functional groups on binding affinity.  
Yet, these modifications may also influence CMC, as the corresponding indole fragments 
have a markedly reduced logP and the aminoindole even a potentially charged basic group 
(Figure 3-6) (203). 
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Figure 3-6. Calculated logP (and pKa) values for 5-nitroindole, 5-aminoindole, and N-(indol-5-
yl)acetamide. 
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3.2.2.2. Replacement of the triazole 
While the use of triazole as a linking heterocycle made sense against the background of the in 
situ click approach, it is not necessarily the best choice with respect to the binding and 
physicochemical properties of the nitroindolyl antagonists. 
Piperazine, a common motif of many marketed drug molecules, was considered as an 
alternative linking heterocycle. It is more hydrophilic (logD7 = -1.2, logP = -0.2; calculated 
for 1,4-dimethylpiperazine) than triazole (logD7 = logP = -0.4; calculated for 1,4-dimethyl-
1H-1,2,3-triazole) and expected to be (partly) protonated at physiological pH (pKa of 
alkylated piperazine ! 9) (203). Thus, the substitution of triazole with piperazine was 
expected to increase the solubility/CMC of the molecule.  
Furthermore, a pair of piperazinyl- and bromine-substituted ligands could in priniple be used 
for an alternative in situ click experiment (see e.g. (204, 205)). While E-selectin did not have 
an accelerating effect on triazole formation, this may be the case for a different type of 
reaction such as a nucleophilic substitution. However, bioorthogonality may be arguable in 
this case because a bromide could react with nucleophilic amino acid side chains of E-
selectin. 
As Figure 3-7 shows, the distance between the attachment points in piperazine and triazole 
differ by only 0.5 Å. Given that linkers with 4 to 6 methylene groups led to high-affinity 
antagonists (Section 2), it is reasonable to assume that such a modification may be tolerated. 
However, piperazine may add some flexibility to the linker and thus have different 
requirements for linker length and pattern. 
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Figure 3-7. Use of piperazine as linking heterocycle. 
3.2.2.3. Synthesis of the piperazinyl antagonist 
The synthesis of piperazinyl antagonist 33 started from commercial 5-nitroindole, which was 
alkylated using dibromopropane to yield P27c. This was coupled to commercial 3-(piperazin-
1-yl)propan-1-ol with quantitative yield to give 34. Using DPPA, the alcohol was converted 
to the azide in one step (! 35), and reduction gave amine 36, which was coupled to diacid 
P24 using the previously described conditions for the synthesis of alkyne amides (Section 2). 
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Scheme 3-3. a) 1,3-dibromopropane, KOH, DMF, r.t.,17 h, 46% (28% of the starting material were 
recovered); b) Et3N, DMF, r.t., 2 h, 100%; c) DPPA, DBU, THF, r.t., 24 h, 79%; d) PPh3, THF/H2O, 
r.t., 3 h, 78%; e) HOBt, HBTU, DIPEA, DMF, r.t., 3 h, 34%. 
3.2.2.4. Determination of binding affinities by Biacore 
As discussed in Section 2, nitroindole substitution in P43 is accompanied by an affinity loss. 
For the substitution of triazole by piperazine, KD was increased approximately 4-fold. 
Table 3-2. Affinities of P57, P58, and 33 determined by Biacore (steady state response fit to a 1:1 
binding model). Measurements performed by Céline Weckerle. 
Analyte KD [!M] 
P57 0.544 
P58 0.186 
33 0.110 
  
3.2.2.5. Determination of physicochemical and pharmacokinetic parameters 
The physicochemical and pharmacokinetic parameters were determined on the PADMET 
platform (206) by Matthias Wittwer and Simon Kleeb. 
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Critical micelle concentration 
The results of the surface activity measurements are summarized in Table 3-3. All 
antagonists are expected to have CMCs in the range of 1 to 10 mM and show beginning 
surface activity (SA) at concentrations of 4 to 30 !M. The increase of surface pressure with 
increasing ligand concentrations is most pronounced for P45 and least pronounced for P35. 
As, in P45 and P35, the linker parts attached to the nitroindole are the longest and the 
shortest in the series, respectively, CMC may depend on the length of this part. All CMC 
values are in a range commonly seen in marketed drugs (198, 200). The values for the 
beginning of SA, but potentially also the CMC, are in a concentration relevant for biological 
assays (see above). Although the amount of molecules in surface interfaces is usually small 
compared to the amount found in solution, caution may be indicated when performing 
measurements at concentrations in these ranges. 
Surprisingly, antagonist 33 appeared to exhibit stronger surface activity than all other 
antagonists, despite the presence of two nitrogens in the linker, of which at least one is 
expected to be protonated at the slightly acidic pH (= 6.5) of the experiment. 
Figure 3-9 indicates a trend towards lower surface activity if the nitroindole is replaced by an 
acetamide (P57) or by an amine (P58). 
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Table 3-3. Critical micelle concentration and begin of surface activity measured at pH 6.5. The 
antagonists are ordered by increasing linker length. In brackets, the linker patter and the indole 
substituents are indicated. 
Compound CMC begin of SA 
P41 (1a3N) 1-10 mM > 8 !M 
P35 (3a1N) 1-10 mM > 16 !M 
P38 (2a2N) > 1 mM > 8 !M 
P51 (2a3C) 1-10 mM > 16 !M 
P45 (2a4N) > 1 mM > 8 !M 
P43 (3a3N) > 1 mM > 8 !M 
P57 (3a3N, NHAc) > 1 mM > 10 !M 
P58 (3a3N, NH2) > 1 mM > 30 !M 
33 (3pip3N) approx. 1 mM approx. 4 !M 
   
 
Figure 3-8. CMC measurement curves of triazole–nitroindole antagonists. 
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Figure 3-9. CMC measurement curves of P43 and its derivatives. 
PAMPA, logD, and plasma protein binding 
Table 3-4 shows the results of the PAMPA (207, 208), logD7.4, and plasma protein binding 
measurements. Due to the difficult analysis of this compound class (e.g. the occurrence of 
nonlinear calibration curves, cf. Section 3.6.4.5), the data are of qualitative rather than 
quantitative nature (209). 
None of the compounds showed permeation in the PAMPA assay (permeation can be 
expected for log Pe values above -5.7 or membrane retention above 80 %Mm/M). Yet, with 
decreasing pH, some membrane enrichment (PAMPA %Mm/M) of P43 was observed.  
The logD7.4 was similar for all compounds except P45. Its logD was remarkable 1.2 units 
higher than the one of its isomer P43, i.e. its concentration in the octanol phase was approx. 
10 times higher than the one of P43.  
Antagonists P43, P57, P58 are reasonably well soluble. However, the substitution of triazole 
by piperazine (! 33) led to a strong decrase of solubility by a factor of at least seven.  
With values in the range 88 to 97%, the extent of plasma protein binding (PPB) is high. This 
may contribute to a prolonged plasma half-life resulting from reduced excretion and/or 
metabolism (87). At the same time displacement of the ligand from plasma proteins by a 
competing ligand (e.g. acetylsalicylic acid) may be clinically relevant (210). 
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Table 3-4. PAMPA parameters, logD7.4, solubility, and plasma protein binding (PPB) of triazole–
nitroindole antagonists; n.p.: no permeation; n.r.: no retention. 
Compound PAMPA log Pe 
PAMPA 
%Mm/M 
logD7.4 
Solubility 
[!g/mL], (pH) 
PPB 
% 
P45 
(2a4N) 
n.p. 
pH 5:       n.r. 
pH 6.2:    n.r. 
pH 7.4:    n.r. 
2.42 not determined 89 
P51 
(2a3C) 
n.p. 
pH 5:       n.r. 
pH 6.2:    n.r. 
pH 7.4:    n.r. 
1.25 not determined 97 
P41 
(1a3N) 
n.p. 
pH 5:       8.7 
pH 6.2:    19 
pH 7.4:    n.r. 
1.83 not determined 94 
P43 
(3a3N) 
n.p. 
pH 5:     41.5 
pH 6.2:  20.5 
pH 7.4:    n.r. 
1.22 > 2400 (6.27) 92 
P57 
(3a3N, NH2) 
pH 5:         n.p. 
pH 6.2:      n.p. 
pH 7.4:      -8.4 
pH 5:       n.r. 
pH 6.2:    n.r. 
pH 7.4:    n.r. 
1.20 > 2000 (6.37) 91 
P58 
(3a3N, NHAc) 
 
n.p. n.r. 1.60 > 3000 (6.53) 88 
33 
(3pip3N) 
– – – 340 (6.61) – 
      
pKa determination of 33 
This experiment is in progress. Preliminary results allowed the to identify three pKas, 
corresponding to the three ionizable groups of 33. 
3.2.2.6. Discussion and conclusions 
In general, none of the antagonists tested exhibited particularly favorable pharmakokinetic 
properties. For example, passive absorption from the gastrointestinal tract cannot be expected 
based on the PAMPA measurements. The replacement of the nitro group had a small effect 
on surface activity, whereas other parameters were not strongly affected. The solubility of 
antagonists P43, P57, and P58 was good. A pronounced reduction of solubility was observed 
for 33, but the value of 340 !g/mL is still in an acceptable range (211). This, as well as the 
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trend to a lower CMC, contradicts the expectation that the introduction of polarity to the 
linker would have a beneficial influence on these properties. Considering the carboxyl group 
of 33 and the definition of the isoelectric point (pI) given by Equation 6, 
 
!!
! 
"" =
"#
#$
+ "#
#%
%
 (6) 
it is evident that 33 is zwitterionic at the pH (! 6.5) of the CMC and solubility measurements 
(pKa of piperazine ! 9, pKa of carboxyl group ! 4). Thus, the molecule's net charge is zero, 
leading to large crystal lattice energies and thus to a high tendency to aggregate. The high 
polarity further implies that passive diffusion through membranes would probably be low 
(212). 
Phospholipidosis, the excessive accumulation of phospholipids in lysosomes, is a (reversible) 
effect exerted by cationic amphiphilic drugs (CADs) (213). Most commonly, the CADs 
inducing phospholipidosis share a hydrophobic ring structure to which a side chain with a 
charged cationic amine group is attached (213, 214). As Figure 3-10 illustrates, 33 has typical 
features of a CAD inducing phospholipidosis.  
Without implying significancy, it is further noteworthy that amiodarone (Figure 3-10) 
induces QT prolongation via blockade of hERG (215). hERG-blocking compounds are, in a 
very simplified view, characterized by one or two hydrophobic moieties attached to a 
positively charged nitrogen (216) – structural features that are also found in 33. Blocking of 
the hERG channel is a highly disfavored property of drug leads, as it is associated to sudden 
death caused by cardiac arrest (215). 
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Figure 3-10. Structure of 33 and some CADs inducing phospholipidosis. Besides inducing 
phospholipidosis, amiodarone is an inducer of QT prolongation. 
Although the clinical implications of phospholipidosis are uncertain and there is a 
considerable number of marketed and experimental drugs inducing this condition, its possible 
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association with toxic or unwanted effects have given it the status of an adverse finding from 
a regulatory perspective (214).  
Given the above results and considerations, the piperazine moiety in 33 cannot be regarded as 
a suitable replacement for the triazole moiety in P43. The loss of affinity caused by replacing 
the triazole by piperazine further implies that the triazole is well suited for the binding to E-
selectin. Yet, from the present data it is not evident whether this is a result of altered linker 
flexibility, differences in polarity or other structural differences. Further insights could be 
achieved by by STD NMR studies to elucidate whether some parts of the linker are in contact 
with E-selectin. 
Results and Discussion (continued) 
126 
3.3. Synthesis of antagonists for an inversed Biacore assay 
As illustrated in Section 1.5.1, usually, the target protein is immobilized in a Biacore 
experiment. To verify this setup, derivatives 37 (derived from the first-site antagonist P3) and 
P38 (derived from the high-affinity triazole–nitroindole antagonist P43) carrying an 
ethyleneglycole linker with a terminal amine were synthesized. These antagonists can be 
immobilized on a Biacore chip via standard amine coupling (133), allowing to perform an 
"inversed" Biacore experiment. Also the free aromatic amine group of P58 was used for 
immobilizing this ligand directly Figure 3-11. 
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Figure 3-11. Schematic representation of ligands immobilized on a Biacore chip. 
3.3.1. Synthesis 
Derivative 37 was obtained via direct aminolysis of methyl ester P3, which gave the amine in 
satisfactory yields (40%) (Scheme 3-3).  
The synthesis of derivative P38 started from indole amine P34 (see Section 2). NHS ester 
P36 was coupled to the indole amine, which was then used in the CuAAC with alkyne P26c. 
After in situ removal of the Fmoc protecting group, the free amine (P38) was obtained 
(Scheme 3-5). 
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Scheme 3-4. 2-2'-(Ethylenedioxy)bis-(ethylamine)/DMF 1:1, 65-70 °C, 2 d, 40%. 
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Scheme 3-5. a) The synthesis of P34 is described in Section 2; b) NHS ester P36, DMF, r.t., 17 h, 
approx. 50%; c) 1) Alkyne P26c, Na-L-ascorbate, CuSO4!5H2O, 
t
BuOH/H2O/THF, r.t., 40 min; 2) 
piperidine, r.t., 3 h, 66%. 
3.3.2. Biacore analysis 
The Biacore analysis war performed by Céline Weckerle (133). As Table 3-5 shows, first-site 
ligand 37 gave identical results in the standard and in the reversed assay. The range of KDs 
given resulted from different etanolamine!HCl (EA) concentrations used for the inactivation 
of residual activated NHS esters on the Biacore chip surface (ligand/EA ratios: 1:1, 1:10, 
1:50, 1:100). Binding kinetics were not affected by the new setup (data not shown). However, 
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as can be seen from Figure 3-12 the response was by magnitudes higher when E-selectin was 
in solution, which is a result of the large mass differences between E-selectin and 37.  
The finding for 37 could not be reproduced with the triazole–nitroindole derivatives P38 and 
P58: Upon immobilization, their estimated KDs increased to the one-digit micromolar range. 
Table 3-5. KDs determined in a conventional Biacore assay (37, P38, P57, P58) and in the inversed 
Biacore assay (37*, P38*, P58*). 
Compound KD
a)
 [!M], free KD
b)
 [!M], immobilized 
37/37* 6.0 4.4-8.9
c)
 
P38/ P38* 0.36 8.2
d)
 
P58/P58* 0.19 7.8
e)
 
P57 0.54 – 
a) Protein used: dimeric E-selectin (E-selectin/IgG); b) protein used: monomeric E-selectin 
(LecEGF_CR2); c) the KD range is a result of different etanolamine"HCl concentrations used for the 
inactivation of residual activated NHS esters on the Biacore chip surface; d) ligand/EA: 1:100; e) 
ligand/EA: 1:50. 
For 37, the reverse assay was performed using dimeric E-selectin (E-selectin/IgG) as well. 
Using this setup, two binding events were observed. The first binding occurred in the 
micromolar (KD,1 = 12.1 !M), and the second in the nanomolar range (KD,2 = 320 nM). This 
result suggested that, for reverse assays, the monomeric form of the protein should be used 
preferably. 
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Figure 3-12. Sensorgrams of 37 in the normal experimental setup (A) and in the reversed assay (B). 
Adapted from (133). 
3.3.3. Discussion and conclusions 
Given that the affinities of P58* and 33* were similar to the ones of the first-site antagonists, 
the immobilization apparently prevented the binding of the triazole–indole moiety, while the 
interaction with the tetrasaccharide part was still possible. An alternative strategy for ligand 
immobilization (Figure 3-13) may provide further insights. 
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Figure 3-13. Alternative synthetic strategy for ligand immobilization. 
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3.4. The influence of linker length on linker flexibility 
In P33 and P34, the NMR signals of the CH2 group linking the triazole and the nitroindole 
moiety differed significantly from the signal in P35 and P36. In the former cases, the protons 
gave two doublets, in the latter a singlet was observed. This indicates that rotation around the 
bonds linking the triazole and the nitroindole is restricted in P33 and P34. Interestingly, the 
amide–triazole part of the linker seems to determine the rotational freedom of the nitroindole, 
as it is the only difference between the molecules. Currently, there are no additional NMR 
data describing this phenomenon, and aggregate formation resulting in restricted linker 
flexibility cannot be excluded. However, the present finding is in agreement with the 
observation that retention times and rates of syn/anti triazole formation are also influenced by 
the linker lengths (cf. Section 3.6.5). 
 
Figure 3-14. NMR signals of the CH2 group linking the triazole and the nitroindole in P33 (left), P34 
(middle; note: the doublet at 6.82 ppm corresponds to the proton at position 3 of the nitroindole) and 
P36 (right; peak in P35 is a singlet as well). The spectra were recorded in deuterated methanol. 
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3.4.1. Spontaneous deuteration of P57 and P58 
Spontaneous proton–deuteron exchange at room temperature was observed at the 3-position 
of the nitroindole moiety of P57. As shown in Figure 3-15, leaving P57 in MeOH-d4 for 
estimated 2 d leads to almost complete exchange of the 3-proton by deuterium. 
 
Figure 3-15. Spontaneous exchange of P58’s nitroindole 3-proton at r.t. by a deuteron and vice versa. 
A) Initial 
1
H spectrum in MeOH-d4, recorded within approx. 1 h after dissolution of the sample; B) 
spectrum recorded after the sample had been left in MeOH-d4 for estimated 2 d; C) spectrum 
recorded after stirring of P58 in MeOH for 48 h. 
As the marked upfield shift of the 3-proton indicates (note that all other aromatic protons 
appear at > 7.15 ppm), the electron density at the 3-carbon is increased due to the +M effect 
of the 1-nitrogen. This is confirmed by DFT calculations (performed by Martin Smiesko; 
Figure 3-16) and is, for example, exploited in the Vilsmeier formylation, which occurs 
selectively at the 3 position (cf. Section 2). 
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Figure 3-16. Electron densities in the indole acetamide (left) and the nitroindole (right) derivative. 
3-carbon in the acetamide: -0.292; 3-carbon in the nitro compound: -0.272. Experimental parameters: 
DFT: B3LYP/6-J11++6(dip); charge population analysis; gas phase optimization. 
Mass spectra showed the same phenomenon to occur in the indole amine derivative P58, too. 
It was not observed in the nitro derivatives, albeit a systematic investigation has not been 
performed. 
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3.5. A theoretical approach to the design of an in situ click experiment 
3.5.1. Background 
Similar to the myelin associated glycoprotein (MAG), E-selectin represents a borderline case 
for the application of the in situ click methodology (160). The sLe
x
 binding site lies at the 
surface of E-selectin, and Figure 3-17 shows that the linker alkyne and azides will likely be 
exposed to the solvent during an in situ click experiment. This is somewhat in contrast to the 
first in situ click experiments of Sharpless and coworkers, where the click reaction took place 
within the spatially restricted active sites of enzymes. However, the most recent in situ click 
experiment performed by Heath, Sharpless, and coworkers (183) may be comparable to the 
E-selectin and MAG cases. It started from a low-affinity peptide fragment (KD ! 500 "M) and 
led to the formation of antibody-like ligands that do not interfere with enzyme activity. 
 
Figure 3-17. E-selectin cocrystallized with sLe
x
 (pdb code: 1G1T). The arrow indicates the expected 
approximate location of the second-site ligand relative to the first-site ligand. Image created by 
Gianluca Rossato, Institute of Molecular Pharmacy, University of Basel. 
In the present case, the binding of the first- and second-site ligands is characterized by low 
affinities (KDs of approx. 1 "M and estimated 5 mM, respectively) and the half-life times of 
the protein–ligand complex are distinctively short (133). Although high substrate affinities 
are not generally required for supramolecular catalysis (e.g. (188, 189)), there may be some 
consequences of low substrate affinity. Namely, proteins (unlike synthetic supramolecular 
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catalysts) are usually available only in limited quantities and concentrations, and thus 
achieving sufficiently high concentrations of ternary complex L1!P!L2 (L1, L2: first- and 
second-site ligand; P: protein) for the detection of triazole formation may be aggravated. 
[L1!P!L2] can be increased by increasing the ligand concentration but this will be 
accompanied by a faster background reaction due to the higher amounts of unbound ligand. 
Indeed, spontaneous triazole formation was readily detected in some preliminary 
experiments. Eventually, the question was raised in which way the experimental conditions 
have to be optimized for detecting the protein-mediated triazole formation, i.e. for the kinetic 
discriminitation of specifically and spontaneously formed triazoles. In lack of a systematic 
theoretical discussion of these aspects in literature, an attempt to rationalize the choice of 
experimental conditions for in situ click experiments is presented in the following section. 
3.5.2. Free and bound ligand 
The extent of ligand binding is an important parameter for the determination of suitable 
conditions for an experiment, as will be outlined in the following. 
Figure 3-18 (blue and red lines) illustrates the consequences of the low affinities of first- and 
second-site ligand for the fraction of unbound ligand. Due to the low affinity of the second-
site ligand (estimated KD = 5 mM) (160), the vast majority of second-site ligand remains in 
solution, independent of the concentration of the ligand added. For the first-site ligand, the 
fraction of free ligand remains low up to concentrations of about 75 "M but then increases 
more steeply. Thus, increasing the concentration of first-site ligand above 75 "M will mainly 
increase the concentration of free ligand.  
The green lines in Figure 3-18 show the fraction of protein bound to both ligands 
simultaneously. As illustrated by the black rectangle, the fraction of protein bound to both 
ligands cannot exceed 15% due to the solubility limit of the second-site ligands. This is of 
relevance because the concentration of ternary complex is related to the speed of protein-
mediated triazole formation (cf. Equation 7 in Section 3.5.3) and because the protein-assisted 
triazole formation is not a truly catalytic process if it leads to high-affinity ligands. These 
may eventually block the binding site and thus cancel the rate-accelerating effect of the 
protein.  
Taken together, Figure 3-18 suggests that there is a practical concentration window for 
performing an in situ click experiment and that the expected concentration of ternary 
complex is rather low. The consequences of this are further discussed in Section 3.5.3. 
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Figure 3-18. Green curves: percentages of protein bound to first- and second-site ligand in relation to 
the concentrations of first- and second-site ligand. Rectangle: accessible concentration range for the in 
situ click experiment. Blue and red curves: fraction of free first- and second-site ligand (in ‰) relative 
to the concentration of ligand added. Values calculated using Equations 11 and 13 with the following 
values: KD(L1) = 1 !M; KD(L2) = 5 mM; [P] = 80 !M. 
3.5.3. Reaction kinetics 
In the in situ click experiment, triazoles are formed via a protein-assisted as well as a 
spontaneous reaction pathway (Figure 3-19), as a significant amount of first- and second-site 
ligands will not be bound to E-selectin. Furthermore, spontaneous triazole formation will 
occur in the control samples containing bovine serum albumin (BSA) or buffer. To be able to 
detect the triazoles formed in the protein-assisted reaction, the speed v' of this reaction must 
be higher than the speed of the spontaneous reaction (v). Therefore, the concentrations of the 
ligands should be chosen in a way that leads to sufficiently high concentrations of ternary 
complex (cf. Section 3.5.2) and at the same time keeps the concentrations of free ligands as 
low as possible. 
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Figure 3-19. Reaction pathways (protein mediated and spontaneous) for triazole formation in an in 
situ click experiment. P: protein; L1: first-site ligand; L2: second-site ligand; L1!P!L2: ternary 
complex; P!L1–L2: complex of protein with newly formed ligand; k: rate constant of spontaneous 
reaction; k': rate constant of protein-assisted reaction; kon, koff: association and dissociation rate 
constants. 
In the target-templated click reaction, azide, alkyne, and the template form a ternary complex. 
With both reactants bound to a common scaffold, the intermolecular reaction now has the 
characteristics of an intramolecular one. Thus, the initial rate v' of protein-mediated triazole 
formation can be described by first-order kinetics (191): 
 !!
! 
"#= $# !%&' "( "&) * (7) 
This equation is only valid if kon,1, kon,2 and koff,3 > k'. While kon,1 and kon,2 are expected to 
fulfill this condition, koff,2 may become rate-limiting if a high-affinity ligand L1–L2 is formed 
in the process. Accordingly, Equation 7 only applies to the beginning of an experiment.  
Spontaneous triazole formation is subject to second-order kinetics, i.e. its rate depends on the 
concentration of azide and alkyne. Assuming that the spontaneous reaction takes place only 
for free ligand (L1,f and L2,f) in the E-selectin or a control sample, we obtain: 
 !!
! 
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Because the rate of triazole formation is very slow at room temperature (" [L]tot >> 
[triazole]) (177, 188, 189) we can assume that [L1]f and [L2]f remain constant during an in 
situ click experiment. 
As mentioned, for the detection of triazoles formed with the assistance of protein, the protein-
mediated reaction must be faster than the spontaneous reaction, i.e. v' > v or: 
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Or, upon rearrangement: 
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Equation 10 allows the quantitative comparison of different experimental setups by 
evaluating the ratio [L1]f [L2]f/[L1!P!L2], which should be kept as low as possible. The ratio 
k'/k, or effective molarity (EM), is commonly used for quantifying the catalytic efficiency of 
supramolecular systems. It has the unit M and corresponds to the concentration of one of the 
reactants required for the pseudo-first-order intermolecular reaction to proceed with the same 
rate like the reaction in the presence of the supramolecular catalyst (191). Hence, the ratio 
[L]f [L2]f /[L1!P!L2] corresponds to the minimal EM value (EMmin) required for detecting 
triazoles formed in the protein-assisted reaction. Besides its usefulness for experimental 
optimization, the minimally required EM value can also be used to compare the present 
system to other supramolecular systems described in literature (cf. Section 3.5.5). 
To calculate the concentrations of free ligand, the fraction of bound ligand (xL,b) is 
determined (217). (Note: Divided by 2, the numerator in Equation 11 corresponds to the 
concentration of ligand–protein complex [Li!P]. For the following calculations, a 1:1 binding 
mode is assumed.): 
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Which leads to Equation 12 for the concentration of free ligand: 
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Likewise, the concentration of ternary complex is calculated. Equation 14 shows that a high 
protein concentration is desireable for the in situ click experiment. 
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These equations were used to evaluate suitable experimental conditions, as outlined in the 
following section. 
3.5.4. Determination of suitable experimental conditions 
As mentioned, the minimal EMmin and the the concentration of ternary complex are crucial 
for a succesful in situ click experiment. Figure 3-20 shows how these parameters depend on 
the concentration of first-site ligand. As already indicated in Figure 3-18, increasing the 
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concentration of first-site ligand above approx. 60 !M leads to steep increase of EMmin, 
whereas the concentration of ternary complex is not further increased. In contrast to this, an 
increase of protein concentration leads to both a reduction of the EMmin values and increased 
concentrations of ternary complex. Consequently, adding the protein in excess is expected to 
be beneficial, as, theoretically, this would allow to keep most of the first-site ligand protein-
bound. 
 
Figure 3-20. Plot of [L1"P"L2] (unit: !M #10
-2
; calculated using Equation 14) and EMmin(Lf) (unit: 
!M; calculated using Equations 12 and 14; Lf: free ligand in the sample containing active protein) 
relative to the concentration of first-site ligand. Red lines: protein concentration of 80 !M; dashed 
blue lines: protein concentration of 40 !M. Concentration of second-site ligand: 450 !M. 
Figure 3-21 illustrates that changes of [L2] (straight lines) have a much smaller influence on 
EMmin and [L1"P"L2] than changes of [L1] (dotted lines). Therefore, the concentration of first-
site ligand must be adjusted more carefully than the one of the second-site ligand. 
Results and Discussion (continued) 
139 
 
Figure 3-21. Comparison of the effect of [L1] (dashed blue lines) and [L2] (red lines) on [L1!P!L2] 
(unit: "M #10
-2
) and EMmin(Lf). For the calculations (cf. Figure 3-20), either the value of [L1] or [L2] 
was kept constant. [L1] = 50 "M; [L2] = 450 "M. 
Figure 3-21 shows the EMmin values for the differentiation of a protein-mediated reaction 
within the reaction vessel containing active protein. This situation corresponds to a multi-
component experiment, where a mixture of substrates is investigated. However, when 
comparing the active protein sample to the control samples, the situation is different, because 
there the ligands are not protein-bound and therefore the rate of spontaneous triazole 
formation is higher in the control samples. Figure 3-22 shows the EMmin values required for a 
differentiation of active protein ($ EMmin(Lf)) and control ($ EMmin(Ltot)) samples. For the 
calculation of EMmin(Ltot), the total ligand concentration is divided by the concentration of 
ternary complex (Equation 15): 
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Figure 3-22. Comparison of EMmin values for the active protein sample (EMmin(Lf), red) and for the 
control samples (EMmin(Ltot), green); [L2] = 450 !M. 
As EMmin(Ltot) is more than a factor of 30 higher than EMmin(Lf), multicomponent 
experiments are considered beneficial in terms of the detectability of specifically formed 
triazoles.  
In such an experiment there is, however, competition for the binding site between the 
different ligands, which causes a drop of [L1"P"L2] and an increase of EMmin(Lf). In the 
following, a way of estimating the extent of this effect is described. 
As the concentration of second-site ligands has a much smaller influence on the relevant 
parameters (cf. Figure 3-18 and Figure 3-21), it should be beneficial to perform the in situ 
click experiment with different second-site ligands. Given that there is a maximal total 
nitroindole concentration (The solubility of a ternary mixture of nitroindoles (P28c, P28d, 
P28b) in HEPES buffer + 5% DMSO was found to be < 675 !M.) and that the different 
nitroindoles compete for the binding site, the ratio of free to bound second-site ligand can be 
estimated as follows (n: number of nitroindole components; xn,i(P): fraction of protein bound 
to ligand i with n nitroindole components; xn,i(Lf): fraction of free ligand i for n nitroindole 
components):  
With n second-site ligands, the total concentration of a ligand i is reduced by a factor n due to 
the total solubility limit. Thus, xn,i(P) is reduced by a factor of approximately n (assuming a 
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linear relationship between concentration and ligand binding, which is realistic in the case of 
the nitroindoles). Additionally, there is competition for the binding site, which reduces xn,i(P) 
by another factor of n (assuming identical KDs for all ligands). 
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With n second-site ligands, the concentration of a ligand i in solution is reduced by a factor n 
due to the total solubility limit. As the binding affinity of the second-ligand is very low, the 
fraction of bound ligand can be neglected here. 
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Upon rearrangement, we obtain the following relationship: 
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Equation 18 indicates that the ratio of free to bound ligand becomes less favorable with an 
increasing number of components, and hence EMmin increases as well. For example, doubling 
the number of components will double the ratio of free ligand fraction to bound protein 
fraction. 
3.5.5. Discussion 
The findings of the previous section were used to calculate the EMmin for different ligand 
concentrations. For comparison, the EMmin of Sharpless' in situ click experiments and of 
Mock's cucurbituril studies were determined (Table 3-6). 
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Table 3-6. Calculated EMmin values and concentrations of ternary complex ([L1!P!L2]) for different 
proteins and for cucurbituril. A: E-selectin; B: acetylcholinesterase (AChE); range of KDs given in 
(177), highest value chosen for calculation; C: AChE (179); D: AChE (180); E: carbonic anhydrase II; 
KD,2: "high micromolar affinities and above" (181); F: HIV-1 protease; KD,1: IC50 > 100 "M, KD,2: IC50 
= 4.2 "M (184); G: cucurbit[6]uril; range of concentrations given in (189), intermediate values chosen 
for calculation. All values are in "M. 
 A1 A2 A3 B C D E F G 
[L1] 500 50 50 30 4.6 4.6 60 500 60'000 
[L2] 450 450 450 66 24 24 400 100 12'000 
KD,1 1.0 1.0 1.0 0.1 0.018 0.023 0.037 150 650 
KD,2 5'000 5'000 5'000 100 1.1 34 500 4.2 2'500 
[P] 80 80 40 1.0 1.0 1.0 30 15 5'000 
          
[L1!P!L2] 8.4 4.0 3.0 0.4 0.9 0.4 13 11 3'784 
EMmin(Lf) 28'659 172 1'890 4'820 87 203 889 3'827 118'897 
EMmin(Ltot) 34'604 5'699 7'391 5'015 116 265 1'836 4'570 190'276 
          
With EMmin values differing by factor of 167 and 6, cases A1 and A2 demonstrate the 
importance of selecting appropriate ligand concentrations: For the detection of a catalytic 
effect, the rate of protein-mediated triazole formation needs to be substantially higher in case 
A1 than in case A2. As illustrated by A3, reducing the protein concentration by a factor of 2 
leads to an increase of EMmin by factors of 11 and 1.2.  
For the optimized conditions in case A2, EMmin(Lf) is 33 times smaller than EMmin(Ltot). In 
other words, in an ISC experiment with multiple components it is easier to detect a specific 
effect of E-selectin. However, as Equation 18 shows, multicomponent reactions have less 
favorable ratios of free ligand to ligand-bound protein, which also lowers EMmin(Lf). 
Therefore, the number of components should be limited for first proof-of-concept 
experiments.  
Cases B to F correspond to experiments of Sharpless and Mock, where actually a catalytic 
effect of the supramolecular template (a protein or cucurbituril) was observed. The EMmin 
values of these experiments are similar to or in some cases even considerably higher than the 
ones obtained in A2. Therefore, the conditions chosen in A2 should be suitable for an in situ 
click experiment, provided that E-selectin is a sufficiently efficient supramolecular catalyst. 
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In a review of 16 different supramolecular catalysts in two-substrate reactions, Mandolini 
found EM values ranging from 10
-3
 to 10
4
 M (191). As the EMmin in Table 3-6 range from 
10
-5
 to 10
-2
 M, it appears that, in general, supramolecular catalysts are quite likely efficient 
enough to allow detection of protein-mediated product formation in setups as used here. 
Interestingly, the most efficient supramolecular catalysts in this analysis mediated the 
(regiospecific) cycloaddition of an alkyne and an azide. The previously mentioned 
cucurbituril (see above) exhibited an EM as high as 16'000 M, and for a different 
encapsulation system catalyzing the cycloaddition between phenylacetylene and phenylazide 
(218), an EM of 120 M was found. Tight encapsulation of the substrates is a common feature 
of these two supramolecular systems and may explain their high catalytic efficiency. Menger 
suggested a "spatiotemporal prinicple" to rationalize the rate acceleration in intramolecular 
reactions (219). According to this principle, "the rate of reaction between functionalities A 
and B is proportional to the time that A and B reside within a critical distance". 
Consequently, the high EMs observed in two examples mentioned above may result from the 
host system's ability to hold the substrates together in critical distance for a sufficient amount 
of time. 
3.5.6. Conclusions 
In this analysis, the kinetics of spontaneous and protein-mediated triazole formation were 
investigated on a theoretical basis. A new paramenter (EMmin) that allows the evaluation and 
comparison of different experimental conditions, was introduced and was used to optimally 
adjust ligand and protein concentrations for an ISC experiment. Furthermore, single and 
multicomponent reactions were compared with respect to the fractions of free ligand, and it 
was shown that EMmin values become less favorable with increasing numbers of components. 
 The EMmin values obtained for the experiments with E-selectin are within the range of the 
values obtained for experiments from literature. Provided E-selectin can act as a 
supramolecular catalyst of triazole formation the conditions chosen should thus be suitable 
for the detection of a catalytic effect. 
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3.6. In situ click experiments 
3.6.1. Preliminary experiments 
3.6.1.1. Solubility of second-site ligands 
Before starting the in situ click (ISC) experiments, the solubility of several fragments was 
roughly estimated by visually assessing precipitation of the nitroindoles from a buffer 
solution with 5% DMSO (Table 3-7). The actual solubility is expected to be lower than these 
values, which was suggested by the findings presented in Section 3.6.6.1. 
Table 3-7. Approximate upper concentration limits in buffer (10 mM HEPES, 150 mM NaCl, 1 mM 
CaCl2, pH 7.4) containing 5% DMSO. 
compound solubility [mM] 
H
N
NO2
N3
P32a  
< 1 
N
NO2
N3
P28b  
< 0.625 
N
NO2
N3
P28d  
< 0.625 
  
3.6.1.2. Fragmentation of triazole antagonists/Determination of the linker pattern 
In a multicomponent ISC experiment, many different products may be formed (Scheme 3-6). 
Ideally, their structure should be assignable directly after the HPLC-MS run, which is 
aggravated by the fact that, depending on the alkyne–azide mixture, several isomers of 
identical mass can be formed. 
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Scheme 3-6. Possible products formed from the reaction of alkynes P26b and P26c with azides P28b 
and P28c. 
One way of structure assignment consists of comparing the observed retention times to the 
ones of known triazoles. This is quite straightforward as the synthesis of the triazoles can be 
performed on analytical scale (cf. Section 3.6.5). Due to the different spatial arrangement of 
the substituents in syn and anti triazoles, these may be well differentiable based on retention 
times (177), which is expected to be more difficult for ligand isomers where just the position 
of the triazole moieties differs (e.g. in the triazoles with m/z = 1035.5 in Scheme 3-6). As a 
solution to this, Ernst and coworkers (160) used HPLC-MS/MS to generate fragment ions 
characteristic for a certain linker pattern. 
Following this approach, a product ion scan in the negative ionization mode (cf. Figure 1-27) 
revealed two characteristic fragments of P38 (m/z = 413.2, m/z = 249.1) containing 
information about the linker pattern (Scheme 3-7). In single reaction monitoring mode, 
optimal fragmentor voltages and collision energies for fragmentation were determined (Table 
3-8 and Figure 3-23). About 3 times higher maximal signal intensities were found for the 
fragment with m/z = 413.2. 
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Table 3-8. Optimized fragmentor voltages and collision energies for P38. 
 positive mode negative mode 
fragmentor voltage [V] 170 290-300 
collision energy [V] n.d. 
m/z 413.2: 50 
m/z 249.1: 70 
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Scheme 3-7. MS/MS experiment with P38. Fragmentation of the precursor ion P38 (m/z = 1021.5, 
negative mode) at a fragmentor voltage of 290 V and at collision energies of 70 V (top) and 50 V 
(bottom). 
 
Figure 3-23. Abundancy of product ions with m/z = 249.1 and m/z = 413.5 plotted against different 
collision energies. 
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3.6.2. Experimental setup of in situ click experiments 
Further experimental details are given in Section 5.1.2. 
3.6.2.1. Sample preparation 
Figure 3-24 shows the typical workflow of an in situ click (ISC) experiment. As the required 
protein concentrations were high (40-80 !M), the reaction volume was restricted to 50 !L, 
allowing 5 measurements per experiment. The reactions were shaken at 20 °C and not at 
37 °C as previously reported (160, 177, 179-181, 183, 184) to prevent the evaporation of 
water, which aggravates sustaining stable experimental conditions and may have led to 
protein denaturation due to concentration of the solutions. For the MS measurements, 10 !L 
of sample were pipetted into 40 !L of water + 0.1% HCOOH, and the mixture was 
subsequently analyzed by HPLC-MS. This dilution step was introduced to reduce pipetting 
errors caused by the small liquid volumes. 
 
Figure 3-24. Schematic representation of the standard sample preparation before injection into the 
MS. HEPES buffer: HEPES 10 mM (pH 7.4), NaCl 150 mM, CaCl2 1 mM. 
The suitability of this sample workup procedure is demonstrated by experiments described in 
Section 3.6.5.8. 
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3.6.2.2. HPLC-MS method 
Figure 3-25 summarizes the HPLC-MS method used for the analysis of the samples. 
The MS was run in negative ionization mode. While sensitivity would have been higher in 
the positive ionization mode, it was found that the selectivity in the positive mode was 
insufficient, leading to a frequent occurrence of nonspecific signals. Single ion monitoring 
was used (cf. Figure 1-27E) to increase both sensitivity and selectivity.  
As a control, the starting materials were monitored along with the triazoles, the first-site 
ligands by MS and the second-site ligands using the diode array detector (DAD). The MS 
analysis was restricted to separate time windows where the elution of the starting materials 
and the triazoles occurred. The use of separate time windows reduces the wear and 
unnecessary contamination of the MS and increases sensitivity. Additionaly, for enhanced 
sensitivity in the time window for triazole detection, the electron multiplier voltage (! EMV) 
was set to 1000 V (higher values of ! EMV correspond to higher sensitivity). 
 
Figure 3-25. Schematic representation of the standard HPLC-MS method used for the analysis of ISC 
and ISCtest experiments. Green line: gradient (percent of acetonitrile + 0.1% HCOOH in the eluent); 
the grey squares represent time windows during which the indicated detection method was used; 
DAD: diode array detector; MS SIM: mass spectrometry, single ion monitoring; EMV: electron 
multiplier voltage. 
3.6.3. In situ click experiments 
The components of the ISC experiments were chosen based on the Biacore affinity ranking of 
the anti triazole antagonists (133) to detect possible differences in the rate of triazole 
formation that may result from differences in preorganization between more and less potent 
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ligands. I.e., alkynes and azides leading to anti antagonists with a KD > 89 nM and anti 
antagonists with a KD < 89 nM were preferentially chosen. Furthermore, the components were 
selected to result in products with different mass or in the least possible number of products 
with identical mass. 
In the following sections, representative chromatograms of the ISC experiments are shown. 
For each experiment, a rationale and a short discussion is given. 
3.6.3.1. In situ click experiment 1 (ISC1) 
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Scheme 3-8. ISC1: P26b: 50 !M; P28d: 450 !M; protein: 81 !M; 20 °C. 
Rationale: 
The protein-mediated reaction between P26b and P28d may lead to formation of the high-
affinity anti triazole P45 (KD = 49 nM). 
Discussion and conclusions:  
There was no accelerated triazole formation in the E-selectin sample. The cycloaddition 
proceeded faster in the two samples containing protein. The syn and anti isomers appear to 
have identical retention times. 
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Figure 3-26. Representative chromatograms of ISC1. 
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3.6.3.2. In situ click experiment 2 (ISC2) 
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Scheme 3-9. ISC2: P26c: 50 !M; P28c: 450 !M; protein: 80 !M; 20 °C. 
Rationale:  
The protein-mediated reaction between P26c and P28c may lead to formation of the high-
affinity anti triazole antagonist P43 (KD = 30 nM). 
Discussion and conclusions:  
There was no accelerated triazole formation in the E-selectin sample. Interestingly, only in 
the BSA sample detectable amounts of triazole were formed. 
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Figure 3-27. Representative chromatograms of ISC2. Note: The peak tailing in the reference 
chromatogram was caused by a worn pre-column. 
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3.6.3.3. In situ click experiment 3 (ISC3) 
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Scheme 3-10. ISC3: P26b: 50 !M; P32b: 250 !M; P32c: 250 !M; protein: 80 !M; 20 °C. 
Rationale: 
In ISC3, anti triazole antagonist P51 (KD = 50 nM) may be formed preferentially over anti 
triazole antagonist P48 (KD > 89 nM). 
Conclusions: 
In none of the samples, any triazoles were detected at a significant level. Thus, in this 
experiment, no catalytic effect of E-selectin could be shown. 
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Figure 3-28. Representative chromatograms of ISC3. 
Results and Discussion (continued) 
155 
3.6.3.4. In situ click experiment 4 (ISC4) 
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Scheme 3-11. ISC4: P26b: 500 !M; P32b: 250 !M; P32c: 250 !M; protein: 80 !M; 20 °C. 
Rationale: 
The components of ISC4 were the same as in ISC3. However, a higher concentration of first-
site ligand (500 !M instead of 50 !M) due to the low signal intensity observed in ISC3. 
Conclusions: 
As can be seen from Figure 3-29, the bovine serum albumin (BSA) sample shows a slightly 
different peak pattern than the E-selectin and buffer samples, and the rate of triazole 
formation is considerably higher. As the peak patterns of the buffer and the E-selectin sample 
are identical, this experiment does not indicate any specific effect of E-selectin. According to 
the reference chromatogram from ISCtest8, the two peaks correspond to the syn and anti 
isomers of the 2s/a3C series. 
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Figure 3-29. Representative chromatograms of ISC4. 
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3.6.3.5. In situ click experiment 5 (ISC5) 
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Scheme 3-12. ISC5: P26c: 50 !M; P26a: 50 !M; P28a: 500 !M; protein: 80 !M; 20 °C. 
Rationale: 
In contrast to the other ISC experiments, only one second-site but two first-site ligands were 
used here. As discussed previously (Section 3.5.4), this setup is actually expected to be less 
favorable because it leads to higher concentrations of unbound ligand, which in turn increases 
the rate of spontaneous triazole formation.  
The combination of fragments may again lead to a high-affinity (P51, KD = 89 nM) and a 
lower-affinity (P33, KD > 89 nM) anti triazole ligand. 
Conclusions: 
Only in the BSA sample some triazole formation was detected. No reference compound or 
experiment is available for ISC5. 
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Figure 3-30. Representative chromatograms of ISC5. 
3.6.3.6. In situ click experiment 6 (ISC6) 
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Scheme 3-13. ISC6: P26a: 50 !M; P26c: 50 !M; P28b: 400 !M; P28c: 400 !M; P28d: 400 !M; 
protein: 80 !M; 20 °C. 
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Rationale:  
Because previous ISC experiments had shown that BSA is not a neutral control sample 
compared to buffer, an additional control sample containing E-selectin + 3 mM EDTA was 
used in ISC6. By complexing Ca
2+
 from the E-selectin binding site, EDTA should eliminate 
binding to the first site, which is calcium-dependent. ISC6 was the first experiment involving 
more than three fragments. Here, 12 different combinations of first- and second-site ligands 
with 5 different masses can be formed. Among these, there are two high-affinity anti triazole 
antagonists (P41, KD = 57 nM; P43, KD = 30 nM). 
Discussion and conclusions:  
Figure 3-31 shows the chromatograms covering all possible masses (! total ion count [TIC] 
traces). An inspection of the extracted chromatograms (! single mass traces) revealed that 
the trace for m/z = 1035.5 accounts for most of the signals in the TIC trace (Figure 3-32).  
Peaks A and B are a result of non-specific signal, as confirmed by a test experiment 
(ISCtest1), where an identical pattern was observed. The test experiment further showed that 
peak group C corresponds to the triazoles formed from alkyne P26c and azide P28b, and 
peak D to triazoles from P26a and P28d. Concluding from the fact that peak group C and 
peak D were not observed in both E-selectin, but in the BSA and buffer samples, E-selectin 
did not have a catalytic effect on triazole formation in this experiment. As previously, the rate 
of triazole formation was highest in the BSA sample.  
In ISC6 and ISC7, a strong variation of retention times was observed between the 
measurements taken at different time points (see Figure 3-33 for an example from ISC6; data 
for ISC7 not shown). ISCtest1 revealed that this was most probably caused by a worn out 
pre-column (Figure 3-42). 
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Figure 3-31. Representative chromatograms of ISC6 (TIC trace). 
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Figure 3-32. Representative chromatograms of ISC6 (single-mass trace for m/z = 1035.5). 
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Figure 3-33. Variations of retention times in ISC6 caused by a worn out pre-column. 
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3.6.3.7. In situ click experiment 7 (ISC7) 
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Scheme 3-14. ISC7: P26a: 50 !M; P26c: 50 !M; P32a: 250 !M; P32b: 250 !M; P32d: 250 !M; 
protein: 80 !M; 20 °C. 
Rationale: 
Like ISC6, ISC7 included 5 fragments. The nitroindole second-site ligands were all C-
alkylated to cover three so far untapped linker combinations. The nitroindole concentration 
was reduced from 400 to 250 !M due to the low solubility of the nitroindoles. 
Conclusions: 
Similar to ISC6, the signals in the TIC trace essentially corresponded to the single mass trace 
for m/z = 1035.5. Again, nonspecific signals (peaks B and C, Figure 3-35) were observed, 
indicated by the fact that peaks B and C were detected already in the samples analyzed 
immediately after starting the experiment. Triazole formation (peak group A) was fastest in 
the BSA sample, and no specific effect of E-selectin could be demonstrated. 
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Figure 3-34. Representative chromatograms of ISC7 (TIC trace). 
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Figure 3-35. Representative chromatograms of ISC7 (single-mass trace for m/z = 1035.5). 
3.6.4. ISC experiments with contaminated E-selectin 
The appereance of some peaks at unexpected retention times and apparently positive results 
in some ISC experiments eventually led to the identification of impurities in 4 batches of E-
selectin. In the following these experiments and the screening of different protein batches for 
contaminations are outlined. 
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3.6.4.1. In situ click experiment 8 (ISC8) 
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Scheme 3-15. ISC8: P26b: 50 !M; P28c: 600 !M; protein: 41 !M (E-selectin protein code: 
0001/AC/3/2/KL/090721); 20 °C. 
Rationale:  
This experiment was performed to investigate the effect of E-selectin on triazole formation 
for a ligand pair that may lead to an anti triazole antagonist of intermediate affinity (KD > 
89 nM). 
Discussion and conclusions:  
The injection of a native sample from the E-selectin batch showed that the apparently higher 
amount of triazole in the BSA sample was the result of a contamination with P42. Peak A is 
the result of a nonspecific signal, as the intensity remained constant over time. Furthermore, 
no corresponding peak was found in the test experiment  
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Figure 3-36. Representative chromatograms of ISC8. 
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3.6.4.2. In situ click experiment 9 (ISC9) 
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Scheme 3-16. ISC9: P26b: 50 !M; P28d: 250 !M; P32c: 250 !M; protein: 80 !M ((E-selectin protein 
code: 0001/AC/3/2/KL/090721); 20 °C. 
Rationale:  
ISC9 was a multicomponent reaction intended to lead to anti triazole ligands with high (P45) 
and lower (P51) affinity to E-selectin. The choice of components was based on the erroneous 
ranking of P51 as the weakest E-selectin ligand. In fact, P45 and P51 have identically high 
affinities (KDs of 49 and 50 nM). 
Discussion and conclusion:  
In all measurements, a single peak was observed in the E-selectin sample, whose retention 
time did not match the peaks found in the corresponding test experiments (ISCtest6 and 
ISCtest8) but corresponded to the one of P42. The peak was also detected in the native E-
selectin batch, indicating that the latter was contaminated with traces of P42. The 
contamination most probably resulted from using re-purified E-selectin hat had previously 
been used in experiments involving P42.  
Triazole formation was faster in the BSA sample than in the buffer sample. It remains unclear 
why no spontaneously formed triazoles could be detected in the E-selectin sample. Yet, the 
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absence of any signal in the E-selectin sample indicates that there was no catalytic effect of 
E-selectin. 
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Figure 3-37. Representative chromatograms of ISC9. 
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3.6.4.3. In situ click experiment 10 (ISC10) 
O
O
O
HO
OH
OBz
COOH
O
HO
OH
OH
O
H
N
O
N
NO2
N3
P28b
N
NO2
N3
P28c
P26a
+
O
O
H
N
O
N
N
N
O
O
H
N
O
N
N
N
O
O
H
N
O
N
N
N
O
O
H
N
O
N
N
N
N
N
N
N
O2N
NO2
NO2
O2N
P37
P41
 
Scheme 3-17. ISC10: P26a: 50 !M; P28b: 250 !M; P28c: 250 !M; protein: 80 !M (E-selectin protein 
code: 0001/AC/4/2/KL/091006); 20 °C. 
Rationale:  
ISC10 was a multicomponent experiment potentially leading to anti triazole ligands with 
high (P41, KD = 57 nM) and lower (P37, KD > 89 nM) affinity to E-selectin. 
Discussion and conclusion:  
In ISC9, an intense peak, which did not match the reference (P41) or the peaks found in the 
corresponding test experiment (ISCtest6), was observed in the E-selectin sample (Figure 
3-38). The peak's retention time was identical to the one of P38, and it was detected in the 
native E-selectin batch, indicating that the latter was contaminated with P38.  
The other peaks corresponding to 1s/a2N and 1s/a3N triazoles were of comparable intensities 
in all samples, which indicates that there was no catalytic effect of E-selectin. 
Note: Figure 3-38 shows that the retention times of the reference compound P38 and P41 
differ by almost 0.8 min. Considering that these isomers differ only by the position of the 
triazole moiety, this finding is quite remarkable and fits in with the observations made in 
ISCtest5 (Section 3.6.5.4). 
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Figure 3-38. Chromatograms of ISC10 after 24 h. Spontaneously formed triazoles in the E-selectin 
sample were only detected in the measurement after 24 h. 
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Figure 3-39. Chromatograms of ISC10 after 188 h. Spontaneously formed triazole could not be 
detectd in the E-selectin sample. 
3.6.4.4. Investigation of protein batches containing recycled protein 
The contaminated protein batches (0001/AC/4/2/KL/091006 and 0001/AC/3/2/KL/090721) 
identified in the ISC experiments contained recycled E-selectin that had been used for some 
NMR and ITC analysis of P38 and P45. Therefore, it was presumed that the recycling 
procedure had failed in fully removing these antagonists and that other batches containing 
recycled E-selectin were contaminated as well. Relevant protein batches were scanned in 
single ion mode for m/z ratios corresponding to the triazole–nitroindole antagonists (m/z = 
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993.4, 1007.5, 1021.5, 1035.5, 1049.6) and three tetrasaccharide mimics (BW69669 (m/z = 
599.6), DS41-15 (m/z = 613.7), DS41-49 (m/z = 717.8)) (131), which had also been analyzed 
with subsequently recycled E-selectin. None of the tetrasaccharide mimics was detected in 
any of the E-selectin batches. But, as Figure 3-40 shows, traces of P38 and, in one case, P42 
were detected in samples containing recycled protein. In a batch (0001/AC/0/1/KL/081117) 
containing only freshly produced protein, no contaminations were found, further supporting 
the assumption that the detected contaminations originated from recycled protein. 
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Figure 3-40. MS analysis of different protein batches. 
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3.6.4.5. Influence of the contaminations on experimental outcomes 
The presence of an E-selectin antagonist (P42: KD > 89 nM) in a protein sample could corrupt 
ISC experiments or biological assays where competition for the sLe
x
 binding site may occur. 
Thus, the concentration of P42 in sample 1 (Figure 3-40) was estimated via a linear 
calibration curve (Figure 3-41). The observed relationship between concentration and the MS 
signal was nonlinear, a property common to the triazole–nitroindole antagonists (209). 
Using the linear calibration curve shown in Figure 3-41, the concentration of P42 in protein 
sample 1 was estimated to be roughly 0.5 !M. Assuming a KD of 100 nM for P42, no more 
than 0.5% of the protein in the undiluted protein batch are expected to be ligand-bound. 
Considering this, a relevant influence on measurements performed with contaminated E-
selectin appears improbable. Accordingly, the conclusions from ISC9 and ISC10 remain 
valid. I.e., E-selectin did not have a catalytic effect on the cycloaddition of the alkynes and 
azides investigated in these experiments. 
 
Figure 3-41. Calibration curve for P42. Measured concentrations: 0.05 !M, 0.1 !M, 0.5 !M, and 
1 !M. A nonlinear relationship between concentration and MS signal was observed. Linear calibration 
curve: y = 10
7
"x – 862040; R
2
 = 0.9698. 
Nevertheless, E-selectin that has been in contact with the triazole–nitroindole antagonists 
should not be recycled, or the recycling procedure should be adapted to ensure complete 
removal of these antagonists. 
Based on the above results, the concentrations of spontaneously formed nitroindolyl ligands 
in the ISC experiments are expected to be in the two-digit nM range. 
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3.6.5. In situ click test experiments 
A series of test experiments was performed to gain insight into spontaneous triazole 
formation. In particular, the information gained from these experiments was useful as a 
reference for the in situ click experiments. 
3.6.5.1. In situ click test experiment 1 and 2 (ISCtest1 and ISCtest2) 
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Scheme 3-18. ISCtest1: P26c: 500 !M; P28b: 500 !M; 37 °C. 
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Scheme 3-19. ISCtest2: P26a: 500 !M; P28d: 500 !M; 37 °C. 
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Rationale:  
These test experiments were performed for the identification of the peaks observed in ISC6. 
Peaks A, B, and C from ISCtest1 and peak D from ISCtest2 corresponded to the one in ISC6. 
Discussion and conclusions:  
Peaks A and B were already present after 3 h, which indicates that they are non-specific. This 
is further confirmed by the fact that only the area under the curve (AUC) of peak C increases 
over time (Figure 3-43). The shifts of retention times, as also illustrated in Figure 3-32, were 
caused by a worn out pre-column. 
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Figure 3-42. Representative chromatograms of ISCtest1 and ISCtest2. 
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Figure 3-43. Peak intensities (AUCs) of ISCtest1. 
3.6.5.2. The influence of EDTA: ISCtest3 
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Scheme 3-20. ISCtest3a: P26b: 500 !M; P28b: 600 !M; 37 °C; ISCtest3b: + EDTA 10 mM. 
Rationale:  
ISCtest3 was performed to investigate the influence of EDTA on triazole formation, as 
EDTA was used in a control sample (ISC6 and ISC7). 
Discussion and conclusions:  
Interestingly, the rate of triazole formation was somewhat lower in the presence of EDTA. 
This result led to the speculation, that traces of copper may have been present in the sample, 
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causing a small catalytic effect. Although the effect was small, the influence of Cu
2+
 on 
triazole formation was investigated in an additional experiment (ISCtest3): 
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Figure 3-44. Representative chromatograms of ISCtest3. 
Results and Discussion (continued) 
180 
 
Figure 3-45. Comparison of the peak intensities (AUCs) of ISCtest3a and 3b. 
3.6.5.3. The influence of Cu
2+
: ISCtest4 
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Scheme 3-21. ISCtest4a: P26b: 500 !M; P32b: 600 !M; 5% DMSO; 37 °C; ISCtest4b: 
+ CuSO4"5H2O (5 mM). 
Rationale:  
In ISCtest3, EDTA was shown to reduce the rate of triazole formation. As EDTA is capable 
of complexing Cu
2+
 ions, one may attribute this effect to the removal of traces of catalytically 
active Cu
I
 species. To validate this hypothesis, the rate of triazole formation was investigated 
in the presence of a high concentration (5 mM) of Cu
2+
. 
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Discussion and conclusions:  
Figure 3-46 and Figure 3-47 show that the addition of CuSO4!5H2O indeed accelerated the 
formation of the anti triazole. After 3 d, its concentration was approximately 6-fold higher in 
the sample containing Cu
2+
 than in the reference sample, while the concentration of syn 
triazoles was essentially unchanged. Given the large amounts of CuSO4!5H2O added, it is not 
expected that possible traces of copper would have a major impact on the outcome of in situ 
click experiments. 
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Figure 3-46. Representative chromatograms of ISCtest4a and 4b. 
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Figure 3-47. Comparison of the peak intensities (AUC) of ISCtest4a and 4b. 
3.6.5.4. In situ click test experiment 5 (ISCtest5) 
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Scheme 3-22. ISCtest5: P26b: 500 !M; P28b: 600 !M; 5% DMSO; 37 °C. 
Rationale:  
As Figure 3-44 from ISCtest3 shows, the 2s/a2N isomers have identical retention times, 
resulting in a sharp single peak in the chromatogram. Thus, ISCtest5 was performed to 
investigate the separation behaviour of 1s/a2N isomers. 
Discussion and conclusions:  
In contrast to the 2s/a2N isomer, the 1s/a2N isomers are well separable using the standard 
gradient. Interestingly, the retention time of the 1s2N triazole is higher than the ones of the 
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2s/a2N isomers, despite the shorter linker. The comparison of these results to ISCtest4, where 
2s/a2C triazoles were analyzed, revealed an inversed elution behavior of syn and anti 
isomers. Additionally, in ISCtest5, the formation of anti triazole was faster than syn triazole 
formation, while it was the other way round in ISCtest4.  
These and other (! Section 3.6.4.3) findings indicate that conformational aspects may be 
important for this antagonist class: small structural changes can apparently lead to relatively 
strong effects on the elution behavior and even seem to influence the selectivity of the 
alkyne–azide cycloaddition. 
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Figure 3-48. Representative chromatograms of ISCtest5. 
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Figure 3-49. Peak intensities (AUC) of ISCtest5. 
3.6.5.5. In situ click test experiment 6 (ISCtest6) 
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Scheme 3-23. ISCtest6: P26b: 500 !M; P28d: 600 !M; 5% DMSO; 37 °C. 
Rationale:  
ISCtest6 was performed to investigate the separation behaviour of the 2s/aN isomers and as a 
reference for the ISC experiments. 
Discussion and conclusions:  
The 2s/a4N isomers were not separable using the standard chromatographic method for the 
ISC experiments. 
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Figure 3-50. Representative chromatograms of ISCtest6. 
 
Figure 3-51. Peak intensities (AUC) of ISCtest6. 
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3.6.5.6. In situ click test experiment 7 (ISCtest7) 
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Scheme 3-24. ISCtest7: P26b: 500 mM; P28c: 600 mM; 5% DMSO; 37 °C. 
Rationale: 
ISCtest7 was performed to investigate the separation behaviour of the 2s/a3N isomers and as 
a reference for the ISC experiments. 
Discussion and conclusions:  
The 2s/a3N isomers are not separable using the standard chromatographic method for the ISC 
experiments. 
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Figure 3-52. Representative chromatograms of ISCtest7. 
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Figure 3-53. Peak intensities (AUC) of ISCtest7. 
3.6.5.7. In situ click test experiment 8 (ISCtest8) 
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Scheme 3-25. ISCtest8: P26b: 500 mM; P32c: 600 mM; 5% DMSO; 37 °C. 
Rationale:  
ISCtest8 was performed to investigate the separation behaviour of the 2s/a3C isomers and as 
a reference for the ISC experiments. 
Discussion and conclusions:  
The 2s/a3C isomers were not separable using the standard chromatographic method for the 
ISC experiments. Their retention times were shorter than the ones of the 2s/a3N isomers (as 
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exemplified by the chromatogram of P42), which may be explained by the hydrogen-bond 
donor ability of the free indole NH group. 
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Figure 3-54. Representative chromatograms of ISCtest8. The deviating retention times of reference 
P51 and ISCtest8 were caused by a worn out pre-column. 
 
Figure 3-55. Peak intensities (AUC) of ISCtest8. 
Results and Discussion (continued) 
190 
3.6.5.8. Protein denaturation – necessity or not? 
This experiment was performed to assess the influence of sample preparation for MS 
analysis. Specifically, the question should be answered whether diluting the protein with an 
organic solvent instead of water and formic acid would influence signal intensity, e.g. by 
better liberating potentially protein-bound ligand from the protein. Thus, MeOH or MeCN 
instead of H2O + 0.1% HCOOH were used to dilute the samples of an ISC experiment (not 
shown; the experimental conditions were identical to ISC6), which led to precipitation of the 
protein. Before injection into the HPLC-MS, the sample was centrifuged, the supernatant was 
removed and the concentration of first-site ligands was analyzed. At ligand and protein 
concentrations of 50 and 80 !M, respectively, 97% percent of the first-site ligand P26c (KD 
used for calculation = 1 !M) is bound to protein. Thus, this setup is expected to be suitable 
for detecting differences in measured ligand concentrations that may result from differential 
ligand liberation. 
It was found that denaturing the protein with an organic solvent is not advantageous over the 
previously used procedure with H2O and formic acid for the following reasons: 1) With 
MeOH or MeCN, the baseline was elevated, as illustrated in Figure 3-56. This may be caused 
by the high elution strength of MeOH and MeCN. 2) The measured TIC signal of the first-
site ligands in the E-selectin sample was actually lower than in the BSA and buffer samples 
(Figure 3-57). Furthermore, the dilution with MeOH led to a generally lower signal, which 
may be a result of the elevated baseline or the additional centrifugation step.  
When water was used for the dilution, the signal was highest in the BSA sample and 
approximately equal in the E-selectin and buffer sample. This further indicates that sample 
preparation using water and formic acid does not lead to an underestimation of ligand 
concentrations in the E-selectin sample. Also in other ISC experiments, a depletion effect 
caused by E-selectin was not observed, as exemplified in Figure 3-58. 
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Figure 3-56. Dependence of peak and baseline shapes from the sample preparation. 
 
Figure 3-57. Depencence of signal intensities of the first-site ligand P26c from the way of sample 
preparation. 
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Figure 3-58. Signal intensities of the first-site ligand P26b as measured in ISC1. 
3.6.6. Nitroindole concentrations in ISC experiments 
In most ISC experiments, spontaneous triazole formation appeared to be faster in the BSA 
sample than in the E-selectin and the buffer samples, an observation that was also made by 
Fokin and coworkers in their in situ click experiment for the identification of inhibitors of 
HIV protease 1 (184). A series of experiments and tests was performed to elucidate the cause 
of this phenomenon. 
3.6.6.1. Course of nitroindole concentrations during an ISC experiment 
Figure 3-59 shows the relative concentrations of second-site ligands in ISC experiment 10 
determined from the UV chromatographic trace, which was recorded along with the MS 
trace. After 24 h, the concentration of P28c in the buffer sample was reduced by a factor of 
5.2 compared to the BSA sample and remained constant for the residual duration of the 
experiment. The decrease was slower in the E-selectin sample, but after 188 h, the nitroindole 
concentration had neverless dropped to about 50% of the original value. Qualitatively, this 
effect was observed in most other ISC experiments as well. Thus, the apparently faster 
reaction rates in the BSA samples may result from a higher ligand concentration. This 
observation can be explained by the pronounced ligand-binding properties of serum 
albumins, which were, for example, investigated at the Instiute of Molecular Pharmacy (220). 
Results and Discussion (continued) 
193 
 
Figure 3-59. Relative concentrations (represented by the AUC of the UV absorption signal at a 
wavelength of 350 nm) of the second-site ligand P28c in ISC10. 
3.6.6.2. The influence of DMSO concentrations on nitroindole concentration 
As the binding behavior of E-selectin was found to remain constant for DMSO 
concentrations up to 10% (221), it was tested whether, at a DMSO concentration of 10%, the 
putative precipitation of the nitroindoles could be prevented (Figure 3-60). However, the 
decrease of nitroindole concentration was just slightly lower in the vial with 10% DMSO: 
after 24 h, it had dropped by 75% compared to the vial with BSA. With 5% DMSO, the 
concentration decrased by 83%.
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Figure 3-60. Concentrations of nitroindole P28c (represented by the AUC of the UV absorption 
signal at a wavelength of 350 nm). Initial concentration of P28c: 500 !M; BSA concentration: 80 !M. 
3.6.6.3. Vialtest 
To assess whether adsorption of the nitroindole to the tube surface might influence the 
nitroindole concentration, an experiment with tubes made of glass, standard polypropylene 
(PP) tubes and "Protein LoBind" was performed (Figure 3-61). Again, only BSA was able to 
prevent the concentration drop, while there was little to no variation between the different 
tube materials. 
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Figure 3-61. Influence of vial material on nitroindole concentrations; PP: polypropylene. 
3.6.7. Discussion and conclusions 
Despite a careful experimental design and the variety of experimental conditions used, in 
none of the ISC exepriments a catalytic effect of E-selectin was found. Based on this 
observation it is concluded that E-selectin does not act as a supramolecular catalyst for the 
1,3-dipolar cycloaddition of alkyne and azide first- and second-site ligands as available in the 
present setup. 
The apparent inability of E-selectin to accelerate the alkyne–azide cycloaddition may well be 
explained by virtue of Menger's "spatiotemparal postulate" mentioned in Section 3.5.5. Due 
to the shallow nature of the binding site (cf. Figure 3-17) and the short half-life time of the 
ligand–receptor complexes (Section 2), E-selectin is probably not suited to fulfill either the 
spacial and/or the temporal requirements for supramolecular catalysis. 
Several test experiments were performed to validate the observations of the in situ click 
experiments. None of these experiments suggested shortcomings in the experimental setup 
that might have caused false-negative results. The test experiments further revealed 
differences in retention times and in rates of syn and anti triazole formation that depended on 
the length of the involved linkers. This finding indicates, along with observations in 
1
H NMR 
spectra (cf. Section 3.4), that the solution conformations of triazole–nitroindole antagonists 
with different linker patterns differ significantly. 
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4. Conclusions and Outlook 
4.1. Conclusions 
The important contributions of E-selectin to chronic inflammatory diseases and cancer make 
it an attractive drug target. However, small-molecule antagonists of E-selectin have been 
suffering from comparably low micromolar affinities, which is a result of the shallow and 
highly solvent-accessible binding site of E-selectin. 
This work aimed at the affinity improvement of carbohydrate-based E-selectin antagonists 
via a fragment-based approach that does not rely on structural information and has 
successfully been applied to another lectin (MAG) previously (160). 
4.1.1. New antagonists 
Second-site ligands were identified using an NMR-based screening (performed by Céline 
Weckerle). The attachment of a TEMPO spin label to a given first-site ligand allowed to 
identify 5-nitroindole as a second-site ligand that binds simultaneously with and in the 
vicinity of the first-site ligand. 
After the identification of the second-site ligand, a library of first-and second-site antagonists 
bearing azido- or alkynyl-functionalized linker moieties of different length was synthesized. 
In situ click experiments, as first described by Sharpless and coworkers (177), were 
performed for the identification of a suitable linker pattern. Because these experiments failed 
(see below), a library of triazole–nitroindole antagonists was synthesized and screened in a 
specifically designed Biacore assay (Céline Weckerle). The five most potent antagonists 
identified in the screening were characterized in detail using Biacore, which revealed 
antagonists with KDs between 30 and 90 nM and ligand–protein half-life times in the range of 
4 to 5 minutes instead of seconds. 
The synthesis of indoleamine and indole acetamide derivatives revealed important 
contributions of the nitro group to binding, as its replacement was accompanied by a loss of 
affinity. The same effect was observed for the substitution of the triazole moiety by 
piperazine. 
Owing to their amphiphilic properties, all antagonists exhibited some surface activity and 
were found to form micelles at concentrations around 1 to 10 mM. The surface activity was 
reduced by the replacement of the nitro group by the more hydrophilic amine and acetamide, 
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but not by the introduction of the piperazine moiety.  
Based on their pharmacokinetic and physicochemical properties (measurements performed by 
Matthias Wittwer and Simon Kleeb), none of the tested angatonists is expected to be 
passively absorbed from the gastrointestinal tract. 
4.1.2. In situ click experiments 
To ensure suitable experimental conditions, the reation kinetics associated with an in situ 
click experiment were analyzed on a theoretical basis. The insights gained were applied to a 
number of in situ click experiments. However, in none of these, a catalytic effect of E-
selectin was observed, and it was concluded that E-selectin does not act as a supramolecular 
catalyst in the present setup. This finding was validated in several control experiments, which 
did not reveal any shortcomings in the experimental setup. Based on other examples of 
alkyne–azide cycloadditions accelerated by supramolecular catalysts, the shallow nature of 
the binding site and the short half-life time of the ligand–receptor complexes were identified 
as possible causes for the absence of a catalytic effect of E-selectin.  
4.2. Outlook 
The triazole–nitroindole antagonists described herein are characterized by higher affinity and 
by markedly altered binding kinetics compared to the tetrasaccharide mimics. To further 
exploit the potential revealed by the discovery of these antagonists, detailed structural 
information from a co-crystal structure of E-selectin is necessary. This is further accentuated 
by observations made in other work (131, 133). For example, STD NMR experiments 
suggesting a direct interaction of subsitutents at the 2'-position of galactose can currently not 
be reconciled with the expected and computationally predicted binding mode of E-selectin 
ligands. In additon, more precise structural knowledge may help explain the failure of the in 
situ click experiment. 
Apart from crystal structure data, ITC and STD NMR studies could provide additional 
insights into the binding of triazole–nitroindole antagonists. However, first experiments were 
hampered by solubility and aggregation problems (cf. Section 3.2.1). 
The structure of the second-site ligand and of the linker were at least partly determined by the 
requirements of the screening process and not by the yet unknown structural needs of the 
protein. The new ligands are thus expected to have a considerable potential for further 
improvement of binding affinity.  
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As outlined in Section 2, the linker may be optimized with respect to flexibility and to 
additional polar or hydrophobic interactions: The linker of the currently best antagonist (P43) 
contains 8 rotatable bonds, the freezing of which may cause entropy costs upon binding. 
Consequently, the introduction of rigidity at appropriate locations, e.g. by double/triple bonds 
or heterocycles other than triazole, may be beneficial in terms of ligand preorganization. The 
studies on piperazine derivative 33 demonstrated that the introduction of positive charges into 
the linker moiety is rather not favorable with respect to physicochemical and 
pharmakokinetic properties. For the reduction of the amphiphilic character, polar but 
uncharged groups, such as ethers, may be more suitable. It must be considered, though, that 
the introduction of additional hydrogen bond acceptors may not be desirable with respect to 
oral bioavailability.  
The nitroindole modifications described in Section 2 have given a first hint of the structural 
requirements of the second binding site. Due to the potentially toxic metabolites of nitro 
groups, future research could be directed towards the investigation of isosteric replacements. 
Owing to limited time, in the present work the screening was limited to anti triazoles. These 
have proven high activity and are readily accessible via the CuAAC. However, based on 
currently available data, high affinities of syn triazoles cannot be excluded. Given the flexible 
linkers of the high-affinity antagonists, bent linker conformations in the bound state appear 
plausible. Such conformations might be achieved by syn triazoles equally well or even better, 
and thus syn triazoles may be of interest in the future. Again, structural informations from a 
crystal structure would be highly beneficial here, as the cost-benefit ratio of another syn 
triazole screening is probably not justifiable. 
Similar considerations apply to future in situ screening experiments with E-selectin. A 
screening may rather be indicated for the in-house P-selectin program, where a second-site 
screening is of interest, too. Based on the failure of the in situ click approach, alternative 
methods should be evaluated for future attempts, however. These may include alternative 
(irreversible) reactions or be based on a dynamic combinatorial approach. 
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5. Experimental Section 
5.1. General Methods 
5.1.1. Chemistry 
See Section 2. 
5.1.2. In situ click experiments 
Composition of the HEPES buffer. 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) 10 mM (pH 7.4), NaCl 150 mM, CaCl2 1 mM, surfactant P20 0.005%. 
QQQ MS. Separation was performed on a Agilent 1100 Series HPLC instrument with a 1200 
series Autosampler, connected to a Agilent 6400 Series Triple Quadrupole mass spectrometer 
for quantification (Agilent Technologies, Santa Clara CA, USA). Bidestilled water with 0.1% 
formic acid and acetonitrile with 0.1% formic acid were used as solvents. A gradient of 
acetonitrile in water (each containing 0.1% HCOOH) was was applied (acetonitrile: 5% ! 
55% within 18 min) at a flow rate of 0.6 mL/min. For the separation a Waters Atlantis T3 
column (2.1 x 50 mm) with a bead size of 3 "m was used (Waters, Milford MA, USA). The 
column was heated to 60 °C and the flow was set to 0.6 mL/min. 50 "L of analyte were 
injected per run. The data were performed with the MassHunter software (Agilent 
Technologies, Version B.01.04). 
5.2. Experiments (Chemistry) 
2,5-Dioxopyrrolidin-1-yl 2-[2-(2-{[(9H-fluoren-9-
ylmethoxy)carbonyl]amino}ethoxy)ethoxy]acetate (P36) 
2-[2-(2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}ethoxy)ethoxy]acetic acid (185 mg, 
0.480 mmol) and N-hydroxysuccinimide (110 mg, 0.956 mmol) were dissolved in anhydrous 
THF (1.5 mL). DIC was added dropwise to the solution at r.t., leading to the precipitation of 
a white solid. After 2 h, the reaction mixture was filtrated through a PTFE membrane filter 
(0.2 "M), and the solvent was removed. The crude product was redissolved in Et2O. The 
organic phase was washed with aq. NaHCO3 and 0.5 M aq. HCl. The organic layer was dried 
over Na2SO4, and the solvent was removed. The crude product was dissolved in CH2Cl2, and 
the solution was filtrated. After removal of the solvent, the crude product P36 (210 mg) was 
used in the synthesis of P35 without further purification. 
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9H-Fluoren-9-ylmethyl-N-{2-[2-({[1-(3-azidopropyl)-1H-indol-5-
yl]carbamoyl}methoxy)ethoxy]ethyl}carbamate (P35) 
Amine P34 (50 mg, 0.232 mmol) and succinimide ester P36 (120 mg, 0.249 mmol) were 
dissolved in anhydrous DMF (1 mL) and stirred at r.t. for 15 h. The solvent was removed in 
vacuo, and the residue was purified using silica gel chromatography (EtOAc in CH2Cl2, 
gradient 0 to 80%). 70 mg (52%) of P35 was obtained as a mixture of inseparable products 
(green-yellow oil). 
1
H-NMR (500 MHz, CDCl3): ! 1.88-1.96 (m, 2H, H-2’), 3.10 (t, J = 6.3 Hz, 2H, H-3’), 3.32-
3.38 (m, 2H, H-6’’), 3.56 (t, J = 5.0 Hz, 2H, H-5’’), 3.64 (d, J = 4.2 Hz, 2H, H-4’’), 3.73 (d, J 
= 4.4 Hz, 2H, H-3''), 4.02-4.11 (m, 5H, H-9'', H-2''. H-1'), 4.25 (d, J = 7.0 Hz, 2H, H-8''), 
6.36-6.40 (m, 1H, Ind H-3), 6.96-6.99 (m, 1H, Ind H-2), 7.15-7.25 (m, 4H, Ind H-6. Ind H-7, 
B), 7.27-7.34 (m, 2H, C), 7.42-7.48 (m, 2H, A), 7.64-7.71 (m, 2H, D), 7.81 (d, J = 1.4 Hz, 
1H, Ind H-4), 8.56 (s, 1H, CONH); 
13
C-NMR (125 MHz, CDCl3): ! 29.43 (C-2’), 40.82 (C-
6’’), 43.23 (C-1’), 47.31 (C-9’’), 48.40 (C-3’), 66.83 (C-8’’), 70.23 , 70.43, 70.90, 71.28, 
101.91 (C-3), 109.60 (C-7), 113.11 (C-4), 115.99 (C-6), 120.11 (Fmoc-C), 125.22 (Fmoc-C), 
127.19 (Fmoc-C), 127.83 (Fmoc-C), 128.91 (Fmoc-C), 128.93 (Fmoc-C), 129.62 (C-8), 
133.63 (C-5), 141.41 (Fmoc-C), 144.06 (Fmoc-C), 156.60 (OCONH), 167.97 (CH2CONH); 
MS: m/z calcd for C32H34N6O5 [M+Na]
+
: 605.25; found: 605.22. 
(1R,3R,4R,5S)-N-(3-{1-[3-(5-{2-[2-(2-Aminoethoxy)ethoxy]acetamido}-1H-indol-1-
yl)propyl]-1H-1,2,3-triazol-4-yl}propyl)-3-[2-O-benzoyl-3-O-((1S)-1-carboxy-2-
cyclohexyl-ethyl)-(!-D-galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-
methylcyclohexanecarboxamide (P38) 
Following general procedure III (Section 2), alkyne P26c (12.0 mg, 14.9 "mol), azide P35 
(13 mg, 22.3 "mol), Na-L-ascorbate (75 "L, 7.50 "mol) and CuSO4!5H2O (38 "L, 
3.80 "mol) were stirred in 
t
BuOH/H2O/THF 1:1:1 (1 mL; no prior degassing) for 2 h, 
followed by the addition of piperidine (4.4 "L). After another hour, further 10 "L of 
piperidine was added, and stirring was continued for 2 h. Following removal of the solvent in 
vacuo, the residue was dissolved in MeOH, filtrated through a PTFE membrane filter, and the 
solution was centrifuged. The supernatant was subjected to preparative HPLC-MS to afford 
P38 as a colorless solid (11.4 mg, 66%). 
1
H-NMR (500 MHz, MeOD): ! 0.39-0.69 (m, 4H, Cy), 0.79-0.93 (m, 1H, Cy), 1.09 (d, J = 
6.4 Hz, 3H, Me), 1.12-1.41 (m, 11H, H-2a, H-6a, 4Cy, Fuc H-6, Lac H-3a), 1.41-1.51 (m, 1H, 
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Lac H-3b), 1.51-1.61 (m, 2H, H-6b, Cy), 1.61-1.73 (m, 1H, H-5), 1.73-1.84 (m, 2H, H-2’), 
2.10-2.15 (m, 1H, H-2b), 2.21-2.29 (m, 1H, H-1), 2.44 (p, J = 6.6 Hz, 2H, H-2''), 2.62-2.69 
(m, 2H, H-3'), 3.05-3.20 (m, 5H, H-1', H-4, H-6*), 3.49 (d, J = 9.2 Hz, 1H, Gal H-3), 3.52-
3.57 (m, 1H, Gal H-5), 3.65-3.83 (m, 12H, H-3, Fuc H-2, Fuc H-4, Gal H-6, H-3*, H-4*, H-
5*, Lac H-2), 3.86 (dd, J = 3.2, 10.3 Hz, 1H, Fuc H-3), 3.89-3.94 (m, 1H, Gal H-4, 4.18-4.25 
(m, 4H, H-2*, H-3''), 4.34 (t, J = 6.7 Hz, 2H, H-1''), 4.64 (d, J = 8.1 Hz, 1H, Gal H-1), 4.94-
5.00 (m, 3H, Fuc H-1, Fuc H-5), 5.39 (t, J = 8.8 Hz, 1H, Gal H-2), 6.44 (d, J = 3.0 Hz, 1H, 
Ind H-3), 7.26 (d, J = 3.0 Hz, 1H, Ind H-2), 7.28 (s, 2H, Ind H-6, Ind H-7), 7.31-7.36 (m, 2H, 
C6H5), 7.43-7.49 (m, 1H, C6H5), 7.61 (s, 1H, H-5’), 7.83 (s, 1H, Ind H-4), 7.95-8.01 (m, 2H, 
C6H5); 
13
C-NMR (125 MHz, MeOD): ! 16.79 (Fuc C-6), 19.29 (Me), 23.54 (C-3'), 26.52, 
26.77, 27.36 (3C, Cy), 30.19 (C-2'), 31.60 (C-2''), 33.03, 34.37, 35.33 (3C, Cy), 35.53 (C-2), 
37.40 (C-6), 39.25, 39.42 (2C, C-5, C-1'), 40.57 (C-6*), 43.23 (C-1), 43.43 (Lac C-3), 44.20 
(C-3''), 48.69 (C-1'')‡, 63.06 (Gal C-6), 67.59, 67.74 (2C, Gal C-4, Fuc C-5), 68.00 (C-5*), 
70.27 (Fuc C-2) 70.33, 71.36 (2C, Fuc C-3, C-2*), 71.48 (2C, C-3*, C-4*), 73.00 (Gal C-2), 
73.94 (Fuc C-4), 76.06 (Gal C-5), 79.75 (C-3), 83.02 (C-4), 83.69 (Gal C-3), 100.39 (Fuc C-
1), 100.62 (Gal C-1), 102.57 (Ind C-3), 110.52 (Ind C-7), 114.43 (Ind C-), 117.31 (Ind C-6), 
123.66 (C-5’), 129.62 (C6H5), 130.13, 130.18 (2C, Ind C-2, Ind C-9), 130.82 (C6H5), 130.96, 
131.66 (2C, Ind C-5, C6H5), 134.16 (C6H5), 135.01 (Ind C-8), 148.82 (C-4'), 166.78 
(O(C=O)Ph), 170.59 (C-1*), 177.03 (CONH); HPLC (" = 350 nm): purity = 95%, tR = 
12.483 min; [a]D
20
 = -44.4 (c = 0.67, MeOH); IR (KBr): # = 3430 (vs, OH), 3137 (m, NH2), 
2925 (vs), 2855 (m), 1724 (m), 1720 (m), 1654 (s), 1649 (s), 1586 (s), 1542 (m), 1489 (m), 
1450 (m), 1401 (w), 1385 (w), 1340 (w), 1293 (w), 1272 (s), 1219 (vw), 1163 (w), 1117 (vs), 
1098 (vs), 1079 (vs), 1032 (s), 997 (w), 967 (vw), 802 (vw), 763 (vw), 714 (w) cm
-1
. 
3-{4-[3-(5-Nitro-1H-indol-1-yl)propyl]piperazin-1-yl}propan-1-ol (34) 
Bromide P27c (176 mg, 0.622 mmol), 3-(piperazin-1-yl)propan-1-ol (278 mg, 1.93 mmol), 
and Et3N (259 $L, 1.87 mmol) were dissolved in anhydrous DMF and stirred at r.t. for 2 h. 
After removal of the solvent in vacuo, the crude product was subjected to silica gel 
chromatography (MeOH in CH2Cl2, gradient 0 to 20 to 80%) to afford 34 (215 mg, quant.) as 
yellow crystals. 
1
H-NMR (500 MHz, CDCl3): ! 1.70-1.76 (m, 2H, H-2''), 1.99 (p, J = 6.7 Hz, 2H, H-2'), 2.04-
3.07 (bs, 8H, Pip-H), 2.23 (t, J = 6.7 Hz, 2H, H-3'), 2.61-2.66 (m, 2H, H-1''), 3.77-3.81 (m, 
2H, H-3''), 4.25 (t, J = 6.6 Hz, 2H, H-1'), 6.66 (d, J = 2.9 Hz, 1H, H-3), 7.27 (d, J = 3.2 Hz, 
1H, H-2), 7.41 (d, J = 9.1 Hz, 1H, H-7), 8.08 (d, J = 9.1 Hz, 1H, H-6), 8.56 (d, J = 2.2 Hz, 
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1H, H-4); 
13
C-NMR (125 MHz, CDCl3): ! 27.06 (C-2''), 27.12 (C-2'), 44.10 (C-1'), 52.92 
(2C, C-a, C-a'), 53.28 (2C, C-b, C-b'), 54.24 (C-3'), 58.61 (C-1''), 64.38 (C-3''), 103.99 (C-3), 
109.44 (C-7), 117.01 (C-6), 118.18 (C-4), 127.58 (C-9), 131.23 (C-2), 138.98 (C-8), 141.39 
(C-5); elemental analysis calcd (%) for C18H26N4O3 (346.42): C 62.41, H 7.56, N 16.17; 
found: C 62.21/62.02, H 7.67/7.64, N 15.96/16.01; IR (KBr): " = 3435 (s, OH), 2947 (m), 
2922 (m), 2826 (m), 1634 (vw), 1610 (w), 1578 (vw), 1513 (s), 1479 (m), 1464 (m), 1404 
(w), 1369 (w), 1328 (vs, NO2), 1306 (s), 1274 (m), 1186 (w), 1157 (m), 1130 (m), 1067 (s), 
1006 (m) 899 (vw), 779 (w), 751 (m), 718 (w) cm
-1
. 
1-{3-[4-(3-Azidopropyl)piperazin-1-yl]propyl}-5-nitro-1H-indole (35) 
Alcohol 34 (181 mg, 0.522 mmol) and diphenyl phosphoryl azide (DPPA; 134 #L, 
0.626 mmol) were dissolved in anhydrous THF (2 mL). The solution was cooled to -15 °C in 
a salt-ice bath, and diazobicyclo undecene (DBU; 93.6 #L, 0.626 mmol) was added dropwise, 
and the solution was allowed to warm to r.t.. After 2 h, NaN3 (71 mg, 1.09 mmol) was added 
to the reaction mixture as there was no reaction progress according to TLC (CH2Cl2, MeOH 
10:1). After 12 h of stirring, additional 0.5 eq. of DPPA (56 #L, 0.261 mmol) and DBU 
(39 #L, 0.261 mmol) were added, and stirring was continued for 2 h. The solvent was 
removed under reduced pressure, the crude mixture was dissolved in EtOAc (30 mL), washed 
with satd. aq. NaHCO3 (20 mL) and brine (20 mL). The aqueous layers were extracted with 
EtOAc (2 x 30 mL), and the organic phase was dried over Na2SO4. After removal of the 
solvent in vacuo, the mixture was purified using silica gel chromatography (MeOH in 
CH2Cl2, gradient 0 to 15 to 70%) to afford a mixture of azide 35 and its diphenyl phosphoryl 
ester (note: in TLC, azide and ester were not separable using CH2Cl2, MeOH 10:1). The 
mixture of azide and ester was dissolved in anhydrous DMF, and NaN3 (171 mg, 2.63 mmol) 
was added. The mixture was stirred at 60 °C for 25 h until TLC (TLC plates were deactivated 
using petroleum ether + Et3N) and MS indicated full conversion of the phosphoryl ester. H2O 
(20 mL) was added, and the aqueous phase was extracted with EtOAc (3 x 50 mL). The 
organic layers were washed with NaHCO3 (20 mL) and brine (20 mL) and subsequently dried 
over Na2SO4. After removing the solvent in vacuo, the crude product was purified using 
silica gel chromatography (MeOH in CH2Cl2, gradient 0 to 10 to 70%) to give azide 35 
(154 mg, 79%) as a viscous yellow oil. 
1
H-NMR (500 MHz, CDCl3): ! 1.74-1.81 (p, J = J = 6.7 Hz, 2H, H-2''), 2.00 (p, J = 6.7 Hz, 
2H, H-2'), 2.23 (t, J = 6.7 Hz, 2H, H-1'), 2.28-2.70 (m, 11H, Pip-H, H-1''), 3.34 (t, J = 6.7 Hz, 
2H, H-3''), 4.26 (t, J = 6.6 Hz, 2H, H-1'), 6.67 (d, J = 3.2 Hz, 1H, H-3), 7.27 (d, J = 3.2 Hz, 
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1H, H-2), 7.43 (d, J = 9.1 Hz, 1H, H-7), ), 8.09 (dd, J = 2.2, 9.1 Hz, 1H, H-6), 8.57 (d, J = 2.2 
Hz, 1H, H-4); 
13
C-NMR (125 MHz, CDCl3): ! 26.35 (C-2''), 27.27 (C-2'), 44.21 (C-1'), 49.65 
(C-3''), 53.07, 53.28 (4C, a/a', b/b'), 54.40 (C-1'), 55.34 (C-1''), 104.05 (C-3), 109.53 (C-7), 
117.13 (C-6), 118.28 (C-4), 127.66 (C-9), 131.30 (C-2), 139.08 (C-8), 141.52 (C5); elemental 
analysis calcd (%) for C18H25N7O2 (371.44): C 58.20, H 6.78, N 26.40; found: C 58.04/58.14, 
H 6.86/6.87, N 25.21/25.41; IR (KBr): " = 2944 (w), 2813 (w), 2777 (vw), 2096 (s, N3), 1611 
(vw), 1514 (m), 1480 (w), 1463 (w), 1452 (w), 1403 (vw), 1333 (vs, NO2), 1274 (w) 1159 
(w), 1142 (vw), 1069 (w), 745 (m) cm
-1
. 
3-{4-[3-(5-Nitro-1H-indol-1-yl)propyl]piperazin-1-yl}propan-1-amine (36) 
Azide 35 (149 mg, 0.401 mmol) and triphenyl phosphine (129 mg, 0.492 mmol) were 
dissolved in THF (4 mL) and H2O (1 mL). The solution was stirred at 60 °C for 3 h, and the 
solvent was removed under reduced pressure. The mixture was redissolved in MeOH and 
subjected to preparative HPLC-MS (H2O/MeCN + 0.2% HCOOH) to afford amine 36 
(108 mg, 78%) as a viscous yellow oil. 
1
H-NMR (500 MHz, MeOD): ! 1.89 (p, J = 7.0 Hz, 2H, H-2''), 2.14-2.21 (m, 2H, H-2'), 2.65-
2.72 (m, 4H, H-1'', H-3'), 2.83 (d, J = 50.9 Hz, 8H, Pip H-b/b', Pip H-a-/a'), 3.01 (t, J = 7.2 
Hz, 2H, H-3''), 4.36 (t, J = 6.8 Hz, 2H, H-1'), 6.72-6.74 (m, 1H, H-3), 7.49 (d, J = 3.2 Hz, 1H, 
H-2), 7.60 (d, J = 9.1 Hz, 1H, H-7), 8.08 (dd, J = 2.2, 9.1 Hz, 1H, H-6), 8.54 (d, J = 2.2 Hz, 
1H, H-4); 
13
C-NMR (125 MHz, MeOD): ! 24.46 (C-2''), 27.05 (C-2'), 39.21 (C-3'), 44.84 (C-
1', 52.20 (C-b/b'), 52.70 (C-a/a'), 55.28 (C-3'), 55.67 (C-1''), 105.10 (C-3), 110.80 (C-7), 
117.81 (C-6), 118.79 (C-4), 129.29 (C-9), 132.83 (C-2), 140.36 (C-8), 142.76 (C-5); IR 
(KBr): " = 2952 (m), 2835 (w), 1632 (s), 1610 (s), 1514 (s, NO2), 1479 (m), 1450 (m), 1400 
(s), 1385 (s), 1334 (vs, NO2), 1267 (vw), 1195 (w), 1145 (vw), 1101 (w), 1069 (w), 764 (w), 
745 (s) cm
-1
. 
(1R,3R,4R,5S)-3-[2-O-Benzoyl-3-O-((1S)-1-carboxy-2-cyclohexyl-ethyl)-(!-D-
galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-methyl-N-(3-{1-[3-(5-nitro-1H-
indol-1-yl)propyl]piperazin-1-yl}propyl)cyclohexanecarboxamide (33) 
Diacid P24 (30 mg, 40.5 #mol) and HOBt (17.0 mg, 126 #mol) were dissolved in anhydrous 
DMF under argon. At r.t., HBTU (18.4 mg, 48.5 #mol) was added. After 5 min of stirring, 
the solution was transferred via a syringe to a flask containing amine 36 (89 mg, 258 #mol) 
and DIPEA (0.3 mL). The solvent was removed in vacuo after another 2.5 h of stirring, and 
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the crude product was purified using preparative HPLC-MS (H2O/MeCN + 0.2% HCOOH). 
33 (14.6 mg, 34%) was obtained as a yellow solid. 
1
H-NMR (500 MHz, MeOD): ! 0.41-0.72 (m, 4H, Cy), 0.80-0.94 (m, 1H, Cy), 1.10 (d, J = 
6.3 Hz, 3H, Me), 1.14-1.42 (m, 11H, H-6a, H-2a, 5Cy, Fuc H-6, Lac H-3a), 1.45-1.53 (m, 1H, 
Lac H-3b), 1.55-1.72 (m, 5H, Cy, H-6, H-2', H-5), 2.00-2.09 (m, 2H, H-2''), 2.11-2.20 (m, 1H, 
H-2), 2.20-2.70 (m, 12H, H-1, H-1'', H-3', Pip-H), 3.13 (t, J = 6.7 Hz, 2H, H-1'), 3.17 (t, J = 
9.6 Hz, 1H, H-4), 3.51-3.61 (m, 2H, Gal H-3, Gal H-5), 3.67-3.83 (m, 6H, H-3, Lac H-2, Gal 
H-6, Fuc H-4, Fuc H-2), 3.89 (dd, J = 3.1, 10.2 Hz, 1H, Fuc H-3), 3.91-3.96 (m, 1H, Gal H-
4), 4.33 (t, J = 6.6 Hz, 2H, H-3''), 4.69 (d, J = 8.1 Hz, 1H, Gal H-1), 4.94-5.04 (m, 2H, Fuc 
H-1, Fuc H-5), 5.42 (t, J = 8.9 Hz, 1H, Gal H-2), 6.72 (d, J = 3.0 Hz, 1H, Ind H-3), 7.43-7.54 
(m, 3H, C6H5, Ind H-2), 7.55-7.66 (m, 2H, C6H5, Ind H-7), 8.00-8.13 (m, 3H, C6H5, Ind H-6), 
8.56 (d, J = 1.9 Hz, 1H, Ind H-4); 
13
C-NMR (125 MHz, MeOD): ! 16.77 (Fuc C-6), 19.31 
(Me), 26.55, 26.80, 26.92 (4C, Cy, C-2'), 27.39 (C-1''), 28.17 (C-2''), 33.03, 34.42, 35.38 (3C, 
Cy), 35.48 (C-2), 37.67 (C-6), 39.06, 39.31 (2C, C-5, C-1'), 43.45 (C-1), 43.54 (Lac C-3), 
45.30 (C-3''), 53.83, 53.92 (4C, Pip-C), 56.06 (C-1''), 57.37 (C-3'), 63.15 (Gal C-6), 67.63, 
67.75 (2C, Gal C-4, Fuc C-5), 70.28 (Fuc C-2), 71.34 (Fuc C-3), 73.03 (Gal C-2), 73.93 (Fuc 
C-4), 76.04 (Gal C-5), 79.69 (C-3), 80.65 (Lac C-2), 82.94 C-4), 83.79 (Gal C-3), 100.36 
(Fuc C-1), 100.64 (Gal C-1), 104.83 (Ind C-3), 110.94 (Ind C-7), 117.64 (Ind C-6), 118.74 
(Ind C-4), 129.20 (Ind C-9), 129.68 (C6H5), 130.89 (C6H5), 131.81 (C6H5), 132.97 (Ind C-2), 
134.21 (C6H5), 140.47 (Ind C-8), 142.63 (Ind C-5), 166.81 (O(C=O)Ph), 176.97 (CONH), 
183.25 (COOH). 
(1R,3R,4R,5S)-N-{2-[2-(2-Aminoethoxy)ethoxy]ethyl}-3-[2-O-benzoyl-3-O-((1S)-1-
carboxy-2-cyclohexyl-ethyl)-(!-D-galactopyranosyl)oxy]-4-[("-L-fucopyranosyl)oxy]-5-
methyl-cyclohexanecarboxamide (37) 
Ester P3 (15 mg, 0.0199 mmol) was dissolved in 2-[2-(2-aminoethoxy)ethoxy]ethan-1-amine 
(0.6 mL) and MeOH (0.2 mL) and stirred at 65 to 70 °C for 2 d. The solvent was partially 
removed under high vacuum at up to 60 °C, and the residual solution was purified by HPLC-
MS (H2O/MeCN + 0.2% HCOOH). 37 was obtained as a colorless solid (6 mg, 35%). 6 mg 
(40%) of the starting material was recovered. 
1
H-NMR (500 MHz, MeOD): ! 0.49-0.73 (m, 4H, Cy), 0.84-0.96 (m, 1H, Cy), 1.11 (d, J = 
6.4 Hz, 3H, Me), 1.14-1.45 (m, 11H, H-2a, H-6a, 5Cy, Fuc H-6, Lac H-3a), 1.44-1.55 (m, 1H, 
Lac H-3b), 1.54-1.63 (m, 2H, H-6b, Cy), 1.63-1.72 (m, 1H, H-5), 2.09-2.18 (m, 1H, H-2), 
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2.22-2.32 (m, 1H, H-1), 3.08-3.19 (m, 3H, H-6', H-4), 3.22-3.38 (m, 2H, H-1'), 3.46-3.53 (m, 
2H, H-2'), 3.53-3.82 (m, 12H, Gal H-3, Gal H-5, H-5', H-3', H-4', Gal H-6, Fuc H-2, Fuc H-
4), 3.82-3.92 (m, 2H, Fuc H-3, Lac H-2), 3.95 (s, 1H, Gal H-4), 4.68 (d, J = 8.0 Hz, 1H, Gal 
H-1), 4.93-5.01 (m, 2H, Fuc H-1, Fuc H-5), 5.43 (t, J = 8.8 Hz, 1H, Gal H-2), 7.46-7.52 (m, 
2H, C6H5), 7.58-7.64 (m, 1H, C6H5), 8.04-8.09 (m, 2H, C6H5) 7.46-7.52 (m, 2H, C6H5), 7.58-
7.64 (m, 1H, C6H5), 8.04-8.09 (m, 2H, C6H5); 
13
C-NMR (125 MHz, MeOD): ! 16.74 (Fuc C-
6), 19.31 (Me), 26.56, 26.77, 27.34 (3C, Cy), 33.15, 34.37, 35.22 (3C, Cy), 35.34 (C-2), 
37.56 (C-6), 39.28 (C-5), 40.06 (C-1'), 40.66 (C-6'), 43.15 (C-1), 62.95 (Gal C-6), 67.76, 
67.92 (2C, Gal C-4, Fuc C-5), 70.31 (Fuc C-2), 70.63 (C-2'), 71.28 (Fuc C-3), 71.38 (2C, C-
3', C-4'), 73.12 (Gal C-2), 73.94 (Fuc C-4), 76.11 (Gal C-5), 79.70 (C-3), 83.05 (C-4), 83.67 
(Gal C-3), 100.41 (Fuc C-1), 100.61 (Gal C-1), 129.70 (C6H5), 130.90 (C6H5), 131.72 (C6H5), 
134.28 (C6H5), 166.79 (O(C=O)Ph), 177.26 (CONH); HR-MS: m/z calcd for C42H66N2O17 
[M+H]
+
: 871.4434; found: 871.4464; [a]D
20
 = -66.3 (c = 0.22, MeOH); IR (KBr): " = 3430 
(vs, OH), 1726 (m, C=O), 1644 (m, C=O), 1077 (s, NH2) cm
-1
; 
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